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ABSTRACT
Somatic mutations in the PTEN gene (Phosphatase and Tensin Homologue 
Deleted on Chromosome Ten) have been found in many types of cancer, but 
most frequently in cancer of the endometrium.
The PTEN gene encodes a D3’ lipid phosphatase of the second messenger 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which activates protein kinase 
B/Akt. Constitutive activation of Akt has been found in cells that lack functional 
PTEN, thus by dephosphorylating PIP3, this enzyme modulates several cellular 
functions e.g. proliferation, differentiation and migration.
The PTEN protein comprises a 403 amino acid, 55KDa protein which is present 
in the cytoplasm but has also been detected in the nucleus of some cells. The 
function of nuclear versus cytoplasmic PTEN has not yet been determined. 
Little is known about modulation of PTEN expression by molecules such as 
hormones and cytokines. It has been reported, however, that NGF, BDNF and 
vitamin D3 analogues can up-regulate PTEN. The steroid hormones oestrogen 
and progesterone have been proposed as mediators of PTEN transcription, 
since their expression in endometrium reflects the menstrual cycle. The role of 
TGFpl in PTEN expression of PTEN in human cells has been also investigated, 
but the results are contradictory. Compounds which stimulate up-regulation of 
PTEN represent potential anti-tumour therapies and therefore merit 
investigation. To further investigate the role of PTEN in endometrial cancer the 
following approaches were taken.
The effect of TGF-pi on two endometrial carcinoma cell lines, HEC-1B and 
Ishikawa were investigated. The cell lines were stimulated with TGF-p1 in the 
presence or absence of serum, and changes in mRNA and protein levels of 
PTEN and other genes analysed by RT-PCR and Western blotting. The 
morphology, cell number and cell viability were also assessed. Modest up- 
regulation of PTEN mRNA was detected in both cell lines, but little change in 
protein levels was observed. In accordance with published data, TGF-p1 
suppressed the growth of, and changed the morphology of both cell lines.
To study PTEN sub-cellular localisation, full-length human PTEN cDNA was 
used in ’RT-PCR to generate a 1.2Kb fragment which was cloned into a green 
fluorescent protein expression vector pEGFP-N1 to create pRC-2. Sequencing 
of pRC-2 confirmed the in-frame cloning of wild-type PTEN. Lipid-based
transfection was used to transiently transfect HEC-1B, Ishikawa and Cos-7 
cells. Strong perinuclear and cytoplasmic localisation was detected in these cell 
lines, and localisation to the endoplasmic reticulum was observed. Stimulation 
with TGF-pi and 17-p-estradiol had no discernable effect on sub-cellular 
localisation of PTEN in either HEC-1B or Ishikawa cell lines.
A mutational study was performed using a large repository of archival 
endometrial carcinomas and normal cervical controls. PCR was used to amplify 
PTEN exons 5 and 8 from extracted DNA and the fragments separated by 
single-strand conformation polymorphism (SSCP) analysis. A number of 
samples exhibiting bandshifts were detected in both exons.
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CHAPTER 1 
INTRODUCTION
1.1 Intracellular Signalling and Phosphatidylinositol 3-kinase (PI-3K)
The regulation of cell growth and death is crucial to the survival of all multi- 
cellular organisms. Environmental stimuli, such as growth factors, control the 
delicate balance between cellular life and death by producing the desired 
response from the target cell. Binding of a stimulating molecule to a 
transmembrane receptor is a common event, which activates transmission of 
the specific signal via the generation of intracellular second messengers such 
as cyclic AMP and phosphoinositols (Pis). Once activated these transient 
molecules elicit activation, usually by phosphorylation, of a downstream 
target. The signalling cascade may involve many molecules and be highly 
redundant, but the net effect includes the modulation of gene expression to 
exert control over cell growth and metabolism.
1.1.1 Signalling Through Receptor Tyrosine Kinases
The generation of intracellular signals can be achieved by the binding of 
extracellular growth factors or cytokines to specific receptor tyrosine kinases, 
which are activated by tyrosine phosphorylation. Ligand binding to a receptor 
tyrosine kinase, which can exhibit autoinhibition in the absence of ligand 
(Schlessinger 2003), causes rapid phosphorylation of the cytosolic domain 
which may induce receptor dimerisation. This can then be followed by the 
activation of G-proteins (Nystrom & Quon, 1999).
G-proteins are 3-subunit transmembrane complexes which bind GTP or 
GDP, and of which there are four subclasses. The G-protein is directly linked
1
to the enzyme which catalyses second messenger generation, for example 
by various isoforms of phospholipase C (PLC). Phosphorylation of the G- 
protein results in the activation of the enzyme, and for the PLCs in the 
generation of inositol-3,4,5-trisphosphate (IP3) and diacylglycero! (DAG) from 
phosphatidylinositol-4,5-bisphosphate (PI4,5P2). IP3 stimulates calcium 
release from the endoplasmic reticulum (ER), and DAG activates protein 
kinase C (PKC) to stimulate proliferation. In addition, DAG is phosphorylated 
by DAG-kinases to phosphatidic acid and transported to the ER, where it is 
combined with inositol to perpetuate the generation of phosphoinositides 
(Payrastre, et al, 2001 & Vazquez-Prado, et al 2003).
Signalling through receptor tyrosine kinases (rTKs) can also occur in a G- 
protein independent manner. Activation by ligand binding causes rapid 
dimerisation of receptors (eg for EGF and PDGF) or conformational changes 
in dimeric receptors, for example for insulin and IGF-1 (Hubbard, et al, 1998). 
This permits activation of the cytoplasmic tyrosine kinase domain by 
autophosphorylation of tyrosine residues in this region. An activated rTK is 
then capable of engaging a wide range of downstream molecules containing 
src homology domains (SH2), including growth factor receptor bound protein 
2 (GRB-2) and phosphatidylinositol 3-kinase (PI3K). SH2 domains are 
characterised by binding specifically to phosphorylated tyrosine motifs and 
can therefore regulate the catalytic functions or localisation of their substrates 
(Baca, 2003).
Binding of the SH2 domain of PI3K, a heterodimer which is composed of a 
regulatory p85 and catalytic p110 subunit, causes a conformational change in 
p85. This change permits activation of p110 and localises the activated PI3K
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to the plasma membrane for the 3’ phosphorylation of phosphatidylinositols 
(Ptdlns). These products are not cleaved by PLC and represent a distinct 
signal transduction mechanism (Vanhaesebroeck, et al, 1999c).
Convergent signalling pathways can be activated by binding of ligand to non­
receptor tyrosine kinases, such as src and JAK (Janus kinase) as observed 
in B- and T-cell antigen receptor signalling (Stephens, et al., 1993). PI3K 
recruitment and activation via p85 may occur due to these kinases binding to 
intermediates containing src homology-3 (SH3) domains. SH3 domains bind 
proline rich motifs on both upstream and downstream molecules 
simultaneously and mediate multiple protein-protein interactions (Jiang & Qui 
2003). The overall effect, as with activation of rTKs, is the localisation of 
active PI3K enzyme to the plasma membrane.
Finally, as signalling is a redundant mechanism, PI3K may also be activated 
by the Ras family members which initiate the mitogen activated protein 
kinase (MAPK) pathways (Vanhaesebroeck, et al, 1997). Ras, like PI3K, is a 
common effector of pathways activated by many growth factor receptors and 
binds GTP with high affinity when activated. PI3K recruitment by GTP-Ras 
occurs via direct interaction with the p110 subunit, restoring catalytic function 
without binding to p85.
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1.1.2 The PI-3K Pathway Intracellular Signal Transducers
The activation and recruitment of PI3K to the plasma membrane is the 
starting point of lipid-mediated signal transduction via a serine/threonine 
phosphorylation cascade. Three distinct classes of PI3Ks have been 
identified based upon p110 lipid substrate specificity and mechanism of 
regulation, with Class IA being most commonly associated with signalling 
through receptor tyrosine kinases and the only class to activate protein 
kinase B (PKB) (Vanhaesebroeck et al., 1999 & Fruman, et al., 1998). All 
mammalian Class I PI3Ks exhibit inhibition by low levels of the small cell- 
permeable compounds wortmannin and LY294002, which are unrelated 
structurally but which bind covalently to p110 (Wymann, et al, 1996) or 
competitively inhibit ATP binding (Vlahos, et al, 1994) . The PI3K class and 
associated inositol lipid products are shown in Table 1.
PI3K
Class Features Substrates
Inositol
products Downstream Roles
I
Activated by 
rTKs & G- 
proteins
PI PI3P Proliferation 
Vesicular Trafficking 
Cytoskeletal 
Rearrangements 
Gene Expression
PI4P PI3,4,5P3
PI4,5P2 PI3,4,P2
II Possess C2 domain
PI PI3P
PI4P PI3,4P2
III Formsheterodimers PI PI3P
Vesicular Transport 
from Golgi 
Gene Expression
Table 1 PI3K Classes, their products and cellular roles
The catalytic p110 subunit exists as isoforms a, p and 5 which associate with 
regulatory/adaptor p85 isoforms a, p and y (Hu et al., 1993) to achieve lipid 
kinase activity. The p110y isoform, however, binds an adaptor protein p101 
and is activated by the Py subunits of G proteins, as is the p110p subunit
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(Stoyanov et al., 1995 & Kurosu et al., 1997). These isoforms are expressed 
in a tissue specific manner and have distinct roles in transducing signals 
generated through distinct receptors. For example, p110a transduces PDGF- 
derived signals and p110p is the transducing factor for insulin (Hooshmand- 
Rad, etal., 2000). p1108 is predominantly expressed in mature B and T cells 
and mediates antigen-receptor signalling (Zhang, Vanhaesebroeck & 
Rittenhouse, 2002), whereas p110y is required for T-cell development and 
CD4/CD8 lineage commitment (Rodriguez-Borlando, et al, 2003).
It is thought that the isoform-specific protein kinase activity of p110 subunits 
towards themselves (by autophosphorylation) and their adaptor proteins 
contributes to the functional specificity of PI3Ks (Vanhaesebroeck et al., 
1999b and c). The isoforms of p85 mentioned above contain a range of 
domains (Cohen et al., 1995) including multiple SH2/3 and a region for 
binding p110 isoforms to regulate kinase activity (Klippel etal., 1994). Recent 
work by Okkenhaugik & Vanhaesebroeck (2001) also indicates a regulatory 
role for p85 in actin cytoskeleton rearrangement.
Membrane localised PI3K specifically phosphorylates the D3 position of the 
inositol ring of phosphatidylinositides to generate phosphatidylinositol-3,4- 
bisphosphate (PI3,4P2) and phosphatidylinositol-3,4,5-trisphosphate 
(PI3,4,5P3, also written as PIP3). These Ptdlns are almost absent unless the 
cell is stimulated by a growth factor, unlike other cellular Ptdlns which are 
constitutively expressed (Carpenter et al., 1996). These include 
phosphatidylinositol-4,5-bisphosphate (PI4,5P2), which is involved in the 
PLC/DAG pathway as previously mentioned, and phosphatidylinositol-3- 
phosphate (PI3P) which has a role in membrane trafficking via the
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recruitment of proteins containing FYVE domains and in receptor sorting 
(Leevers, et al., 1999 & Petiot, et al, 2003). PI3Ks generate molecules which 
activate many downstream effectors, (discussed in detail below), the 
disregulation of which is implicated in pathological disorders such as cancer, 
allergy and cardiovascular diseases.
PI3Ks are now the target of novel drugs to selectively inhibit specific isoforms 
of the kinase, in the hope of eliminating disease without abolishing entire 
signalling pathways (Arcaro, et al 2002 & Wymann, M. P., et al 2003). 
Recently, the p1108/y subunits of PI3K have been found to be essential non- 
redundant mediators of immune function, with implications for treating 
autoimmunity and transplant rejection (Okkenhaug & Vanhaesebroeck, 2003)
1.1.3 Downstream Targets of PI3K Activation
Membrane associated PI3,4P2 and PI3,4,5P3 generated by Class I PI3K are 
capable of activating PKB by binding to downstream target molecules via 
Pleckstrin homology (PH) domains, some of which target the inositol lipids 
and their head groups with high affinity (Vazquez & Sellers, 2000).
Proteins containing PH domains for PI3.4P2 and PI3,4,5P3 in this pathway 
include the Ser/Thr kinases PKB, also known as Akt, and PDK-1 
(phosphoinositide-dependant kinase-1). Akt/PKB exists as a, p and y 
isoforms which are widely expressed in tissues, consisting of an N-terminal 
PH domain, a kinase domain and a C-terminal regulatory tail (Wymann, et al,
1998). These latter two domains contain ser/thr sites (Ser473 and Thr308) 
which must be phosphorylated to fully activate the kinase (Alessi, et al, 
1996a). The PH domain of Akt/PKBa preferentially binds to PI3,4,5P3,
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causing its translocation from the cytoplasm to the membrane and a 
conformational change. This change exposes an activation loop containing 
Thr308 and Ser473, (or equivalent residues in the other isoforms), and 
initiates the phosphorylation of Thr-308 by PDK-1.
The mechanism of Ser473 phosphorylation is thought to occur through 
integrin-linked kinases functioning as adaptors to recruit a Ser473 kinase 
(Lynch et al., 1999), or by other rTKs (eg for IGF) by virtue of an interaction 
between PDK-1 and the C-terminal fragment of PRK-2 (protein kinase C- 
related kinase-2. This fragment, termed PDK1-interacting fragment (PIF) has 
been observed to convert PDK1 in a manner which permits it to 
phosphorylate Ser473 of Akt/PKB. Recent findings implicate Ser473, but not 
Thr308, as being the target residue for modulation of Akt/PKB activity (Wan & 
Helman, 2003, Dery, et al 2003, & Woods, et al, 2003). The interaction with 
PIF also causes a three-fold activation of PDK-1 by PI3,4,5P3 or PI3,4P2 but 
not PI4,5P2 (Balendran et al., 1999a). As PDK-1 complexes with other PKC 
family members, these interactions may form the basis by which modulation 
of PDK-1 towards Akt/PKB is achieved (Pullen et al., 1998, Le Good et al., 
1998, & Balendran, et al, 1999b).
In addition to Akt/PKB, PDK-1 is also capable of activating p70-S6 kinase to 
initiate cell cycle progression via increased translation of immediate-early 
genes such as cyclin D (Takuwa, et al, 1999) and E2F transcription factor 
(Brennan, et al, 1999). Some components of the PI3K pathway demonstrate 
the ability to travel between the nucleus and cytoplasm, including PI3K, 
Akt/PKB and insulin signal mediators. Recently, PDK-1 has also been 
verified as existing in the nucleus, and this may represent a mechanism for
7
sequestering the protein to prevent it from participation in the cytosolic 
signalling cascade (Lim, M. A., et al 2003).
1.1.4 Downstream Targets of Akt
Once activated, Akt/PKB is capable of phosphorylating serine and threonine 
residues in small peptides in vitro containing the motif RXRXXSU *, where X 
is any amino acid and * is phenylalanine or leucine (Alessi et al., 1996). 
Many of Akt/PKBs substrates are inactivated by this phosphorylation, at least 
in vitro, and therefore include pro-apoptotic factors such as BAD, Caspase 9, 
GS3Kp and Forkhead transcription factors (Downward, 1998). 
Overexpression of Akt/PKB isoforms is anti-apoptotic and delays cell death, 
as observed in cancer cell lines representing pancreas (Cheng et al., 1996), 
breast (Nakatani et al., 1999) and ovary (Cheng, et al., 1992). An overview of 
the possible substrates of Akt/PKB are illustrated in Figure 1.
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Akt/PKB Signaling Pathways
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Figure 1 Akt/PKB Pathways Figure legends overleaf. 
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BAD
The BAD protein (Bcl-2/Bcl-XL-antagonist, causing cell death) exists as a 
heterodimer with either Bcl-2 or BcI-Xl, which are anti-apoptotic, and inhibits 
their function. When phosphorylated on Ser136 or Ser112, BAD is bound by 
14-3-3 adaptor proteins and releases Bcl-2/Bcl-XL which inhibit apoptosis. 
(Downward, 1999). Not all cell types express BAD, however, and other 
mechanisms of cell survival regulation exist independently of BAD 
phosphorylation and Akt/PKB activation (Hinton & Welham, 1999).
Caspase-9
Caspase-9 is an important protease in the initiation of the terminal apoptotic 
cascade and directly cleaves and activates the executioner molecule 
caspase-3 (Alnemri, 1999 and Wolf, et al, 1999). Akt/PKB has been shown to 
phosphorylate and inactivate human caspase-9 (Cardone, et al, 1998 and 
Takeuchi & Ito, 2003) but the phosphorylated residue is not conserved in rat, 
mouse or monkey homologues (Fujita, et al, 1999). There is also evidence 
that Akt/PKB may intervene at an earlier stage in the apoptotic cascade, prior 
to caspase-9 activation, by stabilising the mitochondrial membrane 
(Kennedy, etal, 1999).
ASK1
The apoptosis signal-regulating kinase-1 (ASK1) is a recently discovered 
substrate of Akt/PKB. ASK1 is a mitogen-activated protein kinase kinase 
kinase (MAPK kinase kinase) which acts upstream of p38 (Liao & Hung, 
2003) and c-Jun N-terminal kinase (JNK) pathways, which are activated by
11
stress and pro-inflammatory cytokines to induce apoptosis. Work by Kim, et 
al (2001) demonstrated phosphorylation of ASK1 by Akt/PKB at Ser83 in a 
consensus region similar to other Akt/PKB substrates. The two proteins also 
co-immunoprecipitated in a manner observed in Akt/PKB-BAD interactions 
(Datta, et al, 1997) and could associate constitutively, but activation of 
Akt/PKB was necessary for ASK1 phosphorylation.
Modulation of ASK1 by Akt/PKB phosphorylation results in an inhibition of 
JNK and p38, which initiate and modify transcription through a range of 
transcription factors including ATF-2 and AP-1. These factors promote 
apoptosis via expression of Bel homologues such as Bax and Bak, and may 
therefore indicate a transcription-based regulatory mechanism for Akt/PKB in 
apoptosis (Kyriakis, 1999 and Tibbies & Woodgett, 1999). Recently, Atk/PKB 
has been shown to bind to JNK interacting protein-1 (JIP1) in mouse primary 
neurones. This interaction inhibited JIP1-mediated activation of JNK pathway 
kinases and thus decreased apoptosis (Kim, et al 2002).
Additional targets in the stress-activated protein kinase (SAPK) pathways 
may include the Rac1 G-protein which activates the JNK pathway (Kwon, et 
al, 2000). The involvement of Akt/PKB is complex, and illustrates the cross­
talk between lipid signalling and MAP kinase cascades. This is further 
complicated by observation that although a single stimulus may activate 
multiple pathways, not all of these pathways are required to elicit the 
appropriate cellular response (Kirit, et al, 2000).There is additional evidence 
that Akt/PKB may phosphorylate multiple targets simultaneously and act as a 
central regulator of multiple signalling pathways (Kim, et al, 2001).
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Forkhead Transcription Factors
Akt/PKB is known to interfere with apoptosis at the transcription level via two 
mechanisms, the first of which involves members of the Forkhead (FH) 
transcription factor family. Three members of this superfamily, FKHR, 
FKHRL1 and AFX have been shown to be phosphorylated by Akt/PKB on 
three residues (Kops, et al, 1999, Rena et al, 1999 and Brunet et al, 1999). 
During cellular stimulation, FH transcription factors are translocated from 
their normal location in the nucleus to the cytoplasm (Brunet, et al, 1999). It is 
thought that phosphorylation by Akt/PKB prevents FH target gene 
transcription by promoting nuclear export of the FH proteins to the cytosol 
where they are sequestered by 14-3-3 adaptor proteins, thus preventing 
access to their pro-apoptotic target genes (Guo, et al, 1999 and Biggs, et al, 
1999).
Recent findings have implicated Akt/PKB-regulated FH transcription factors, 
now termed FOXO (Burgering & Medema, 2003) in the control of expression 
of proteins directly involved in the cell cycle. A clone of HL60 human 
leukaemia cells with constitutive Akt/PKB (HL60AR) displayed higher levels 
of phosphorylated FH transcription factors Fox01 (FKHR) and Fox03 
(FKHRL1) than parental cells. These factors were permanently restricted to 
the cytoplasm resulting in increased proliferation. The cyclin-dependent 
kinase (CDK) inhibitor p27K,p1 protein was observed to be both decreased 
and hyperphosphorylated, levels of cyclin D1 were increased as were the 
activities of cdk2, 4 and 6, and the retinoblastoma (Rb) protein was also 
phosphorylated (Cappellini, et al, 2003). These findings indicate control of the 
cell cycle by Akt/PKB via nuclear exclusion of FOXO transcription factors,
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and similar results have been observed in hepatocytes (Wolfrum, et al, 2003) 
and glioma cells (Ciechomska, et al, 2003). FOXO factors are capable of 
both inhibiting proliferation and initiating apoptosis via distinct mechanisms, 
and could be especially important in cells of the immune system (Birkenkamp 
& Coffer, 2003).
NFkB & IkB kinases (IKK)
The second anti-apoptotic transcription-based mechanism employed by 
Akt/PKB involves the transcription factor nuclear factor k-B (NF-kB), which is 
at the endpoint of many signalling pathways. NF-kB exists in the cytoplasm 
bound to its inhibitor, IkB, until it is phosphorylated by IkB kinases (IKKs) and 
degraded, allowing NF-kB to translocate to the nucleus (Mercie, et al, 1998 
and Dent et al, 2003). Here, transcription of anti-apoptotic genes occurs, 
including inhibitor-of-apoptosis (IAP) proteins C-IAP1 and 2 (Wang, 1998). 
Akt/PKB has previously been shown to associate with IKKs (Kane, et al,
1999) and to mediate IKKa phosphorylation at Thr23 (Ozes, et al, 1999). As 
with human caspase-9, the predicted phosphorylation site on IKKa does not 
lie within the optimal consensus sequence for Akt/PKB (Ozes et al, 1999), 
and may involve additional mediators such as protein kinase CK2 (Romieu- 
Mourez, et al, 2002) which is upregulated in some tumours.
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GSK3p & Insulin Signalling
Akt/PKB appears to have a crucial role in mediating insulin signalling, as 
over-expression of activated Akt/PKB elicits the same effects as insulin in 
responsive cells (Barthel, et al, 1999), and PI3K inhibitors prevent insulin 
signalling (Shepherd et al, 1998). Although the exact mechanism is unknown, 
Akt/PKB has been shown to phosphorylate and inactivate glycogen synthase 
kinase-3p on Ser9 (Grimes & Jope, 2001). GSK3p phosphorylates cyclin D1 
on Thr286 (Diehl, et al, 1998), causing its degradation by the proteasome 
and preventing G1-S transition of the cell cycle. Phosphorylation and 
inhibition of GSK3p would therefore allow the accumulation of cyclin D1 and 
progression of the cell cycle.
Other targets of Akt/PKB downstream of the insulin receptor include insulin 
receptor substrates -1&-2 (IRS-1 &-2), mammalian target of rapamycin 
(mTOR) and phosphodiesterase-3B (PDE-3B). IRS-1 is tyrosine- 
phosphorylated and activated by the insulin receptor allowing association 
with p85a of PI3K. Akt/PKB appears to positively regulate IRS-1 by 
phosphorylation of one or more of four possible Ser residues in a feedback 
mechanism which protects active IRS-1 from dephosphorylation by protein 
tyrosine phosphatases (Paz et al, 1999). Recently Ser302 has been shown to 
be one of the residues phosphorylated (Giraud, et al, 2003 and Johnston, 
Pirola & Van Obberghen, 2003). IRS-2 is modulated through both mRNA 
transcription and protein regulation, but the exact mechanism is unknown 
(Hirashima, et al, 2003).
The mTOR protein is critical in the integration of signals which detect nutrient 
availability and allow cell cycle progression, and is inhibited by rapamycin
15
and its analogues. (Abraham, 2002). mTOR is a downstream target of 
Akt/PKB and PDK-1 (Section 1.1.3) which activate the protein and initiate an 
increase in the synthesis of proteins required for cell cycle progression such 
as cyclin D1. This pathway has been found to be elevated in several cancer 
cell lines including pancreas, lung and prostate, and inhibitors of mTOR are 
potential anti-tumour agents (Gera, et al, 2003 and Gao, et al, 2003).
In response to insulin binding, Akt/PKB also phosphorylates and activates 
PDE-3B on Ser273. PDE-3B is present in adipocytes and pancreatic (3 cells 
where it controls cellular levels of the second messengers cAMP and cGMP, 
and prevents lipolysis (Kitamura et al, 1999), and possibly promotes cell 
survival and cell cycle progression (Ahmad et al, 2000)
Endothelial Nitric Oxide Synthase (eNOS)
eNOS is produced by endothelial cells in response to VEGF and shear stress 
and activated by Akt/PKB, which can phosphorylate eNOS on Ser1177 
(Dimmeler, et al, 1999). Recently, insulin has also been shown to regulate 
eNOS expression, but not activity, via increasing the binding of the 
transcription factors AP-1 and Sp1 (Fisslthaler, et al, 2003). Increased eNOS 
expression has been implicated in the onset of diabetes and hypertension 
(Pieper, 1998). Nitric oxide (NO) production by eNOS causes vasodilation 
and can modulate apoptosis, exerting both pro- and anti-apoptotic effects 
depending on concentration and cell type (Pervin, Singh, & Chaudhuri, 
2003). NO produced in response to VEGF increases angiogenesis, and may 
be a mechanism by which tumours increase their blood supply.
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BRCA1
The breast cancer susceptibility gene BRCA1 encodes a nuclear 
phosphoprotein that acts as a tumour suppressor and is inactivated in breast 
and ovarian cancers. BRCA1 is regulated through the cell cycle by CDK2 and 
also in response to DNA damage by Cds1, and its phosphorylation prevents 
its activity in attenuating the cell cycle (Lee, et al, 2000). The growth factor 
family of heregulins have been implicated in the survival of breast cancer cell 
lines, and are known to inactivate BRCA1 via Akt/PKB-mediated 
phosphorylation of Thr509 (Altiok, et al, 1999). Furthermore, inactivation of 
BRCA1 has been shown to be enhanced by the extracellular matrix (ECM), 
which often interacts abnormally with tumour cells to promote invasion of 
surrounding tissue (Miralem & Avraham, 2003).
In addition to the substrates discussed in detail above, new targets of 
Akt/PKB are continually adding to the repertoire of this kinase in regulating 
cell survival via multiple pathways. Recent discoveries include the negative 
regulation of Elk-1 mRNA translation, a transcription factor downstream of 
MAPK signalling (Figueroa & Vojtek, 2003) and the MAP kinase activator Raf 
in some cell lines (Zimmerman & Moelling, 1999). Direct phosphorylation 
and inhibition of the CDK inhibitor p27kip1 at Thr198 and Thr157 by Akt/PKB 
has been reported, preventing constraint of G1 progression by relocalising 
p27k,p1 to cytoplasmic 14-3-3 proteins (Shin, et al, 2002 and Fujita, Sato & 
Tsururo, 2003). Akt/PKB also causes IGF-induced phosphorylation of WNK1 
(with no K [lysine] protein kinase-1) on Thr60, a kinase that is mutated in an 
inherited hypertensive disorder (Vitari, et al, 2003).
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1.2 PTEN Tumour Suppressor & PI3K Signalling
The importance of regulating intracellular signalling is dramatically illustrated 
by the many disorders resulting from mutation or otherwise inactivation of the 
genes which govern these pathways. The most prominent pathological 
process is cancer, described as a disease of the cell cycle, whose many 
forms provide insight into the complexities of cell life and death. Many genes 
have been characterised in the role of guardian of the cell cycle, termed 
proto-oncogenes and tumour suppressors. Of the latter p53 and Rb are 
perhaps the best understood, but recently a new tumour suppressor was 
isolated. Called PTEN, this gene rivals p53 for the most commonly mutated 
gene in human cancer.
1.2.1 PTEN - A Tumour Suppressor Discovered Twice
In 1997 a novel tumour suppressor gene was simultaneously discovered by 
two groups focussing on the high incidence of mutations and allelic loss on 
human chromosome 10. The gene, which localised to the long q arm at locus 
23.3, was named PTEN (Phosphatase and Tensin Homologue Deleted on 
Chromosome Ten, (Li, et al, 1997) and MMAC-1 (Mutated in Multiple 
Advanced Cancers-1, Steck, et al, 1997) respectively. A third group 
submitted their findings shortly afterwards, named the gene TEP-1 (TGF-p 
Regulated and Epithelial Cell Enriched Phosphatase-1, (Li & Sun, 1997). As 
the names suggest, analysis of PTEN cDNA revealed a sequence coding for 
a 403 amino acid 55KDa protein of 9 distinct exons, with N-terminal 
homology to the cytoskeletal proteins auxilin and tensin. The sequence also 
contained a highly conserved catalytic motif IHCKAGXXRTG at residues
18
122-133 (Denu & Dixon, 1995 and Tonks & Neel, 1996), which is found in 
protein tyrosine and dual-specificity phosphatases (PTP and DSP). DSPs, 
such as yeast CDC14 (Li, et al, 1997) and PTPs, such as the yeast PTEN 
homologue CDC25 (Flint, et al, 1997 and Li & Sun, 1997), are components of 
signal transduction and the cell cycle regulatory machinery in S.cerevisiae. 
The presence of the phosphatase motif therefore indicated a possibly crucial 
role for PTEN as a protein tyrosine phosphatase in cell cycle modulation, and 
therefore in the development of cancer.
1.2.2 PTEN Structure and Function
1.2.2.1 PTEN Gene and mRNA Structure
Although the cDNA sequence for PTEN (illustrated in Appendix II) has been 
known for some years, it is only recently that the 5’ promoter region upstream 
of the PTEN genomic sequence has been described. A lack of classical 
promoter motifs, such as TATA boxes, added to the question of how PTEN 
mRNA was transcribed. Sheng, et al (2002) investigated this problem by 
constructing various minimal promoter cassettes from a 2212bp genomic 
fragment previously cloned by Steck, et al, (1998) named BAC-46B12. This 
fragment contained a portion of the 5’ untranslated region of exonl and a 5’ 
portion of the flanking PTEN sequence. The investigation revealed nine 
potential transcription start sites from -958 to -821 prior to the initiation codon 
ATG (+1) in a 599bp fragment termed the minimal promoter region. Of these, 
three sites at -972, -869 and -837 were identified as potential major 
transcription initiation sites, with the 137bp prior to +1 being the absolute
19
minimum required for transcription. The minimal promoter region is shown 
schematically in Figure 2.
Additional features uncovered by Sheng, et al (2002) included several 
consensus sites for binding transcription factors including Sp1 and Egr- 
1 (between -958 and -821), which may have opposing effects on promoter 
activity. The cyclin inhibitor p15INK4B is upregulated by TGF-01 via Sp1 (Feng 
& Derynck, 2000), suggesting that Sp1 may play a role in PTEN expression. 
The presence of a p53 binding site was investigated but the group found that 
p53 caused only a modest increase in PTEN expression. The relationship 
between p53 and PTEN is discussed in detail further in this section.
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1.2.2.2 PTEN Protein: A Structure-Function Relationship
As previously mentioned, analysis of the PTEN sequence revealed an N- 
terminal phosphatase domain, and also C-terminal putative phosphorylation 
sites. Notably, the protein lacked a nuclear location sequence, and appeared 
to be cytoplasmically located. The determination of the crystal structure of 
PTEN by Lee, et al, (1999) gave greater insight into the functional aspects of 
this protein. The resolved structure is shown in Figure 3.
The structure revealed several interesting features of PTEN. Firstly, the PTP- 
like N-terminal domain forms part of an enlarged active site, and the C- 
terminus contains a C2 domain. Calcium independent C2 domains bind lipid 
vesicles in vitro, and the presence of a membrane-binding motif in addition to 
the active site is common in enzymes against inositol phospholipids 
substrates (Lee, et al 1999). A PDZ motif found in protein-protein interaction 
domains (Kocher, et al 2003) was located in the C-terminus, as were two 
PEST sequences which target proteins for degradation (Rogers, et al 1986). 
The domains are shown in cartoon form in Figure 3.
Initial studies to determine the physiological substrate(s) of PTEN indicated 
that phosphoproteins and peptides were not major targets, due to weak 
activity of the enzyme. Highly acidic peptides did undergo dephosphorylation 
by PTEN in vitro (Myers, et al, 1997 & Maehama & Dixon, 1998), but the 
major cellular substrate was found to be PI3,4,5P3 which is 
dephosphorylated to PI3,4P2. PTEN was therefore characterised as a lipid 
phosphatase, and its connection to the PI3K pathway was established 
(Myers, et al, 1998, Maehama & Dixon, 1999 & Stambolic, et al, 1998).
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Figure 3 The Crystal Structure of PTEN
A .The structure of PTEN as determined by Lee, J. O., et al (1999), PDB 
1DR5. The N-terminus is composed of p-sheets surrounded by a-helices and 
the C-terminus is composed of p-sheets. The catalytic site in the 
phosphatase domain is shown as red ball-and-stick area. B. Cartoon 
representation of PTEN. N-terminal phosphatase domain (aa 1-185 & 
catalytic motif 123-130), C-terminal domain (186-403) with C2 (186-351), 
PEST (350-375 & 379-396) and PDZ. Phosphorylation sites for CK2 (S380, 
T382 & T383) shown as a circled P.
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In light of its substrate PI3,4,5P3, the features of the PTEN protein and their 
relevance to possible function are discussed below.
C-Terminal Domain
This domain contains C2, PDZ and PEST domains found in many other 
signal transducing molecules. The C2 domain, as previously mentioned, is 
associated with phospholipids and membrane binding. The C2 domain of 
PTEN does bind to phospholipid membranes in vitro (Rizo & Sudhof, 1998 & 
Hurley & Meyer, 2001) but lacks the acidic residues for Ca2+ binding seen in 
Ca2+-dependant lipid phosphatases (Hurley, et al 2000). Functionally, 
mutations in this domain dramatically reduce lipid binding and cellular levels 
of PI3,4,5P3 are not reduced (Georgescu, et al, 2000 & Leslie, et al, 2001). 
Many mutation studies have shown that the minimal catalytic unit consists of 
the phosphatase and C2 units. Removal of a few bases in the C2 region is 
sufficient to disrupt all phosphatase activity, even against soluble PI3,4,5P3. 
Mutations in the C-terminal tail distal to the C2 domain however have little 
effect on catalysis (Georgescu, et al, 1999 & Tolkacheva & Chan, 2000.) It is 
thought that the C2 domain may not only allow PTEN to associate with 
membranes, but also to ensure the correct orientation of the active site 
relative to PI3,4,5P3 (Georgescu, et al, 2000).
The PDZ motif has been observed to affect the stability but not the activity of 
PTEN against lipid substrates (Georgescu, et al, 1999), but deletion of the 
PDZ disrupts cell spreading (Leslie, et al 2001). Work by Wu, et al, 2000a & 
Wu, et al, 2000b demonstrated a PDZ-specific interaction between PTEN 
and MAGI-2 and -3 (membrane-associated guanylate kinase inverted)
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scaffold proteins. This interaction enhanced the ability of very low levels of 
PTEN to act on its substrate, suggesting such interactions may have a role in 
regulating PTEN activity and stability.
The two PEST sequences are also apparently required for stabilising the 
PTEN protein. Deletion of these motifs can cause a decrease in expression 
of the protein, but can also increase phosphatase activity of some C2 domain 
mutants (Georgescu, et al, 1999 & 2000). When phosphorylated the second 
PEST sequence can decrease PTEN activity (Vazquez, et al, 2000), 
suggesting that modifications to the PEST sequences can alleviate abnormal 
C2 mutations. Possible conformational changes may occur to correct the 
function of C2 mutants in a manner observed for p53 mutants (Foster, et al,
1999).
Finally, the C-terminus also contains several phosphorylation sites located in 
the last 50 amino acid "tail” of exons 8 and 9. These sites may be essential 
for PTEN stability and have a role in regulating cellular levels and activity of 
the protein. Phosphorylation of the C-terminal tail has been observed by 
protein kinase CK2 (Torres & Pulido, 2001) and is discussed further in this 
section.
N-Terminal Domain
The N-terminal domain contains the catalytic phosphatase core with the 
conserved motif residing in exon 5 at amino acids 123-130 (see Figure 3). 
Although similar to other protein phosphatases (PTPases and DSPs), the 
active site of PTEN is somewhat larger. For example, the active cleft of 
PTP1B is narrow and deep whereas that of the DSP VHR is shallower
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(Tonks & Neel, 2001). The enlarged active site of PTEN is deep but also 
broad to accommodate the large inositol ring headgroup, and highly basic 
reflecting its preference for acid substrates (Lee, et al, 1999). Mutations are 
common in this region with ~30% of somatic and germline changes affecting 
exon 5. Mutations, and their associated diseases, are discussed in Section 
1.5. Recently, the N-terminus has been shown to be involved in membrane 
targeting, and along with the C2 domain may ensure correct orientation of 
PTEN relative to its acidic substrate. Moreover, disruption of the N-terminal 
motif prevents catalysis of substrate in vivo, which can be restored by adding 
a myristoylation signal which enables targeting to the plasma membrane 
(Walker, et al, 2004).
Nuclear Localisation
As PTEN targets PI3,4,5,P3 it is ubiquitously expressed in the cytoplasm and 
has no nuclear location sequence (repeated positive aa flanked by proline 
residues), therefore little study was allocated to nuclear PTEN. Now, 
however, several immunohistochemical studies have reported PTEN in the 
nucleus of normal cells, with a shift to cytoplasmic localisation in 
corresponding tumour cells (Perren, et al 2000, Gimm, et al 2000, Tachibana, 
et al 2002 & Whiteman, et al 2002). Nuclear PTEN has been associated with 
G0 -Gi in MCF-7 breast carcinoma cells, whereas the protein accumulates in 
the cytoplasm during S-phase, suggesting PTEN may directly regulate the 
cell cycle in the nucleus (Ginn-Pease & Eng, 2003). Differential localisation of 
PTEN in immature, mature and differentiating neural cells also indicates a 
role for nuclear PTEN in CNS development (Lachyankar, et al 2000).
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Regulation of Protein Activity
Phosphorylation of the C2 Domain
As previously mentioned the 50 amino acid C-terminal ‘tail’ of PTEN protein 
contains several phosphorylation sites. Ser380, Thr382 and Thr383 are 
required to be phosphorylated to stabilise the protein, but this stabilisation 
may also reduce activity (Vazquez, et al 2000) and association with PDZ 
proteins (Adey, et al 2000). Constitutive P-PTEN has been observed in acute 
myeloid leukaemias and is associated with advancement of the disease and 
poor clinical outcome (Cheong, et al 2003). The protein kinase CK2 has been 
shown to phosphorylate Ser370, 380 and 385, and Thr383 and this appears 
to prevent degradation by the proteosome, thus influencing PTEN protein 
levels. (Torres & Pulido, 2001). This has very recently been investigated in 
vivo using cilostazol, a 3-phosphodiesterase inhibitor used as an anti-platelet 
drug which is neuroprotective. This drug decreased CK2-mediated PTEN 
phosphorylation in both ischemic rat brains (Lee, J. H., et al 2003) and SK-N- 
SH neuroblastoma cells (Kim, et 2003b), thus permitting degradation of 
PTEN and activation of Akt/PKB. However, mechanisms controlling the 
degree to which PTEN is phosphorylated are unknown.
Vazquez, et al (2001) have proposed a mechanism in which phosphorylation 
of the tail causes a conformational change from ‘open’ to ‘closed’ and 
prevents the recruitment of PTEN into protein complexes by masking the 
PDZ domain. The recruitment of PTEN into the protein complex may permit 
targeting to the membrane to bind PI3,4,5P3, therefore phosphorylation of 
the tail would effectively inhibit the lipid phosphatase function of PTEN. A 
second proposal by Das, et al (2003) suggests that phosphorylation of the tail
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does not block the PDZ domain, but interferes with the electrostatic 
membrane binding capability of the protein. By blocking membrane docking, 
phospho-PTEN is not degraded, but it is still not clear how even the 
membrane-bound form is degraded or whether a phosphatase exists to 
dephosphorylate PTEN.
Another phosphorylation-dependant mechanism of PTEN regulation may be 
via Src family kinases. Lu, et al (2003) demonstrated that Src family kinases, 
but not purified Src or Lck, can tyrosine-phosphorylate PTEN, suggesting an 
intermediary protein is involved. The 5-phospholipid phosphatase SHP-1 can 
regulate Src kinases and dephosphorylate many Src targets (Somani, et al, 
1997 & Cuevas, et al, 1999), and can regulate PI3,4,5P3 via PI3K (Freeburn, 
et al, 2002 & Lu, et al 2003). It is possible therefore that SHP-1 may restore 
the function of PTEN by acting as a PTEN phosphatase (Lu, et al 2003). 
Recently, fluorescent microscopy has indicated that nuclear PTEN in VCSM 
cells is phosphorylated and its activity reduced, whilst the 5’-phospholipid 
phosphatase SHIP-2 is active. The presence of nuclear PI4,5P2 and 
PI3,4,5P3 has been reported in may cell lines, but their role in the nucleus is 
unclear (Deleris, et al 2003).
C2 phosphorylation also appears to protect PTEN from cleavage by TNFa- 
activated caspase-3, which also targets MAGI-2 scaffold proteins to which 
PTEN has been shown to associate with. Torres, et al, (2003) have identified 
several aspartate residues in the C2 domain of PTEN which are targeted by 
caspase-3, and these sites overlap with the CK2 phosphorylation sites in this 
region. The group demonstrated that phosphorylation by CK2 blocks 
caspase-3 cleavage, and may therefore protect PTEN from cleavage. During
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apoptosis, cleavage of the C2 domain could change the interaction of PTEN 
with structural and regulatory proteins, such as MAGIs, and vault proteins 
which are involved in nuclear-cytoplasmic transport (Yu, et al 2002).
I n h i b i t i o n  o f  t h e  C a t a l y t i c  s i t e
A study analysing the effect of oxidative stress on PTEN levels has revealed 
that reactive oxygen species (ROS), which are produced as a by-product of 
metabolism, by macrophages, and through growth factor signalling (Meng, et 
al 2002), could decrease PTEN activity (Leslie, et al 2003). ROS have 
previously been shown to inactivate and regulate PTPs by oxidising a critical 
cysteine in the active site (Tonks & Neel, 2001).These enzymes, including 
PTEN, therefore require reducing conditions for catalysis (Maehama & Dixon, 
1998).
The findings of Leslie, et al (2003) indicated that as tumours, and some 
specialised immune cells such as phagocytes, produce high levels of ROS, 
this may represent a mechanism by which these cells down-regulate PTEN 
activity and thus evade apoptosis. Moreover, the ROS can be produced by 
the NADPH oxidase complex in the plasma membrane by binding PI3,4,5P3 
(Welch, et al 2002). As PTEN’s substrate PI3,4,5P3 is in close proximity to 
the ROS-producing complex, increases in PI3,4,5P3 via receptor signalling 
could be a mechanism of actually inhibiting PTEN.
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1.2.3 PTEN & Attenuation of PI3K/Akt Signalling
Activation of the serine/threonine protein kinase Akt/PKB by PI3,4,5P3 is an 
important mechanism in cell survival, but one which must therefore be 
regulated. The observation that expression of PTEN caused an increase in 
levels of inactivated non-phosphorylated Akt indicated that PTEN prevents 
phosphorylation of Akt/PKB, thus antagonising PI3K activity. Conversely, 
deletion of PTEN results in constitutively activated, phosphorylated Akt 
(Cantley & Neel, 1999). By restraining Akt activation, PTEN could therefore 
prevent the activation of Akt substrates such as mTOR, PDE-3B and IKK, 
and promote activation of pro-apoptotic substrates such as BAD and FOXOs. 
The main physiological substrate of PTEN is the phosphatidylinositol lipid 
PI3,4,5P3, which is specifically dephosphorylated by PTEN at the 3’ position 
on the inositol ring. The role of PTEN in the restriction of PI3K signalling and 
Akt/PKB activation is illustrated in Figure 4. Recently, an activation 
mechanism has been described for PI3,4,5P3 binding. In this model, PI4.5P2 
binds to a distinct N-terminal site on PTEN and causes an allosteric 
conformational change in the active site which favours PI3,4,5P3 binding. A 
feedback loop therefore exists as PTEN regenerates its activator PI4,5P2 
from PI3,4,5P3 (Campbell, et al 2003).
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Several components of the Akt/PKB pathway, including PTEN, are highly 
conserved in C. elegans (DAF-18) and D. melanogaster (dPTENJ, 
underlining an evolutionarily important mechanism in development and 
homeostasis (Huang, et al 1999, & Gao, et al 2000). Work by Myers, et al 
(1998) and Furnari, et al (1999) revealed human mutations of PTEN in both 
germline and sporadic tumours which disrupted the lipid phosphatase 
activity. Additionally, PTEN-null cell lines (Myers, et al (1998) and murine 
PTEN-/- fibroblasts (Stambolic, et al, 1998) showed increased levels of 
PI3,4,5P3. The PI3K inhibitor LY294002 can also mimic the effects of PTEN 
by effectively blocking Akt/PKB phosphorylation (Li & Sun, 1998).
Although PTEN reduces activation of Akt and therefore prevents cell cycle 
progression, the ultimate fate of the cell depends upon the cell type. PTEN 
can either cause G1 arrest or apoptosis via inhibition of the PI3K pathway, 
and evidence for these outcomes will be discussed.
1.2.3.1 PTEN & Induction of Cell Cycle Arrest
The mechanism by which PTEN can induce cell cycle arrest has been 
studied in a variety of cell types, but the consensus implicates inhibitors of 
cyclin-dependent kinases p27Kip1 as a target for PTEN. The induction of G1 
cell cycle arrest in PTEN-null cell lines by addition of wild-type PTEN has 
been noted in the glioblastoma cell lines U87-MG and U178 (Li & Sun, 1998, 
Furnari, et al 1998 & Cheney, et al., 1998), 768-0 renal carcinoma cells 
(Ramaswamy, et al 1999) MCF-7 (Weng, et al 1999) and ZR-75 (Hlobilkova, 
et al., 2000) breast cancer cell lines, several thyroid carcinomas (Weng, at al, 
2001a), two bladder cancer cell lines (Tanaka, et al 2000) and several cell
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lines of endometrial origin (Matsushima-Nishiu, et al 2001). This effect was 
only observed under low-serum conditions, suggesting that serum 
components such as mitogens can modulate the function of PTEN. 
Furthermore, addition of mutant forms of PTEN into the glioblastoma cell 
lines indicated that only the lipid phosphatase activity was essential for 
growth suppression by G1 arrest (Furnari, et al, 1998).
P27Kip1
It has been shown by several groups that G1 growth arrest by PTEN is 
effected by up-regulation of p27K,p1 and down-regulation of cyclin D1 
(Cheney, et al 1999, Medema, et al 2000, Weng, et al 2001b & Gottschalk, et 
al 2001), cyclin D3 (Zhu, et al 2001) or cyclins A, and B (Seminario, et al, 
2003), and inhibition of Rb phosphorylation (Lu, et al, 1999, Paramio, et al 
1999 & Radu, et al 2003). Notably, the expression of p27Kip1 is reduced in 
various tumour cell lines (Graff, et al 2000, Gesbert, et al 2000 & Yang, et al
2000).
By mutating key residues in the active site of PTEN, Weng, et al (2001b) 
determined that PTEN down-regulates cyclin D1 through its ambiguous 
protein phosphatase activity but up-regulates p27Kip1, p57 and p21 (Wu & Li,
2000) via downstream events orchestrated through the lipid phosphatase 
activity. The p27Kip1, p57 and p21 CDK inhibitors are therefore up-regulated 
via the inhibition of Akt/PKB by PTEN, possibly via activation and nuclear 
translocation of Forkhead transcription factors (FOXOs).
Nakamura, et al (2000) demonstrated that a constitutively expressed form of 
FKHR (Fox01) which could not be phosphorylated by Akt/PKB could cause
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G1 arrest or apoptosis in PTEN-null cells. PTEN also appears to be capable 
of affecting not only transcription of p27Kip1 but also the stability of the protein. 
Inhibition of Akt/PKB by PTEN causes a decrease in the levels of the 
ubiquitin E3 ligase SCFSKP2 which degrades p27KIP1, thus contributing to 
p27KIP1 protein accumulation (Mamillapalli, et al 2001 & Nakayama, et al
2001). Interestingly, treatment of nasopharangeal carcinoma cells with 
ceramide induced G1 arrest and up-regulation of p27Kip1 in a PTEN/PI3K 
independent manner, possibly via dephosphorylation of Akt by CAPP, a 
ceramide-activated protein phosphatase (Zhu, et al 2003).
GSK30 and 0-catenin
Other possible elements involved in the induction of G1 arrest by PTEN as a 
protein phosphatase are GSK3p, involved in insulin-mediated signalling and 
the signalling/cell adhesion protein p-catenin (Polakis, 1998). p-catenin is 
involved in many pathways, with complex regulation, and when activated 
enters the nucleus to effect gene transcription (Stambolic, 2002). Two 
possible mechanisms of control by PTEN over the level of cyclin D1 have 
recently been proposed by Radu, et al, 2003.
The first is via phosphorylation of nuclear cyclin D1 by GSK3p-mediated 
phosphorylation and inactivation of p-catenin, and the subsequent export of 
cyclin D1 to the cytoplasm for degradation. GSK3p is activated when 
Akt/PKB is inhibited, thus PTEN may inhibit transcription and promote 
degradation of cyclin D1 by preventing nuclear accumulation of the protein. In 
support of this mechanism, levels of activated nuclear p-catenin have been 
shown to be reduced by exogenous PTEN expression (Persad, et al 2001).
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Additionally, some tumours show activating mutations in the degradation 
targeting box of p-catenin, which is normally phosphorylated to cause nuclear 
exclusion and breakdown of the protein (Koch, et al 1999, Fukuchi, et al 1998 
& Palacios & Gamello, 1998).
The second mechanism proposes that PTEN decreases cytoplasmic ‘free’ 
cyclin D1 by a GSK3p-independent pathway, which has been reported 
previously (Germain, et al (2000), although the exact mechanism of 
degradation is unknown. The novel tumour suppressor MDA-7 has recently 
been shown to down-regulate PI3K, redistribute p-catenin to the cytoplasm 
and up-regulate GSK3p and PTEN levels in breast and tumour cells, adding 
another regulatory mechanism to these pathways (Mhashilkar, et al 2003).
1.2.3.2 PTEN & Induction of Apoptosis
Reconstitution of wild-type PTEN into some PTEN-deficient cell lines may 
induce apoptosis rather than cell cycle arrest. Restoration of wild-type PTEN 
to several breast cancer cell lines induced G1 arrest followed by apoptosis 
(Li, et al., 1998) and similar results have been observed in endometrial cell 
lines (Sakurada, et al., 1999). Apoptosis was also induced by PTEN 
restoration into glioma cell lines (Davies, et al, 1998, Wick, et al 1999 & Tian, 
et al.,1999). Under serum-starved conditions apoptosis is induced rapidly in 
breast cancer cells (Lu, et al, 1999) and more slowly in prostate carcinoma 
cells (Davies, et al, 1999). One explanation is that under conditions where 
apoptotic stimuli are absent (eg Fas ligand, TNF) PTEN causes early G1 
arrest. PTEN could then inhibit survival by growth factors and induce
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apoptosis, depending upon the strength of the proliferative extracellular 
signal (Di Christofano & Pandolfi, 2000).
clAP (Inhibitor of Apoptosis) Proteins
It has been shown that PTEN reconstitution into PTEN-null endometrial cell 
lines Ishikawa and RL-95-2 causes a decrease in expression of the survival 
factor clAP-1 (Gagnon, et al, 2003). Human inhibitors of apoptosis, (IAP), 
proteins belong to a family consisting of six members which can inhibit the 
proteolytic activity of caspase-3, -6 and -7. Downstream activation of pro- 
casapase 9 is therefore prevented, and the cell escapes apoptosis induced 
by pro-apoptotic stimuli such as Fas, chemotherapeutic agents and serum 
starvation (Wang, et al 2003).
NFkB
PTEN may also initiate apoptosis via the inhibition of NFkB induced by TNF- 
a. This has been shown to occur via two possible mechanisms. Firstly, by 
inhibition of Akt/PBK which can activate IKKa and NFkB, in a manner that 
appears to be cell-type specific (Gustin, et al 2001). Secondly, PTEN has 
been shown to inhibit NFkB independently of IkB degradation (Koul, et al
2001), possibly by preventing TNF-mediated activation of the p65 
transactivation domain of NFkB, which is essential for activating the NFkB 
complex (Mayo, et al 2002). The exact mechanisms are yet to be 
determined, and may involve complex feedback regulation of PTEN itself by 
the NFkB pathway (Kim, et al, 2003).
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1.2.4 Expanding the Cellular Role of PTEN
PTEN has become established as a key player in the regulation of 
phospholipid signalling through Akt/PKB, but a definitive in vivo substrate for 
its in vitro protein phosphatase activity remains elusive. Additionally, other 
downstream effects of PTEN are becoming apparent, suggesting that the 
tumour suppressor could be involved in multiple signalling pathways involving 
both protein and lipid phosphatase functions.
1.2.4.1 PTEN & Cell Migration
As PTEN is a protein phosphatase in vitro against acidic phospho- 
Tyr/Ser/Thr peptides, it has been postulated that the integrin-mediated 
signalling proteins FAK (focal adhesion kinase) and She may be targets. 
These proteins are involved in cell motility and spreading, and modulation by 
PTEN could contribute to growth suppression. Loss of PTEN is correlated 
with anchorage-independence, and in PTEN-null tumour cells expressing 
exogenous PTEN, forced detatchment from the ECM causes up-regulation of 
PTEN (Wu, et al 2002). PTEN does exhibit dephosphorylation of FAK and 
She in vitro, and work by Gu, et al (1998) & Tamura, et al (1998 & 1999) 
proposed this to be the case in vivo using U87-MG cells.
However, lipid phosphatase mutants of PTEN with intact protein phosphatase 
activity have been shown to have no effects on FAK phosphorylation or 
motility (Maier, et al, 1999 & Liliental, et al, 2000), and other groups have 
been unable to repeat the original work in U87-MG. Additionally, evidence 
may link PTEN directly to FAK and She through its normal lipid phosphatase 
role in the Akt/PBK pathway (Lopez-llascala, et al, 1997 & Casamassima &
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Rozengurt, 1998), thus implicating PTEN in MAPK pathway responses. 
Work in human PC3 cells implicates the integrin-linked kinase (ILK) in 
attachment. Here, ILK is bound and activated by the ILK-activating proteins 
CH-ILKBP and localised to focal adhesions, where Akt/PKB is stimulated and 
GSK3p is inhibited. The generation of PI3,4,5P3 further activates ILK, 
causing re-organisation of F-actin and paxillin to direct attachment and 
migration. PTEN appears to disrupt the ILK:CH-ILKBP complex by an 
unknown mechanism (Attwell, et al 2003).
It now appears that mechanisms exist to compartmentalise PTEN during 
chemotaxis and prevent it from disrupting complexes forming at the leading 
edge of the motile cell. Recent studies in mammalian leukocytes and the 
amoebae D. discoideum have shown that when sensing cAMP as a 
chemoattractant, PI3K localises to the leading edge of the cell where a 
PI3,4,5P3 gradient forms. This enhances signalling through Akt/PKB and 
directional movement, whilst PTEN is localised to the posterior away from the 
concentrated PI3,4,5P3.
Cells lacking PTEN show multiple, random pseudopodia and a lack of 
directional movement (Comer & Parent, 2002 & lijima & Devreotes, 2002). 
The localisation mechanisms of PI3K and PTEN are currently under 
investigation. In D. discoideum, recent work suggests that activation of 
chemoattractant receptors provides G-protein-coupled binding sites on the 
cytosolic face of the plasma membrane which bind PI3Ks at the leading edge 
(Huang, et al 2003).
A study of chemotaxis in neutrophils concurred with the findings in D. 
discoideum, and described a mechanism for localising PTEN via the
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cytoskeletal proteins PIXa (PAK-associated guanidine nucleotide exchange 
factor) and Cdc42. In this system, the two proteins direct F-actin formation at 
the leading edge, but PIXa actively repels PTEN (Zhong, et al 2003).
1.2.4.2 PTEN and Regulation of Pathways Other Than PI-3 kinase 
MAPK Signalling
The MAP and ERK kinase pathways are activated in response to binding of 
cell surface receptors such as EGF, or the interaction of integrins with the 
extracellular matrix to control adhesion, growth and differentiation. The 
pathways are redundant and partake in complex cross-talk; a diagrammatic 
overview of MAPK/ERK is shown in Figure 5. The She adaptor couples 
receptor tyrosine kinases and associated receptors to these pathways, and is 
believed to be regulated by recruitment from the cytosol to the plasma 
membrane. Here, it binds Grb-2/Sos complexes and causes transfer of the 
guanine nucleotide exchange factor Sos to Ras, resulting in Ras activation 
(Plyte, et al 2000). Downstream of Ras are members of the Raf family which 
activate MAPKs/ERKs and/or JNK/SAPK to effect gene transcription.
PTEN has been shown to be involved in the MAP/ERK kinase pathway in 
several ways. Firstly, PTEN can act in a Shc-dependant manner, 
dephosphorylating this protein and inhibiting the formation of Grb-2/Sos 
complexes and thus activation of Ras (Gu, et al 1998). Secondly, PTEN can 
inhibit MAPK and ERK via Shc-independent mechanisms involving Gab1 and 
IRS. Gab1 contains a PH domain that interacts with PI3,4,5P3-rich 
membranes (Ong, et al 2001) via PI3K and the tyrosine phosphatase SHP2.
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MAPK/ERK in Growth and Differentiation
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Dephosphorylation of PI3,4,5P3 could prevent Gab1 from interacting with 
SHP2, thus inhibiting MAPK activation (Yart, et al 2001). Recently, Gab1 
decoys have been shown to inhibit EGF-induced ERK and Atk/PKB activation 
in tumour cell lines lacking functional PTEN (Ren & Wu, et al 2003).
Several groups have now reported that PTEN negatively regulates ERK- 
mediated signalling of estradiol in endometrial carcinoma (Zhang, et al 2003) 
and hepatoma cell lines (Marino, et al 2003), and that ERK may regulate 
PTEN levels. Binding of PDGF to its receptor activates both PI3-K and 
ERK/MAPK pathways. Work by Mahimainathan & Ghosh (2004) has 
demonstrated that PTEN binds directly to the cytosolic domain of the PDGF 
receptor through its C2 and C-terminal domains, causing dephosphorylation 
of the autophosphorylated tyrosine residues in the receptor. The group 
propose that PTEN may inactivate other receptors, such as for EGF, in this 
manner to regulate signalling in the absence of ligand binding.
A role for PTEN in negatively regulating BCR (B-cell antigen receptor)- 
mediated proliferation has recently been described (Brown, et al 2004). The 
low-affinity IgG receptor FcyRllb, involved in immune regulation, is thought to 
recruit PTEN and the immune cell-restricted 5’ inositol phosphatase SHIP 
(Kalesnikoff, et al 2003). PTEN converts PI3,4,5P3 to PI,4,5P2, whilst SHIP 
uncouples BCR from the GTPase Ras and converts PI3,4,5P3 to PI3,4P2, 
the overall effect being to prevent ERK/MAPK activation.
The involvement of PTEN in insulin signalling is well known, and it is believed 
that it may achieve attenuation of the pathway via direct dephosphorylation of 
IRS-1. This would prevent the formation of an IRS-1/Grb2/Sos complex and 
thus MAPK activation (Weng, et al 2001c & Yeon, et al 2003). Up-regulation
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by PTEN of IRS-2, which is a component of insulin signalling, has also been 
observed (Simpson, et al, 2001). Work by Weng, et al (2003) has 
demonstrated that in MCF-7 breast cancer cells, PTEN can inhibit insulin- 
mediated signalling, but not EGF-mediated signalling, by blocking 
phosphorylation of the transcription factor ETS-2. This was shown to occur 
independently of PI3K via ERK/MAP kinases, and involved the protein 
phosphatase activity of PTEN. The apparent specificity of PTEN as a protein 
phosphatase for different receptor tyrosine kinases implies that the role of 
PTEN may be cell-type specific, and that therapeutic targeting of PI3K/Akt in 
some cancers may not be effective.
Hypoxia & Angiogenesis
Under ‘normoxic’ conditions, PTEN has been shown to downregulate 
hypoxia-inducible factor 1a (HIF-1a), normally expressed under low oxygen 
conditions or by EGF stimulation (Zhong, et al 2000 & Zundel, et al 2000). 
HIF-1a is a transcriptional activator of genes for glucose transporters, 
glycolytic enzymes and VEGF, the latter of which is commonly up-regulated 
in tumours and increases vascularisation. Recently, restoration of PTEN into 
glioma cells has shown that PTEN down-regulates HIF-1a and VEGF 
expression, with an increase in p27K,p1 orchestrated via PI3K and not 
p38/MAPK (Gomez-Manzano, et al 2003 & Abe, et al 2003). Similar findings 
have been made in gastric carcinomas, where a lack of PTEN causes 
increased MMP-7 expression, (Zheng, et al 2003) which could synergise with 
VEGF to contribute to increased angiogenesis and invasiveness. 
Conversely, over-expression of wild-type PTEN in primary microvascular
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endothelial cells stimulated with VEGF caused inhibition of angiogenesis 
(Cai, et al 2003). Interestingly, in cells lines with abnormally expressed pro- 
apoptotic Myc, which cannot activate p53 death genes (Bringold & Serrano,
2000), PTEN and HIF transcription were unaffected and hypoxia-induced 
death occurred by other mechanisms (Brunelle, et al 2003). It is now known 
that a close relationship exists between PTEN and p53, which will be 
discussed in Section 1.3.
Androgen Insensitivity
Androgen insensitivity is a feature of some prostate cancers, and it has been 
demonstrated that androgens can protect prostate cancer cells from PTEN- 
induced apoptosis via Akt/PKB (Li et al 2001). This is probably due to 
aberrant ligand binding and activation of the androgen receptor (AR), or 
activation via MAPK pathways (Ueda, et al 2002) which could explain why 
the AR is required for survival. Unsurprisingly, loss of functional PTEN could 
enhance AR signalling and progression to the androgen independent state 
(Nan, et al 2003). The exact mechanisms involved are controversial, but 
evidence exits for two Akt consensus sites, Ser213 and 791, in AR which Akt 
can phosphorylate to activate the receptor (Lin, et al 2001).
Antagonism of PI3K by PTEN therefore leads to negative regulation of AR 
signalling in an Akt-dependant manner (Sharma, et al 2002), and down- 
regulation of the AR co-activator p-catenin has also been observed in this 
model (Trucia, et al 2001). Another group have recently detected binding of 
FKHR/FOX01 to the NT region of AR which prevents transcription of pro-
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apoptotic genes. As Akt/PKB can also inhibit FOXOs, this may represent 
multiple mechanisms by which prostate cancers survive (Li, et al 2003).
Inositol Phosphates and PTEN Substrate Specificity
It is accepted that inositol lipids and inositol phosphates have their own 
dedicated phosphatases and kinases, with little cross-over in substrate 
specificity. Until recently, PTEN was thought to exhibit negligible activity 
towards inositol phosphates and has been shown to be a poor 3’ 
phosphatase towards inositol 1,3,4,5-tetrakisphosphate (lns(1,3,4,5)P4) 
(Maehama & Dixon, 1999). Evidence was presented for the hydrolysis of 
inositol 1,3,4,5,6-pentakisphosphate (lnsP5) by PTEN in vitro via its 3’- 
phosphatase activity to lns(1,4,5,6)P4 (Caffrey, et al 2001). lns(1,4,5,6)P4 is 
an antagonist of PI3,4,5P3 (Eckmann, et al 1997) and these substrates could 
theoretically compete for PTEN binding. lns(1,4,5,6)P4 is also associated 
with transcriptional regulation (Odom, et al 2000), and Rho-GTPase 
activation (Zhou, D et al, 2001).
Work by Orchiston, et al (2003) suggest that wild-type PTEN, which is active 
against 3’ phosphatidylinositol phospholipids, does not regulate inositol 
phospholipids in vivo. This group used a C2 domain mutant form of PTEN 
(M-CBR3) initially described by Lee, et al (1999). The mutant had little effect 
on 3-phosphoinositide lipids, but selectively dephosphorylated lnsP5. 
Decreased levels of lnsP5 corresponded with a decrease in cell growth and 
anchorage-independence, suggesting that lnsP5 acts as a proliferative agent 
of unknown physiological role.
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1.3 Regulation of PTEN Expression
Despite the large amount of data regarding the role of PTEN in the control of 
various important pathways, detail regarding the regulation of mRNA and 
protein levels has only recently begun to emerge. Several mechanisms have 
been proposed for the regulation of PTEN expression, including 
transcriptional control via interaction with p53, PPARy and Egr-1, promoter 
methylation (see Section 1.5) and modulation of protein expression by 
cytokines.
1.3.1 Transcriptional Control of PTEN mRNA 
Interaction of the PTEN Promoter with p53
The tumour suppressor p53 is well-characterised and one of the most 
commonly mutated genes in cancer. The p53 protein acts as a transcription 
factor to induce growth arrest or apoptosis by up-regulating pro-apoptotic 
genes such as p21, and Bax. Activity of the p53 protein is regulated by a 
feedback loop with MDM2, which p53 up-regulates. MDM2 protein binds to 
p53, inhibits its transcriptional activity and causes nuclear exclusion and 
proteasome degradation (Freedman & Levine 1998). p53 can be inactivated 
by growth factors and hormones such as oestrogen, and expression of such 
stimulatory factors is often uncontrolled in tumours, as is the case in breast 
carcinomas (Molinari, et al 2000).
The discovery of a putative p53 binding site in the promoter of PTEN 
between -1190 and -1157 (Stambolic, et al 2001) indicated a possible 
transcriptional mechanism for PTEN regulation (see Figure 2). This group 
reported transactivation of PTEN by p53 via transfection into the PTEN-null
46
U87-MG glioblastoma cell line, and defined the region between -1001 and - 
427 as a positive regulatory element which drives constitutive PTEN 
expression. Both mRNA and protein levels of PTEN were significantly 
increased. Analysis of p53-mediated apoptosis revealed that the p53 binding 
sites in the PTEN promoter were essential for efficient p53-mediated cell 
death, and a lack of functional PTEN inhibited this process (Mayo & Donner,
2002).
Recent evidence of decreased PTEN expression in p53-/- mice supports the 
idea that p53 up-regulates PTEN (Hesselager, et al 2003) and that p53 and 
PTEN proteins can physically bind in vivo and in vitro to regulate PI3K 
signalling and also to protect p53 from MDM2-mediated degradation (Zhou, 
et al 2003). Moreover, the PI3K inhibitor LY294002 was shown to synergise 
with introduction of exogenous PTEN into U87-MG cells to transactivate p53 
expression and its target genes p21Waf_1 and IGFBP3 (Su, et al 2003).
The requirement of both PTEN and p53 for effective suppression of tumours 
has been reinforced by work using irradiated mice. Here, PTEN 
heterozygotes were just as sensitive to irradiation and lymphoma 
development as p53 heterozygotes, suggesting that the two genes are 
complementary (Mao, et al 2003).
The hepatitis B virus X protein (HBx), which is involved in hepatocellular 
carcinoma, has been shown to interfere with p53 binding to its binding site on 
the PTEN promoter and thus down-regulates PTEN transcription (Chung, et 
al 2003). Hepatitis B infection may therefore promote tumourigenesis via 
inhibition of PTEN through decreased p53 transactivation, and the resulting 
downstream activation of Akt/PKB.
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PPARy
The nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPARy) is a transcription co-factor that has been shown to regulate 
differentiation and/or cell growth in a number of cell types (Chen, et al 
2003a). It acts as an anti-inflammatory mediator and may also act as a 
tumour suppressor, and is a therapeutic target for type-ll diabetes. Patel, et 
al (2001) demonstrated that the PPARy ligand rosiglitazone (an insulin- 
sensitising drug) upregulates PTEN expression in human macrophages, 
MCF7 breast cancer cells and Caco2 colorectal cancer cells, and decreases 
Akt/PKB phosphorylation. Two PPARy binding elements were identified in the 
PTEN promoter at positions -15376 and -13339bp upstream of the PTEN 
transcription start site (assigned at -1035 relative to the translational start 
site).
Other groups have shown PPARy-mediated up-regulation of PTEN in 
pancreatic tumour cell lines (Farrow & Evers, 2003), and vascular endothelial 
cells (Goetze, et al 2002). These results suggest that PTEN up-regulation 
may be one mechanism by which PPARy agonists ameliorate inflammation 
and tumourigenic processes. One problem with this is that PPARy agonists, 
such as rosiglitazone, are used successfully to treat type II diabetes 
(Poulsen, et al 2003), which logically could cause potentially harmful 
elevation of PTEN. However, as PTEN also up-regulates IRS-2 which leads 
to an insulin-mediated increase in Akt/PKB activity (Simpson, et al 2001), 
PPARy agonists would be beneficial in this disease.
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E g r-1
The immediate-early Egr-1 is a transcription factor that is known to respond 
to the breast cancer mitogen insulin-like growth factor II (IGF-II) via IRS-1 
(Tsuruzoe, at al 2001), and up-regulates the IGF-II promoter in response to 
hypoxia (Bae, et al 1999). Work by Virolle, et al (2001) identified a functional 
Egr-1-binding site (GCGGCGGCG) in the PTEN 5' untranslated region 
between positions -947 and -939, which up-regulated PTEN transcription in 
response to irradiation in mice. Moorehead, et al (2003) demonstrated 
induction of PTEN transcription via Egr-1 in developing mammary cells 
stimulated with IGF-II, but not in mammary cells undergoing involution 
(Moorehead, et al (2001). The differences in response seen between 
developing and involuting mammary cells may reflect the divergent hormonal 
exposure of the cells. Moorehead, et al (2003) also proposes that the 
induction of PTEN could involve a regulatory loop where IGF-II signals 
through Egr-1 to induce PTEN, and then Egr-1 also induces IGF-II.
TGF-/31
Transforming growth factor-p1 is a pleiotropic cytokine which is capable of 
exerting a huge range of cellular effects, including proliferation, differentiation 
and apoptosis. Several papers have reported modulation of expression of 
PTEN by TGF-pi, but the data is conflicting. Li & Sun, (1997) first described 
rapid down-regulation of PTEN (TEP1) mRNA by TGF-pi in a responsive 
asynchronously growing HaCaT keratinocyte cell line. A second group have 
also demonstrated PTEN mRNA down-regulation in pancreatic 
adenocarcinomas over-expressing TGF-pi and synchronous (serum-starved)
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cell lines treated with TGF-p1 (Ebert, et al 2002). These two reports 
concluded that a reduction in PTEN may impart a growth advantage under 
TGF-pi stimulation, and may contribute to aggressiveness in the pancreatic 
study.
A third report, however, described the up-regulation of PTEN mRNA in a 
synchronous U937 monoblastic leukaemia cell line in response to TGF-pi 
(Lee, et al 1999b). The study also found up-regulation of anti-apoptotic Bcl- 
XL and resistance to Fas-mediated apoptosis. These apparently 
contradictory findings could be due to various factors, including cell type, 
dose of cytokine, and incubation times and conditions of growth. In light of 
current understanding, the results presented by (Lee, at al 1999) may be 
explained by the inhibition of PTEN protein by one or more of the various 
mechanisms previously described.
The TGF-p superfamily contains over 30 members with three isoforms, p i, 2 
and 3, but only TGF-pi will be discussed here. TGFp isoforms signal through 
ser/thr kinase receptors type I and II (TpRI and II). Binding of TGF to the 
constitutively active TpRI I initiates recruitment of the receptor/ligand to TpRI 
and transphosphorylation of TpRI at its GS-box Quxtamembrane gly/ser-rich 
region). This creates a binding site for Smads, the signal transducing 
elements of TGFp which are activated by phosphorylation of their C-termini, 
and the internalisation of the receptor into endosomes for recycling.
Eight vertebrate Smads have been identified. These include receptor- 
activated Smads (R-Smads) Smad2 and 3 for the TGF-beta/activin pathway, 
or Smad 1/5/8 for the bone morphogenetic pathway, (BMP). C-terminal 
phosphorylation of Smads by activated receptors results in their binding to
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the common signalling transducer (Co-Smad) Smad4 and translocation to the 
nucleus. The R-Smads also compete for binding to TpRI with inhibitory 
Smads (l-Smads) Smad 6 and 7 (Attisano & Lee-Hoeflich, 2001).
The Smads have a conserved, modular structure composed of MH1, linker 
and MH2 domains. The MH1 domain contains a DNA-binding motif, an NLS 
and regions for binding transcription factors such as ATF-2, c-Jun/Fos, 
Forkheads and Sp1 (Shi, et al 2003). The linker contains consensus sites for 
MAPK phosphorylation, which causes sequestration of R-Smads to the 
cytoplasm and prevents nuclear translocation, for example the R-Smad1 is 
phosphorylated by ERK (Kretzschmar, et al 1999). In both R- and l-Smads 
this region also contains sites recognised by E3 ubiquitin ligases Smurfl and 
2 for degradation, and in the Co-Smad4 the linker has an additional nuclear 
export signal (NES).
The MH2 domain mediates many protein-protein interactions including 
Smad-receptor association and the formation of Smad homo- and 
heteromeric complexes consisting of up to six units. For example, Smads 
2,3, and 4 are required as a complex to effect transcription of the CDK 
p15'NK4B vja SP1 transcription factor (Li, et al 1995 & Feng, et al (2000). 
These complexes are thought to permit differential signalling thresholds to 
act on target gene expression.
Phosphorylated Smads are released from microtubules (Dong, et al 2000), 
and inhibitory l-Smads, and bind to endosomes containing transport proteins 
(Di Guglielmo, et al 2003), all of which increase Smad activation (Lutz and 
Knaus, 2002). Association with Smad4 and other R-Smads follows, and the 
complexes translocate to the nucleus via their NLS. Here, many genes are
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activated as previously mentioned, but others are repressed to inhibit cell 
cycle progression, such as c-myc (Chen, et al (2002). An overview of TGF-pi 
signalling through Smads in shown in Figure 6.
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TGF-(5 Signaling Pathway
TGF-(i sub-family ligands: 
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Figure 6 TGF(31 Signalling to the Nucleus
Figure legends are overleaf. Taken from www.cellsignal.com
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In addition to the traditional Smad-dependant signalling, TGF-p1 also 
activates p38 MAPK/ERK/JNK pathways which are able to regulate Smads 
themselves. However, the activation-response kinetics are too rapid to be 
Smad-dependent, suggesting an alternative mechanism (Massague, 2000). 
Activation of Ras by TGF-p1 by has been observed in induction of 
ERK/MAPK (Yue, & Mulder, 2001), and the TGFp-activated kinase-1 (TAK1) 
is a MAPKKK that can activate both p38MAPK and JNK (Dowdy, et al 2003). 
TAK1 can also activate anti-apoptotic NF-kB by phosphorylating IkB, thus 
TGF-pi may also be involved in NF-icB-mediate responses (Bhat, et al 
2003). Work by Vasudevan, et al (2004) has demonstrated that NF-k B is 
capable of inhibiting PTEN transcription through its p65 subunit by 
sequestering the transcriptional co-activators CBP/p300. Thus, during pro- 
apoptotic TNF stimulus, NF-kB can prevent apoptosis by down-regulating 
mRNA and protein levels of PTEN.
Other pathways may be activated in a cell-type specific manner. These 
include Cdc42 and Rac, also involved in MAPK and cytoskeletal 
arrangement, and Rho-like small GTPases which may effect gene expression 
responses (Derynck & Zhang, 2003). Additionally, TGF-p1 can down-regulate 
Rb and a variety of associated CDKs and cyclins to cause G1 arrest (Hu, et 
al 2001 & Bhowmick, et al 2003).
TGF-pi has also been widely implicated in cancer, but its involvement is 
complex. During the early stages of tumourigenesis, the cytokine acts to 
suppress tumour formation via its cell-cycle restrictive functions detailed 
above. However, during neoplastic change, many tumours show progressive 
lack of responsiveness to growth inhibition by TGF-pi and actually produce
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large amounts of the protein (Boyd & Kaufman, 1990 & Lei, et al 2002). This 
seems to provide autocrine stimulus to the cells which increases 
angiogenesis and motility, via up-regulation of plasminogen activator 
inhibitor-1 (PAI-1) (Kutz, et al (2001) and has an immunosuppressive effect 
(Reiss, 1999).
Tumours may display mutant TGF receptors which signal in an aberrant 
manner, most commonly in TpRII, (Oft, et al 1998, Heldin, et al 1999 & Waite 
& Eng, 2003) and/or Smads, have reduced levels of the CDK inhibitors such 
as p27K,p1 , increased MDM2 which inactivates p53 (Gold, 1999) and 
increased cyclin D1 (Kornmann, et al 1999). Steroid hormones such as 
oestrogen are also implicated in abnormal TGF-pi signalling, and have been 
shown to down-regulate TpRII and allow ovarian cancer cells to evade TGF- 
pi-mediated growth suppression (Evangelou, et al, 2000 & Frasor, et al
2003).
Of particular relevance to this thesis, TGF-pi has been shown to activate 
PI3K through Smad2 (Bakin, et al 2000), ERK/MAPK (Lhuillier & Dryer, 2003) 
and may invoke EGF receptor activation, (Vinals & Pouyssegur 2001).
1.3.2 Post-Translational Modulation of PTEN Protein Expression 
Progesterone & oestrogen
The high incidence of PTEN loss or mutation in some cancers, and in 
particular endometrial carcinomas (see Section 1.5), has indicated that 
steroid hormones could play a role in PTEN regulation. Studies on PTEN 
expression in the endometrium, which undergoes complex morphological 
changes in response to cyclic levels of oestrogen and progesterone, have
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shown that these hormones do indeed regulate PTEN mRNA and protein 
expression levels.
Mutter, et al (2000) demonstrated that levels of PTEN mRNA in endometrial 
cells were higher during the post-ovulatory secretory phase compared to the 
proliferative phase of the menstrual cycle. The secretory phase has a high 
progesterone level whilst the proliferative phase is dominated by oestrogens, 
suggesting that progesterone is responsible for changes in PTEN levels. The 
protein levels and localisation were more complex and cell-type specific. 
Oestrogen-driven dividing epithelial and stromal cells were seen to have 
nuclear and cytoplasmic protein, with increased nuclear localisation during 
decidualisation and menstrual apoptosis. During the secretory phase, 
progesterone levels rise which caused epithelial cells to lose PTEN protein 
whereas stromal cell levels increased, particularly in the cytoplasm.
An investigation into PTEN expression in the endometrium was made in the 
light of the current evidence for PTEN protein regulatory mechanisms. 
Guzeloglu-Kayisli, et al (2003) have described PTEN expression in the 
menstrual cycle and early pregnancy consistent with the work of Mutter, et al 
(2000). This group showed that estradiol increased phospho-PTEN after 5-15 
minutes of treatment in stromal cells, which could account for the observation 
that during the proliferative phase these cells are resistant to apoptosis. 
Additionally, the oestrogen receptor-a is activated by CK2 which inactivates 
PTEN, providing an additional feedback mechanism for increased oestrogen 
signalling and PTEN down-regulation. Progesterone increased PTEN protein 
levels after 24 hours in stromal and glandular cells, and in decidual and 
glandular cells during pregnancy.
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This suggests that this hormone may dephosphorylate PTEN and increase 
protein activity levels in a long-term manner, to cause the increase in 
apoptosis observed in these cells. In conclusion, Guzeloglu-Kayisli, et al 
2003 proposed that the two steroid hormones may target PTEN to affect the 
concentration and spatial localisation of the protein in different endometrial 
compartments.
Other Positive Modulators of PTEN Protein Expression
Several additional factors have also demonstrated the ability to up-regulate 
PTEN expression, these being a vitamin D3 analogue, nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF) and bone morphogenetic 
protein (BMP).
Vitamin D3 Analogues
Vitamin D3 is a secosteroidal hormone involved in bone metabolism, which is 
also capable of inhibiting proliferation and inducing differentiation in tumours 
of diverse origin (Banerjee & Chatterjee, 2003). The growth inhibition effects 
of this molecule are thought to be via G0/G1 arrest and up-regulation of CDK 
inhibitors such as p27KIP1, p21Waf1 and induction of p53 and apoptosis (Yang 
& Burnstein, 2003, Audo, et al 2003 & Flanagan, et al 2003). Despite its 
efficacy against tumours, it is of little clinical use as at the doses required for 
effectiveness a side effect of treatment is calceamia (Kensler, et al 2000). 
Novel D3 analogues have been designed to be anti-proliferative without the 
dangerous side effects (Chen, et al 2003b).
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The novel D3 analogue Gemini-19-nor was shown to be more potent in 
mediating growth, G0/G1 arrest and p27KIP1 expression, apoptosis and 
differentiation than vitamin D3 in leukaemic, breast and prostate cancer cell 
lines. Interestingly HL-60 myeloid leukaemic cells, which are wild-type for 
PTEN, also demonstrated up-regulation of PTEN protein during Gemini-19- 
nor -induced differentiation (Hisatake, et al 2001). This group also showed 
up-regulation of PTEN in HL-60 cells treated with the phorbol diester TPA 
and all-trans-retinoic acid (ATRA), which induced macrophage-like or 
granulocyte-like differentiation respectively in this cell line.
These results suggest that PTEN is involved in myeloid differentiation, and 
may indicate that vitamin D3 analogues are a potential therapy for myeloid 
leukaemias. Another D3 analogue, Seocalcitol (EB1089), has been shown to 
inhibit the growth of aggressive pituitary tumours without increasing PTEN 
expression (Liu, et al 2002), highlighting the cell-type specificity of PTEN 
involvement.
NGF & BDNF
It has been reported that NGF, which stimulates neurite extension, 
upregulates PTEN mRNA levels in rat neuronal pheochromocytoma PC12 
cells (Li & Sun, 1997). An increase in PTEN protein has also been observed 
in the same cell line stimulated with NGF (Lachyankar, et al 2000). This 
group also demonstrated increased PTEN protein in immature and mature 
mouse CNS stem cells during BDNF-induced differentiation. PTEN protein 
could only be detected weakly in immature astrocytic cells and was absent in 
mature astrocytes. This indicates that PTEN plays a role in neural
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development and the extension of neurites, and that perhaps the absence of 
PTEN in glial precursors (astrocytes) is important for glioma development.
B o n e  m o r p h o g e n e t i c  p r o t e i n  ( B M P ) .
BMP signals through the TGFp-family receptor BMPR1A, and mutations in 
this receptor have been noted in patients with Cowden disease, a 
proliferative disorder associated with PTEN mutation (see Section 1.4). 
Recently, Waite & Eng, (2003b) demonstrated up-regulation of PTEN protein 
in MCF-7 breast cancer cells stimulated with BMP2. The increase in PTEN 
protein was due to inhibition of degradation, through inhibition of association 
of PTEN with ubiquitin-conjugating enzymes UbCH7 and UbC9.
1.4 PTEN and Disease
It is now apparent that mutation or loss of PTEN is a feature of many 
malignant and non-malignant human proliferative disorders, ranging from 
aggressive carcinomas to benign hamartomas. Aberrations in genomic PTEN 
contribute to tumourigenic phenotypes in a cell-type specific manner and may 
be germ-line or somatic. The incidence of PTEN mutation or loss is strikingly 
high for some cancers, notably endometrial, but almost absent from 
haematological malignancies. The current understanding of the contribution 
of PTEN mutation or loss in human proliferative diseases is discussed below.
1.4.1 Germline Mutations
PTEN Hamartoma-Tumour Syndrome (PHTS)
PHTS broadly identifies several related autosomal dominant disorders
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resulting from germline PTEN mutations, which display overlapping 
phenotypes. Diagnosis can be problematic as the disorders can share both 
phenotypic features and identical PTEN mutations. It is likely that individual 
genotypes, with loss or mutation of other disease-related genes, contribute to 
this lack of distinction, as a small number of patients do not have PTEN 
mutations (Merks, et al 2003 & Waite & Eng, 2002). The four main disorders, 
Cowden disease (CD), Bannayan-Ruvalcaba-Rily syndrome (BRRS), 
Lhermitte-Duclos disease (LDD), and Proteus syndrome (PS) are described 
below.
Cowden Disease (CD)
CD is associated with a susceptibility to breast and thyroid cancers, 
increasing the risk of breast cancer in affected females to 25-50% and 
lowering the age of tumour development by approximately 10 years from the 
population average. Affected individuals commonly display hamartomas, or 
mucocutaneous lesions (papillomas and trichilemmomas), carcinomas of 
breast, thyroid follicular carcinoma and macrocephaly.
Approximately 10-50% of CD cases are familial, but the true figures are 
unknown due to underdiagnosis. Up to 80% of CD cases contain a germline 
mutation of PTEN, and mutation of PTEN correlates with tumour 
aggressiveness (Zhou, et al 2003b & Marsh, et al 1998). Many such 
mutations in the PTEN gene have been described, and ~65% of these 
appear to affect the first 5 exons coding for the phosphatase domain and the 
promoter region (Eng, 2003).
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In a murine model developed by Podyspanina, et al (1999), mice containing a 
deletion in exon 5 developed neoplasms in multiple organs reminiscent of CD 
and BRRS . Cases of CS without intragenic PTEN mutation could be due to 
mutations in BMPR1A (Waite & Eng 2003b), or promoter mutation which has 
been detected in -10% of samples (Zhou, et al 2003b).
Bannayan-Ruvalcaba-Rily syndrome (BRRS)
This familial disorder is characterised by lipomatosis, speckled penis, 
hemanigiomatosis and macrocephaly, and -60% of patients harbour a 
germline PTEN mutation (Hendriks, et al 2003) Such mutations occur in the 
four exons at the 3' region of the gene which mainly encode the C2 domain 
(Eng, 2003). Deletion and translocation of PTEN have also been described in 
some cases (Marsh, et al 1999 & Ahmed, et al 1999). Once again, BRRS 
patients with PTEN mutations are more likely to develop breast cancers, and 
BRRS and CS are now regarded as phenotypic variations of the same 
syndrome. The causes of the remaining -40% of BRRS cases without PTEN 
mutation are unknown (Dahia, 2000), but PTEN deletion has been detected 
in -11% of these cases (Zhou, et al 2003b).
Lhermitte-Duclos Disease (LDD)
LDD is regarded as a neurological manifestation of CD, and is characterised 
by hamartomatous overgrowth of cerebellar ganglion cells, which replace 
granular and Purkinje cells (Vantomme, et al 2001). Patients suffer ataxia 
and seizures due to increased intracranial pressure, and PTEN 
haploinsufficiency is sufficient to mimic these symptoms in mice (Li, et al
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(2003b). LDD is usually sporadic rather than familial, but it is unclear as to 
how PTEN mutations contribute to this disease, which has only recently been 
recognised as part of PHTS.
Zhou, et al (2003b), presented data suggesting a high incidence (83%) of 
adult-onset LDD cases had germline mutations in PTEN, resulting in little or 
no protein expression in 75% of the samples which also had elevated P-Akt. 
They also propose that LDD in children and adults have distinct underlying 
causes, as very few children diagnosed with the disease carry PTEN 
mutations. The majority of somatic PTEN mutations in LDD are truncating 
(Koch, et al 1999), but there have been reports of germline mutations in exon 
5 more usually seen in CD patients, which reduce phosphatase activity 
(Sutphen, et al 1999 & Robinson & Cohen, 2000).
Proteus Syndrome (PS)
PS, like LDD, has only recently been included under the PHTS grouping and 
is a rare sporadic, hamartomatous disorder of vascular, skeletal, and soft 
tissues with mosaic distribution. Patients can present with asymmetry of the 
skull, body, limbs and partial gigantism of the hands or feet, hypertrophy of 
long bones, haemangiomas, lipomas, macrocephaly, and focal growths of the 
skin and vascular tissues (Bilkay, et al 2003). PS-like (PSL) cases show less 
pronounced symptoms, and are more stable with less sporadic outbreaks of 
abnormal growth (Zhou, et al 2000b). Up to 20% of PS cases and 50% of 
PSL cases harbour germline PTEN mutations (Eng, 2003). Mutations unique 
to PS, which are not seen in CD, BRRS or LDD are W211R and C211X, and 
in PSL the mutation M35T (Zhou, et al 2001c).
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As previously mentioned, the various phenotypes of PHTS diseases can 
arise from the same PTEN mutations. Common mutations in CD, BRRS and 
PS are Q110X, R130X, R233X, R335X, (CpG dinucleotides in the 
phosphatase domain) and P246L (C2 domain), emphasising the importance 
of these regions for PTEN function. Mutations in the CpG islands could 
possibly increase promoter silencing by methylation, and in the C2 domain 
mutations can have profound effects on the stability of PTEN protein, as 
previously described.
1.4.2 Somatic Mutations
Over 300 somatic mutations of PTEN have now been described in various 
types of tumour, including endometrium, breast, prostate and melanomas. ~ 
70% of mutations in PTEN are frameshift, missense or splice mutations 
which truncate the protein. Approximately half of the ~100 missense 
mutations, or ~23% of all mutations, are found in the exon 5 phosphatase 
domain and may affect activity. Additionally, the structural abnormality known 
as loss of heterozygosity (LOH), where mutations in one allele lead to the 
deletion of the other, has been detected in ~90% of tumours. LOH is difficult 
to accurately detect, therefore this figure may not be truly representative 
(Bonneau & Longy, 2000).
Glioblastoma (GB)
PTEN mutations have been described in several neurological tumours as a 
late event which correlates with tumour progression and aggressiveness 
(Davies, et al 1999b) rather that predisposition (Sanson, et al 1999).
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Glioblastoma (GB) is the most common and most malignant form of 
astrocytic tumour in adults, with a survival rate of <1 year (Reis, et al 2000). 
Loss of PTEN is seen in ~20-30% of primary tumours (Kato, et al 2000, 
Zhou, et al 1999 & Backlund, et al 2003) and is often accompanied by 
amplification of EGFR and aberrations in the Rb1 pathway and p53 (Reis, et 
al, 2000). LOH and promoter methylation have also been observed in GB 
(Baeza, et al 2003).
The molecular mechanisms underlying this disease remain elusive, but it has 
been proposed that mutations in EGFR and p53 are very early events, and 
that disruption of the Rb1 pathway (e.g., pRb, CDK4), in conjunction with 
“second hit” loss of PTEN may be progression factors. This could provide a 
diagnostic tool for the early detection and treatment of this disease 
(Backlund, et al 2003, Krex, et al, 2003). Studies in PTEN knockout mice 
suggest that inhibitors of mTOR, a downstream target of Akt/PKB, correct 
abnormal growth and could be useful in the treatment of LDD and 
glioblastoma (Kwon, et al 2003).
Together with the phenotypes observed in LDD and various murine models, 
the crucial role of PTEN in the development of the CNS has been highlighted 
(Di Christofano, et al 1998). Expression of PTEN protein in human foetuses 
has been observed to be the highest in the central and peripheral nervous 
systems, and with less intensity in adult brains (Gimm, et al 2000b). PTEN 
appears to be important for orchestrating brain architecture, cell size and 
migration, and has a much more important role in the development and 
maintenance of this organ than previously thought (Li, et al 2003).
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Prostate Cancer
As in GB, PTEN mutation is a late event in prostate cancer which correlates 
to increasing grade of the tumour. Abnormal PTEN has been observed in 
~15% of primary tumours and ~60% of advanced prostate cancers, with a 
high LOH frequency of ~40% being related to metastatic potential 
(Fernandez & Eng, 2002 & Deocampo, et al 2003). Low expression of the 
CDKI p27 is also indicative of aggressiveness and poor outcome (Halvorsen, 
et al 2003). It is believed that promoter hypermethylation is more important in 
this cancer, and there have been many reports of PTEN silencing in prostate 
tumours (Whang, et al, 1998 & Rennie & Nelson, 1999). Additionally, as 
prostate cancers frequently display androgen independence (See Section 
1.2.4.2), loss of PTEN function may facilitate the activation of AR signalling 
and progression to this state in prostate cancer (Snabboon, et al 2003).
A recently developed murine model of the precancerous prostatic 
intraepithelial neoplasia (PIN) may be useful in the further elucidation of the 
molecular mechanisms in prostate carcinoma (Abate-Shen, et al 2003). The 
mouse model carries a heterozygous mutation in the NKX3.1 prostate- 
specific homeobox gene which is deleted in ~80% of early lesions. 
Heterozygous loss of PTEN in this model leads to androgen independence, 
invasiveness and metastasis also observed in advanced prostate 
adenocarcinoma.
Malignant Melanoma
Frequent PTEN mutations have also been described in ~30% of late-stage 
malignant melanomas (Guldberg, et al 1997)and up to ~60% in advanced 
metastatic disease (Birck, et al 2000) , but PTEN loss again appears to be
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absent in early tumours (Poetsch, et al 2001). LOH of the PTEN locus is also 
very common in advanced melanomas, affecting of 30-50% of tumours and is 
associated with poor prognosis (Robertson, et al 1998 & Healy, et al 1998).
Breast Cancer
Primary sporadic carcinomas of the breast also harbour PTEN mutation, but 
at a much lower level of <5% compared to the cancers listed above (Rhei, et 
al 1997), and is therefore not implicated in the early stages of this disease 
(Ueda, et al 1998). LOH is observed in ~40% of invasive carcinomas in 
conjunction with loss of oestrogen receptors and increasing tumour grade 
(Bose, et al 1998). PTEN does not appear to be involved in inheritable breast 
cancer unless Cowden disease is also present, where it causes a 
predisposition to early-onset breast cancer (Mincey, 2003 & Carroll, et al, 
1999).
More recently, loss of protein expression has been studied by several 
groups. Decreased or lack of PTEN was observed in ~38-50% of metastatic 
tumours, and also correlated with loss of oestrogen receptors and 
invasiveness (Depowski, et al 2001 & Bose, et al 2002).
In primary advanced breast adenocarcinoma, ~33% of tumours had 
decreased or no PTEN protein with LOH (Perren, et al (1999). The evidence 
indicates that PTEN loss is a late event in breast carcinogenesis which 
correlates with increased progression (Bose, et al 2002), and mutation in 
other genes such as p53 and BRCA1/2 (Kurose, et al 2002 & Buchholz, et al
2002). Constitutive activation of erbB2 autocrine signalling and increased P- 
Akt/PKB has been observed in breast cancer cell lines negative for PTEN,
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and may be one mechanism promoting progression in these cells (Nicholson, 
et al 2003).
Endometrial Carcinoma (EC)
Endometrial cancers are the most common gynaecological malignancy 
affecting ~188,000 females worldwide per year (WHO, 2003), and are now 
recognised as having the highest rate of somatic PTEN mutation (Tashiro, et 
al 1997). Endometrial carcinomas (EC) display ~30-50%, adenocarcinomas 
(EAC) 50-85% and ~20% of the precursor lesion endometrial hyperplasia 
(EH) exhibit PTEN mutations. The figures for EAC represent the highest 
PTEN mutation rate in primary tumours, with all the mutations being in 
tumours of the endometrioid (Type I) variety which accounts for 80-90% of all 
ECs (Mutter, et al 2000). The predisposition to EC via PTEN mutation has 
been demonstrated in knockout mice, which develop atypical hyperplasia, the 
endometrioid precursor to EC (Podyspanina, et al 1999).
Mutation of PTEN appears to be an early event in EC, as aberration in the 
gene can be detected in early hyperplasias, (Levine, et al 1998), and such 
mutations may provide a diagnostic marker for the disease (Mutter, at al 
2000, Gao, et al 2003b & Ricci, et al 2003). PTEN loss and Akt 
phosphorylation are indicative of poor prognosis, and survival rates are lower 
in patients who are immunohistochemically PTEN-negative (Terakawa, et al
2003). LOH at the PTEN locus has also been reported to be present in ~20- 
50% of advanced endometrial carcinomas, and may indicate progression of 
the disease (Tsuda, et al 2002 & Toda, et al 2001). The current mutational 
spectra for PTEN in EC is shown in Table 2.
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Some correlation has also recently been reported between the amplification 
of the oncogene cMYC and PTEN mutation in early and advanced EC. In 
PTEN+/cMYC' tumours, PTEN mutations were most frequent in exons 1-5, 
and less frequent in exons 7-8 (66.7% and 33.3%, respectively). In contrast, 
in PTEN+/cMYC+ carcinomas the PTEN mutations were found mainly in 
exons 7-8 (85.7%). The group implicate subtle genetic variations and 
interaction with different PTEN mutations for the different subsets of EC 
(Konopka, et al 2003).
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The location of mutations in PTEN also appears to have significance in EC. 
There have been several reports of PTEN mutations giving a better 
prognosis in endometrioid tumours (Risinger, et al 1998 & Maxwell, et al 
2000), although the specific mutations were not analysed. Minaguchi, et al 
(2001) described better survival rates in patients with mutations outside of 
exons 5, 6 and 7, although the tumours were histopathologically 
indistinguishable from those with PTEN mutations inside these exons. They 
associated exon 8 mutation with a better prognosis as these mutations affect 
only the C2 domain and may still retain phosphatase activity (refer to Section 
1.2.2). Exon 7 mutation was however correlated with poor outcome as most 
mutations here are frameshifts or nonsense, which lead to truncation of the 
CBR3 region of the phosphatase domain and the C2 domain. This mutation 
would be comparable to an exon 5 catalytic site mutation and most likely 
would disrupt PI3,4,5P3 binding.
In addition to mutation, PTEN promoter methylation has been detected in 
~20% of EC lesions and correlated with increasing tumour grade and 
metastasis (Salvessen, et al 2001 & Risinger, et al 2003).
Microsatellite instability (MSI) due to replication errors occurs frequently in 
hereditary tumors and appears to be an early event in EC. MSI is caused by 
mutations in DNA mismatch repair genes hMLH1 and hMSH2, but errors are 
seen in hMLH1 more often in EC (Piero, et al 2002). Reports have detected 
loss of hMLH1 and PTEN expression in 55% of EC samples (Orbo, et al 
2003), and also in endometriosis, which has the potential to become 
malignant (Martini, et al 2002). MSI has been associated with a favourable 
prognosis in endometrioid EC (Maxwell, et al 2001, Wong, et al 1999 &
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Tibilietti, et al, 1999), and colorectal cancers (Gryfe, et al 2000). One possible 
reason for the more favourable prognosis is that lymphocytic invasion is 
higher in EC lesions with MSI, suggesting augmentation of host immune 
recognition of these tumours (Kihana, et al 1998).
PTEN mutations in EC could provide useful prognostic and therapeutic 
information, and aid in the decision to perform surgical removal of metastatic 
tumours or to offer treatments such as chemotherapy or radiotherapy. 
Additional studies on PTEN genetic alterations, regulation and cellular 
localisation in EC cells may help to clarify the tumor suppressor function of 
PTEN in this disease.
Other Malignancies
Aberrations of PTEN have now been reported in a wide range of other 
cancers, but the implications of PTEN mutation are less well understood in 
these diseases with regard to initiation and progression. Decreased PTEN 
expression has been detected in higher grade gastric cancer (Zheng, et al 
2003b), colorectal cancer (Zhou, et al 2002), bladder (Aveyard, et al 1999) 
and pancreatic cancer (Perren, et al 2000).
PTEN mutation has also been analysed in haematological malignancies. 
Abberant PTEN has been detected in ~20% of acute myeloid leukaemias 
[AML] (Liu, et al 2000 & Aggerholm, et al 2000). The high incidence of loss 
of protein expression in the presence of high levels of PTEN mRNA in 
primary leukaemia and Non-Hodgkins’ lymphoma indicate that gene 
silencing, probably by promoter methylation, is important in haematological 
cancers (Dahia, et al 1999). Recently, high levels of P-PTEN, P-Akt/PKB
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and phosphorylated Forkhead factors have been detected in this disease 
indicating poor prognosis (Cheong, et al 2003a & b). Conversely, PTEN 
mutations are rarely seen in lymphoma (Melendez, et al 2003), although 
lower expression levels have been observed (Abbott, et al 2003).
Loss of PTEN may also play a role in autoimmune diseases, as it has been 
shown that in during clonal selection T-cells with PTEN deficiency become 
resistant to CD95-induced death and gain long-term activity (Strauss, et al 
2003). Loss of PTEN also disrupts B-cell immunoglobulin class switching and 
differentiation in the spleen (Anzelon, et al 2003) and can increase 
autoantibody titres (Suzuki, et al (2003).
1.4.3 PTEN Promoter Methylation
Promoter methylation is an alternative method of silencing tumour 
suppressor genes (Herman, 1999) and has been observed in a variety of 
tumour types for many cancer-related genes including p16 (Yu, et al 2002), 
BRCA1 (Baldwin, et al 2000) and Rb (Simpson, et al 2000). Methylation 
occurs at ‘CpG islands’, dinucleotides which are usually present within or 
near the promoter. Hypermethylation by DNA methyltransferases prevents 
transcription of the downstream gene, and elevated expression of DNA 
methyltransferase I is frequently observed in cancers (Wamecke & Bestor, 
2000).
Several papers have reported methylation of the PTEN promoter in a number 
of tumour cell types, including gastric carcinomas (Kang, et al 2002), 
endometrial carcinomas (Salvesen, et al 2001), thyroid cancers (Frisk, et al 
2002) and prostate carcinomas (Whang, et al, 1998). Soria, et al (2002) also
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report methylation of the PTEN promoter in non-small cell lung carcinoma 
(NSCLC) which often presents constitutive Akt/PKB. This group were able to 
demethylate PTEN in a NSCLC cell line with 5-axa-2’-deoxycytidine which 
restored mRNA transcription. They report that as demethylating agents are 
undergoing clinical trials, their finding is of particular therapeutic significance. 
It is noted by Zysman, et al (2002) that many of the methods used to 
determine the methylation status of the PTEN promoter cannot differentiate 
between PTEN and the pseudogene vj/PTEN which are discussed below.
1.5 The PTEN Pseudogene & Tissue-Specific PTEN Homologues 
\lPTEN, the Pseudogene
Shortly after the discovery of PTEN, a highly conserved processed 
pseudogene (Mighell, et al 2000), named xj/PTEN was located on human 
chromosome 9p21 (Dahia, et al 1998). ij/PTEN differed from PTEN by 19 
nucleotides and 12 amino acids (see Appendix III), had no initiation 
methionine and was intronless. Despite these features, several groups have 
described varying levels of transcription of \|/PTEN mRNA in a range of 
tissues but were unable to detect any protein expression (Fujii, et al, 1999, 
Yokoyama, et al 2000).
PTEN Homologues TPTE, PTEN-2 and TPIP
Several PTEN homologues have now been reported in both human and 
mouse genomes. In 1999 a testis-specific conserved PTEN homologue 
called TPTE (transmembrane phosphatase and tensin homology) was cloned 
from human chromosome 21. Multiple copies also mapped to chromosomes
80
13, 15, 22 and Y, but this group did not characterise the protein (Chen, et al 
1999). Work by Guipponi, et al (2000) has described the DNA structure of the 
copy on the short arm of chromosome 21 as having 24 exons spanning 
87Kb. The same group also cloned murine TPTE, of which 3 major 
transcripts a, b, and c were described, each coding for proteins containing a 
protein tyrosine phosphatase motif and four potential transmembrane 
domains which localised to the golgi (Guipponi, et al 2001).
A highly conserved murine PTEN homologue, named PTEN 2, has recently 
been identified (Wu, et al (2001). This form appears to be expressed only in 
the testis and is localised to the golgi, possibly via an extended N-terminus 
containing four potential transmembrane domains. This association with the 
golgi may indicate a specialist role in membrane trafficking and regulation of 
terminal spermatocyte development. PTEN 2 also demonstrates enzymatic 
activity against PI3,4,5P3, and has a greater specificity for 3’ and 5’ 
phospholipids than PTEN although the reason for this is unclear.
Walker, et al, (2001) have also described another human PTEN homologue 
termed TPIP (TPTE and PTEN homologous inositol lipid phosphatase). This 
homologue has two splice variants, TPIPa and p, the former which has 
phosphatase activity and binds membranes, and the latter which is inactive 
and cytosolic. TPIPa contains up to three possible transmembrane domains 
that are absent in TPIPp, and localises to the endoplasmic reticulum (ER), 
where it may regulate phosphoinositide signalling. This group also 
demonstrated that TPTE was catalytically inactive against phospholipids, but 
protein phosphatase activity was not assessed. Additionally, none of the 
three homologues could regulate Akt/PKB.
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1.6 Project Aims 
Overview
Endometrial carcinoma is the most common gynaecological malignancy and 
has the highest rate of PTEN mutation over any other cancer. Over 100 
mutations have been described, but none of the studies have been 
performed using archival endometrial material. A repository of ~50 patients 
was made available for use in this project, consisting of a histologically 
normal cervical sample and up to three tumour samples of varying 
histological grade. These samples permitted the analysis of the PTEN 
sequence in both normal and tumour cells. The role of TGF-p1 in the 
regulation of PTEN levels is contradictory and may be cell-type specific, and 
has not yet been assessed in endometrial cells. Compounds which 
upregulate PTEN may have therapeutic value and therefore merit 
investigation. The subcellular localisation of PTEN has been reported to be 
both cytoplasmic and nuclear, and this may depend on both cell-type and 
stimulating compound. As PTEN levels respond to cyclic hormones in the 
endometrium, the cloning of PTEN into a plasmid encoding a green 
fluorescent protein tag (EGFP) would enable rapid study of PTEN protein 
behaviour in endometrial cell lines under hormone and cytokine stimulation. 
Specific project aims are detailed overleaf.
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Specific Aims
The major aims of this project were threefold:
1. To analyse PTEN mRNA and protein expression in endometrial cell lines 
stimulated with TGF-pi.
The transcriptional and post-translational effects of this cytokine were 
evaluated in two cell lines of endometrial origin, HEC-1B and Ishikawa, to 
compare the response of cells with wild-type PTEN (HEC-1B) or mutant 
PTEN (Ishikawa). Expression of PTEN, phospho-PTEN and several other 
genes were studied using RT-PCR and Western blot to determine the nature 
of any changes in expression produced by exposure to TGF-p1. Expression 
levels of PTEN mRNA and protein were correlated to time and dose of 
cytokine stimulation. As serum in the growth medium can contain varying 
levels of TGF-p1, stimulation of endometrial cell lines with cytokine was also 
performed in low-serum conditions and the results compared to normal 
serum conditions. The effect of TGF-pi on cell morphology and viability was 
also investigated.
2. To determine the sub-cellular localisation of PTEN protein in endometrial 
cell lines.
Localisation of PTEN protein has not previously been described in cell lines 
of endometrial origin. To assess localisation of PTEN in endometrial cell 
lines, the cloning of full-length human PTEN tagged with green fluorescent 
protein (GFP) was undertaken. Cell lines were transfected with PTEN-GFP 
and the localisation of the protein to cellular compartments observed. The 
effect of treatment with compounds reported to change PTEN expression
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(TGF-p1 and oestrogen) were also evaluated to determine whether the 
localisation of PTEN could be altered by such compounds.
3. To detect novel mutations of PTEN exons 5 and 8 in DNA derived from 
archival endometrial material.
Mutation of PTEN is especially prevalent in endometrial cancer, and by 
describing such mutations the specific role of PTEN in this disease can be 
analysed. Using PCR fragments amplified from tumour DNA for PTEN exons 
5 and 8, the presence of sequence variations in the samples were detected 
by Single-Strand Conformation Polymorphism (SSCP) analysis. Samples 
with sequences differing from a PTEN control sample were detected as 
bands with aberrant mobility. Samples displaying such bandshifts may 
contain polymorphisms or mutations, which can be determined by automated 
sequencing of the PCR products.
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CHAPTER 2 
MATERIALS & METHODS
2.1 MATERIALS & SUPPLIERS
2.1.1 Reagents & Kits
McCoy’s 5A Modified Medium, (M8403), Sigma 
Minimal Essential Medium Eagle’s, (M2289), Sigma 
Human recombinant TGFp-1, (240-B), R&D Systems, UK 
Protease Inhibitor Cocktail for Mammalian Cells, (P8340), Sigma 
Bradford Reagent, (B6916), Sigma
Colour SDS Molecular Weight Markers, High Range, (C3312), Sigma 
Biotinylated SDS Molecular Weight Markers, (MW-SDS-100B), Sigma 
ECL Blocking Powder, Amersham
Western Blotting Detection System, (RPN 2209), Amersham 
CellTiter One Solution Cell Proliferation Assay Solution, (G3580), Promega 
Normal Goat Serum, (G9023), Sigma 
GenElute Plasmid Miniprep Kit, (PLN-10), Sigma
GeneRuler 1Kb molecular weight marker 0.25mg/ml, (SM0313), MBI 
Fermentas
Poly-D-Lysine, (P7405), Sigma
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DAPI, (D8417), Sigma
Fluoromount G, (0100-01), Southern Biotechnology 
Lipofectamine, (18324), Liopfectamine 2000, (11668), Invitrogen 
fc-17 Estradiol (E8875) Sigma
CMV-PEGFP-N1 Courtesy of Dr E Blair, Dept Molecular Biology, University 
of Leeds, UK
CMV-pECFP-N1 Courtesy of Dr C Fenech, Sheffield Hallam University, UK
2x MDE gel solution, (50620),Bio Whittaker Molecular Applications
PlusOne DNA Silver Staining Kit, (17-6000-30), Amersham Pharmacia 
Biotech
100bp Molecular Weight Marker, (N3231S), NEB
Sequencing performed to order by:
Lark Technologies Inc 
Radwinter Road 
Saffron Waldon 
Essex CB11 3HY
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2.1.2 Antibodies
Mouse monoclonal lgG1anti-PTEN, Clone A2B1, 0.5 mg/m,I (68731 A), BD 
Transduction Laboratories
Mouse monoclonal IgG anti-PTEN, Clone 6H2.1, 0.5 mg/ml Alexis 
Biochemicals
Mouse monoclonal anti-p-Actin, Clone AC15, (A5441), Sigma
Mouse monoclonal lgG1anti-PAI-1, 0.25 mg/ml, (612024), BD Transduction 
Laboratories
Mouse monoclonal lgG1anti-p27KIP1, Clone G-173-524, 0.5 mg/ml, 
(554069), BD Transduction Laboratories
Mouse monoclonal lgG2a anti-Phospho-AKT Ser 473, Clone 4E2, (#9276), 
NEB
Rabbit Polyclonal anti-Phospho-PTEN Ser 380, (#9551) NEB
Vector Elite anti-mouse IgG detection kit & anti-Universal detection kit, Vector 
Laboratories
AlexaFluor 594 goat anti-mouse IgG (H+L) Highly cross-adsorbed, 2 mg/ml, 
(A-11005), Molecular Probes
Anti-Hsp47, (Colligin), mouse monoclonal 0.85mg/ml, (SPA-470), Stressgen
Anti-Mannosidase II, Courtesy of Prof D Parkinson, Sheffield Hallam 
University
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2.1.3 Oligonucleotides
The oligonucleotides used for PCR were synthesized by Sigma-Genosys with 
HPLC purification. Lyophilised oligonucleotides were re-suspended in 0.5- 
1ml of sterile water, aliquoted and stored at -20°C. The location of each 
PTEN primer is illustrated in Appendix 11.2.
PTEN 1# Forward Exonic
5’ CGGCATATGACAGCCATCATCAAAGAGATC3’
PTEN 2a# Reverse Exonic
5’ CCC GTC GAC TCA GAC TTT TGT AAT TTG TG 3’
PTEN 3# Forward Exonic
5’ CGG CAT ATG TGT GAT CAA GAA ATC GAT AGC 3’
PTEN 4# Reverse Exonic 
5’ CCCGTCGACTCACCCATAGAATCTAGGG3’
PTEN 5A* Forward intronic 
5’ TATTCTGAGGTTATCTTTTA 3’
PTEN 5B* Reverse exonic 
5’ CTTTCCAGCTTTACAGTGAA 3’
PTEN 5C* Forward exonic 
5’ GCTAAGTGAAGATGACAATCA 3’
PTEN 5D* Reverse intronic 
5’ AGAAAAAACAT CAAAAAATAA 3’
PTEN 8A* Forward intronic 
5’ ACACATCACATACATACAAGTC 3*
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PTEN 8B* Reverse Exonic
5’ GTG C AG ATAAT G AC AAG G AATA 3’
PTEN 8C* Forward Intronic
5’ TTAAATATGTCATTTCATTTCTTTTTC3’
PTEN 8D* Reverse Exonic 
5’ CTTTGTCTTTATTTGCTTTGT 3’
PTEN 10# Forward Exonic
5’ CCC GTC GAC GGA CTT TTG TAA TTT GTG TAT 3’
dJLPTEN 11 Reverse Exonic
GGC GAA TTC AGC ATG ACA GCC ATC ATC AAA GAG 3’
PTEN 10b# Forward Exonic
5’ CAC CAC CTG TCG ACT GGA CTT TTG TAA TTT GTG TAT 3’
jULPTEN11a Reverse Exonic
5’ CGG ACT GAA TTC AGC ATG ACA GCC ATC ATC AAA GAG 3’ 
(Sal I sites are highlighted in red and the EcoRI sites in blue).
GAPDH 472F7 Forward Exonic
5’ TGA TGA CAT CAA GAA GGT GGT GAA G 3’
GAPDH 472R/ Reverse Exonic
5’ TCC TTG GAG GCC ATG TGA GGC CAT G 3’
PAI-1F* Forward Exonic
5’ GCT GAA TTC CTG GAG CTC AG 3’
PAMR* Reverse Exonic
5’ CTG CGC CAC CTG CTG AAA CA 3’
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TPIPFf Forward Exonic
5’ TAT TCT GAT AAG AAT TTT TCA TCT GC 3’
TPIPR* Reverse Exonic
5’ CCT CGG CAG TTA AAA ATA TTT CG 3’
Bcl-2A5 Forward Exonic
5’ GTT CGG TGG GGT CAT GTG TGT GGA GAG CG 3’
Bcl-2Ba Reverse Exonic
5’ TAG CTG ATT CGA CGT TTT GCC TGA 3’
Denotes primer sequence taken from *Risinger et al (1997), ta lk e r , et al, 
(2001). All other primers designed from Entrez sequences #AF067844, 
*M 16006, §BC040499, *X05744, ^M14745, 'NM002046.
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2.1.4 Enzymes
Red Hot Taq Polymerase, 5U/pl, (AB 0406/B), ABGene
Superscript II RNAse H- Reverse Transcriptase, 200U/pl, (18064-014), 
Invitrogen
Placental RNAse Inhibitor, 50,000U/ml, (R2520), Sigma
Platinum Pfx DNA Polymerase, Invitrogen
Sal I, 20,000 U/ml, (R0138S), NEB
Eco Rl, 20,000 U/ml, (R0101S), NEB
Mse I, 10,000 U/m,l (R0525S), NEB
Hha I, 20,000 U/ml, (R01395), NEB
T4 DNA Ligase, 400,000 U/ml, (M0202S), NEB
RNase A, (R6513), Sigma
2.1.5 Bacterial Strains and Cell Lines
E. coli JM109 courtesy of Dr A. Fairclough, Sheffield Hallam University 
E. coli DH5a Subcloning Efficiency Chemically Competent Cells, (18265- 
017), Invitrogen
HEC-1B cell line courtesy of Dr Sue Laird, Sheffield Hallam University, UK 
Ishikawa cell line purchased from ECACC (99040201)
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2.2 ANALYSYS OF EXPRESSION OF PTEN AND SELECTED GENES IN 
HEC-1B & ISHIKAWA CELL LINES STIMULATED WITH TGF-B1
To assess the effect of TGF-B1 on mRNA expression in HEC-1B and 
Ishikawa cells, RT-PCR was used to amplify mRNA species for PTEN, 
GAPDH and PAM.
2.2.1 Cell culture
Human endometrial cell lines HEC-1B and Ishikawa were routinely 
maintained in McCoy’s 5A and Minimal Essential Eagles medium 
respectively (see Appendix 1.1), at 37°C in 5% C02 atmosphere. Cells were 
passaged at a ratio of 1:10 every three to four days when 80% confluence 
was reached. The growth medium was discarded, 5 ml of Trypsin-EDTA 
solution added and cells were incubated at 37°C until they detached from the 
flask surface. Trypsinised cells (0.5ml) were then diluted in 9.5 ml of fresh 
complete medium in a new flask and returned to the incubator.
2.2.2 TGF-B1 stimulation
To analyse the effect of TGF-B1 on gene expression in HEC-1B and 
Ishikawa cell lines, cell populations were expanded in 250 ml flasks, prior to 
passaging 5ml of cells into 75 ml flasks. The cells were grown to 100% 
confluence in complete medium then washed once with fresh complete 
medium. For serum-starved samples the cells were washed with reduced- 
serum medium (Appendix 1.1) and incubated in reduced-serum media for 24 
hours.
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Solutions of TGF-B1 at concentrations of 2ng/ml and 5ng/ml of TGF-B1 were 
freshly prepared from a sterile 2pg/ml stock of the human recombinant 
cytokine by diluting with complete or reduced-serum medium. Concentrations 
were chosen based on previous work by Lee, et al (1999). Medium was 
discarded from the cells and replaced with medium containing TGF-S1 at the 
appropriate concentration, then cells were returned to the incubator for four, 
eight or twenty-four hours prior to RNA extraction. Duplicate flasks were 
prepared for each concentration and time, and controls included cells without 
TGF-B1 at each time point and a pre-starvation ‘10% serum’ sample for the 
serum-starved experiments.
2.2.3 Analysis of RNA Expression
2.2.3.1 RNA Extraction
Medium was discarded from each flask and the cells washed with sterile 1x 
PBS. The PBS was discarded and 2.5ml cold TRI Reagent (Sigma) added 
per flask in accordance with the manufacturers’ recommendations. The cells 
were resuspended by repeated pipetting and immediately transferred to 
sterile Eppendorf tubes, using two tubes per sample. The cells were 
incubated on ice for 5 minutes to lyse before the addition of 150pl of ice-cold 
chloroform and a further incubation on ice for 10 minutes. The samples were 
centrifuged at 12,000 rpm for 15 minutes at 4°C in a Heraeus microcentrifuge 
and the upper layer transferred to fresh sterile tubes. An equal volume of ice- 
cold isopropanol was added to each sample and the tubes incubated for 20 
minutes at -70°C.
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The RNA was pelleted by centrifugation at 12,000 rpm for 15 minutes at 4°C 
and the supernatant discarded. The pellets were washed with 375jul of ice- 
cold 80% ethanol, centrifuged at 10,000 rpm for 5 minutes at 4°C and the 
supernatant carefully aspirated. The RNA samples were air dried at room 
temperature for 10 minutes and dissolved in 20pl of ice-cold sterile water and 
immediately stored at -70°C.
2.2.3.2 RNA Quantitation and RT-PCR
For each RNA sample 2.5pl aliquots of RNA were added to 497.5pl of ice- 
cold sterile water to give a dilution of 1:200 and stored on ice. The 
absorbance at 260nm and 280nm was determined for each sample on a 
Cecil Aquarius spectrophotometer, using water to zero the machine at each 
wavelength. Readings were obtained from the spectrophotometer for each 
sample for the concentration at 260nm, and the purity ratio of 260 /  280 as 
calculated by the machine. Measurements were performed in duplicate. Each 
sample was adjusted to a concentration of 1pg/pl with ice-cold sterile water.
2.2.3.3 cDNA Synthesis
For cDNA synthesis, Superscript II RNAase H- RT enzyme (Invitrogen) was 
used according to the manufacturers’ instructions. This enzyme lacks the 
ability for RNA hydrolysis, thus increasing product yield 
(www.invitrogen.com). Briefly, a master mixture containing 3pl 5mM dNTPs, 
3pl 0.1M DTT, 6pl 5x RT buffer, 0.5pl Oligo (d)i6T and 14.5jliI sterile water 
per reaction was prepared on ice and mixed by brief vortexing. Aliquots of 
27pl were added to each reaction tube. For each RNA sample two reactions
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were prepared, consisting of a positive ‘cDNA’ containing 1pl of RNA (1pg), 
and a -RT also containing 1pl of RNA. An additional reaction tube without 
RNA (-RNA) was included in which sterile water (1pl) replaced RNA. The 
samples were mixed and heated at 65°C for 5 minutes on a thermal cycler, 
then immediately transferred to ice for 3 minutes. To each tube 1pl of 
placental RNase Inhibitor and Reverse Transcriptase were added; 1pl of 
sterile water was pipetted into the tubes labeled -RT in the place of RT. The 
samples were then incubated at 42°C for 1 hour on a thermal cycler and the 
cDNAs and controls stored at -20°C.
2.2.3.4 PCR
PCR was performed using cDNA diluted 1:4 with sterile water and a master 
mixture containing 2.5pl 10x Taq Buffer, 2.5pl 2mM dNTPs, 1pl 50mM MgCfe, 
100pM forward primer, 100pM reverse primer, 15pl sterile water and 1pl 
BioTaq Red DNA Polymerase per reaction. The master mixture was mixed 
by flicking gently and 24pl was aliquoted into each reaction tube, to which 1pl 
of diluted cDNA was added. The PCR reactions were mixed gently, briefly 
microfuged and placed in the thermal cycler on the appropriate programme 
(Appendix V). Samples were stored at 4°C when the PCR cycle had ended. 
PCR products were analysed by electrophoresis of 10pl aliquots using a 2% 
agarose gels as described below. Samples were loaded as a time-course for 
each concentration of TGF-S1 and control.
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2.2.3.5 Analytical Scale Agarose Gel Electrophoresis of DNA
Analytical agarose gels were prepared by adding 300mg or 600mg of 
molecular grade agarose to 30ml of 1x TAE buffer (Appendix I.8) to give 1% 
or 2% gels respectively (Maniatis, Sambrook & Fritsch, 1989). The gel slurry 
was heated for 1 minute in a microwave oven on full power until the agarose 
had fully dissolved, and then allowed to cool briefly before the addition of 
1.5pl of 10mg/ml ethidium bromide solution. The molten agarose was poured 
into a gel former with a comb inserted and allowed to set for 30 minutes at 
room temperature.
The comb was removed from the prepared gel which was then placed in a 
mini-submarine electrophoresis tank and submerged in 1xTAE buffer to the 
manufacturer’s indicated mark. 10pl of PCR product was added to 2pl of 
loading dye (Appendix I.8) and the entire sample loaded through the buffer 
into a pre-formed well of the gel. 1pl of 100bp molecular weight marker was 
also included in one well. Electrophoresis was carried out at a constant 110V 
for approximately 45 minutes and the gel visualized on a UV transilluminator 
and photographed using a KODAK DC120 digital camera.
2.2.3.6 Densitometric Analysis of RT-PCR products
Gels were analysed using Kodak 1D Image Analysis Software (Version 2.0.1) 
using a 100bp molecular weight marker as a standard for mass calculations, 
and the band intensities expressed in nanograms.
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2.2.4 Analysis of Protein Levels in HEC-1B and Ishikawa Cell Lines 
stimulated with TGF-B1
2.2.4.1 Protein Extraction and Quantification
For preparation of whole-cell extracts, TGF-G1 stimulation was carried out in 
75 ml cell culture flasks as described in section 2.2. Following stimulation, the 
flasks were removed from the incubator, the medium discarded and the cells 
washed twice with ice-cold sterile PBS. The PBS was discarded and 750pl of 
ice-cold phosphoprotein lysis buffer (Appendix 1.2) added to each flask, with 
brief homogenization by pipetting. The cell lysates were transferred to sterile
1.5 ml Eppendorf tubes and incubated on ice for 30 minutes to allow 
complete lysis of the cells. The lysates were cleared of insoluble material by 
microfuging for 10 mins at 13,000 rpm at 4°C and the supernatant transferred 
to clean tubes on ice.
2.2.4.2 Determination of Protein Concentration by the Bradford Assay
Protein concentration in each sample was determined using the Bradford 
Assay. This simple, rapid method quantitates the amount of protein in a 
sample by the proportional binding of coomassie blue dye to the protein, 
which can be measured at an absorbance of 595nm (Friedenauer & Berlet, 
1989). For each sample, 5 pi was diluted in 995pl of sterile water to give a 
1:200 dilution; 500pl of these dilutions were then transferred to clean 1.5ml 
Eppendorf tubes and 500pl of Bradford Reagent (Sigma) added to each tube. 
The reactions were vortexed and incubated at room temperature for five
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minutes, prior to recording the absorbance of each sample at 595 nm using 
disposable plastic cuvettes. All samples were prepared in duplicate.
Average absorbance values were used to calculate the concentration of 
protein in the undiluted samples by reading from the BSA standard curve 
(Appendix IV) and adjusting for the dilution factor. The volume of each 
sample required to give 10 jug of protein was calculated and aliquots 
prepared for storage at -20°C.
2.2.4.3 Separation of Proteins by SDS-PAGE
SDS-polyacrylamide gels were prepared based on the Laemmli two-phase 
system of protein separation (Laemmli, 1970) using the Bio-Rad minigel 
(8x10cm) format system. Proteins separated by this method are denatured to 
single strands by the presence of SDS, which exposes the charged amino 
acid residues. Exposure of these residues permits electrotransfer of the 
proteins to a membrane, and subsequent detection by western blotting using 
antibodies.
The glass plates were cleaned with ethanol prior to assembly and an 8% 
resolving gel mix (Appendix 1.3) pipetted between the plates. The gel was 
overlayed with ethanol and allowed to polymerize at room temperature for 
one hour. The ethanol overlay was then discarded and the surface of the gel 
washed six times with distilled water and freshly prepared 4% stacking gel 
mix (see Appendix 1.3) pipetted on top of the resolving gel. A 10-well Teflon 
comb was carefully inserted into each stacking gel, avoiding air bubbles, and 
pressed down into the solution to give approximately 5 mm of stacking gel 
between the bottom of the wells and the resolving gel interface.
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The stacking gel was left to polymerize for 30 minutes, then the combs 
carefully removed and the wells washed thoroughly with 1x Running buffer 
(Appendix I.3). The prepared gels were clamped into the electrophoresis 
module and both anode and cathode chambers filled with 1x Running buffer 
according to the manufacturer’s recommendations.
Protein samples were prepared by mixing 10 pg of each sample with 1 jliI of 
loading buffer (Appendix 1.9) and boiling at 100°C for 1 minute on a thermal 
cycler, with the lid heater set at 110°C. A coloured molecular weight marker 
was also boiled at 100°C for 1 minute, according to the manufacturer’s 
instructions.
The entire volume of each sample was loaded into the wells of the SDS- 
PAGE gel using gel loading pipette tips, ensuring that the samples sank to 
the bottom of each well. To one well of each gel was added 4 pi of boiled 
colour marker and 0.5 pi of a biotinylated molecular weight marker (Appendix 
II). Gels were connected to a power supply and electrophoresed at 120 V for 
90 minutes.
2.2.4.4 Electrotransfer of Proteins to PVDF Membrane
Following separation of proteins by SDS-PAGE, the gels were carefully 
removed from the tank and released from the glass plates into a volume of 
ice-cold Towbin Buffer (Appendix II.3) sufficient to cover the gel, in separate 
containers. An 8x10 cm piece of PVDF membrane was cut for each gel, pre­
wet for a few seconds in methanol and submerged in Towbin buffer. The gels 
and PVDF were allowed to equilibrate on the bench for 15 minutes; the fiber
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pads and blotting paper sheets were also wetted with buffer for the same 
period of time.
The transfer was set up as shown below in Figure 7.
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Figure 7 Western blotting transfer assembly 
The assembled sandwiches were inserted into the blotting module and 
placed into the tank along with a small magnetic stirrer bar and an ice pack. 
The tank was filled with Towbin buffer to the manufacturer’s recommended 
level, the lid and electrodes attached and electrotransfer performed at 150V 
for 1 hour with stirring (transfer protocol modified from 
www.bdbiosciences.com/pharmingen/protocols) After the transfer was 
completed, the PVDF membranes were removed from the sandwiches and 
air dried on paper towels. To assess the efficiency of the transfer, a gel was 
carefully retrieved and equilibrated in destain solution for 15 minutes prior to 
staining with coomassie blue overnight (Appendix 1.3). The stained gel was 
then destained to show the presence of any residual protein in the gel.
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2.2.4.5 Detection of Proteins by Western Blot and Enhanced 
Chemiluminesence
PVDF membranes which had been electroblotted were pre-wet with 
methanol for a few seconds, then washed 3 times with T/P-BST, (Appendix 
II), for 5 minutes per wash. A sufficient volume of buffer was used to 
completely cover the membrane, and gentle shaking was applied during all 
stages of the Western process. The colour marker, placed to the left at all 
times, was used to orientate the membrane so that the proteins faced 
upwards. The Western protocol was modified from existing protocols 
(www.bdbiosciences.com/pharmingen/protocols and Maniatis, Sambrook & 
Fritsch, 1989). Membranes were incubated in the blocking buffer (Appendix 
1.3) for 1 hour at room temperature, then washed 3 times as previously 
described. The primary monoclonal antibodies were diluted in 1% BSA/PBST 
at 1:300 (a-PTEN), 1:20,000 (a-fc-Actin), and 1:2000 (a-PAI-1). The blots 
were incubated with primary antibodies at room temperature for 90 minutes, 
washed three times, and incubated with anti-mouse secondary antibody 
diluted to 1:800 in 1% BSA/PBST at room temperature for 40 minutes. Anti- 
phospho-PTEN antibodies were used according to the manufacturer’s 
instructions. The membranes for all primary antibodies were washed three 
times prior to incubation with Vector ABC reagent (avidin-biotin-horesradish 
peroxidase complex), prepared according to the manufacturer’s instructions, 
for 30 minutes and again washed three times.
The ECL reagent was prepared according to the instructions supplied and 
applied to the membrane for 1 minute. Excess reagent was removed by 
touching the corners of the membranes with absorbent tissue, and the
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membranes quickly sandwiched between two sheets of cling film with the 
colour marker to the left. Membranes were taken to the darkroom and 
exposed to film for 1 minute before developing according to the instructions 
supplied with the film and manual processing chemicals.
2.2.4.5.1 Densitometric Analysis of Protein levels
Photographic films which had been produced by the method described in
2.2.3 were scanned by Mr R Stewart, Academic Unit of Pathology, University 
of Sheffield and scanning densitometric analysis performed. The software 
used in the analysis was QuantityOne version 2.4 from the PDI Discovery 
package (Pharmacia).
2.2.5 HEC-1B Cell Proliferation Assay
To assess the effect of TGF-&1 on HEC-1B cell proliferation, a Cell Titer 96 
Aqueous One Solution Cell Proliferation Assay was used, according to the 
protocol. This MTT-based assay measures the cellular reduction of the assay 
reagent to a blue formazan product, which can only be performed by 
metabolically active cells (Mosmann, 1989). Briefly, cells were seeded on 
three 96 well plates corresponding to 4, 8 and 24 hours stimulation and 
grown to confluence in complete medium (Appendix 1.1). Cells were serum- 
deprived in reduced-serum medium (Appendix 1.1) for 24 hours and then 
stimulated with 0, 1, 2, 4, 5, 7 and 10 ng/ml TGF-&1 in reduced serum 
medium. Controls either consisted of unstimulated cells prior to serum- 
starvation or they did not contain cells (growth medium and assay solution 
alone). Four replica wells were performed for each condition. Results were
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obtained by reading the absorbance of the wells at 490nm in an automated 
plate reader, 1 hour after the addition of the assay solution.
2.2.6 Assessment of the effect of cell density on PTEN expression in 
HEC-1B cells.
To determine the effect of increasing cell density on PTEN expression levels 
in the HEC-1B cell line, cells were seeded at 4.5x105 and 9x105 cells per 
small (T25) culture flask. Cells were grown in complete medium for 1, 2, 3 
and 4 days, plus 4 days with a growth medium change on day 3 (modified 
from Boyd & Kaufman, (1990). RNA extraction, cDNA synthesis and PCR 
were performed as described in Section 2.2.3. PCR products were analysed 
by running 10pl of each sample on a 2% agarose gels.
2.2.7 Morphological changes in HEC-1B and Ishikawa cell lines in 
response to TGF-B1
The effect of TGF-G1 on the morphology of HEC-1B and Ishikawa cells was 
investigated using a modified protocol previously described by Boyd & 
Kaufman, (1990). The cells were plated in triplicate onto two 24 well culture 
plates at an initial density of 1x104 cells/well in 1ml of complete medium. 
Cells were allowed to attach for 24 hours, then they were rinsed twice with 
reduced-serum medium (Appendix 1.1) and maintained in this medium for 48 
hours to induce synchronization. The medium was replaced with fresh 
reduced-serum medium containing 10ng/ml TGF-S1 or an equivalent volume 
of vehicle, (4mM sterile HCL with 1% BSA). The medium containing TGF-&1 
or vehicle was replaced daily.
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The morphology was observed after 48 and 72 hours by taking phase 
contrast light micrographs at x 200 magnification with a Leica DM/L inverted 
microscope using a Polaroid MicroSLR unit and 661 film. After photographing 
the cells, a cell count was performed by washing each well twice with PBS, 
trypsinising for 15 minutes and resuspending the cells in 1ml of complete 
medium. Cells were counted on a haemocytometer and the triplicate results 
shown graphically.
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2.3 CLONING OF FULL LENGTH HUMAN PTEN INTO CMV-pEGFP-N1 & 
ANALYSIS OF SUBCELLULAR LOCALISATION.
2.3.1 Cloning Strategy
PCR primers were designed to amplify full length PTEN from cDNA. These 
primers, the sequences of which are shown in Section 3.1, were designed to 
add restriction endonuclease sites to the PCR product for directional cloning 
into the CMV-pEGFP-N1 vector (Figure 8).
The forward primer, (PTEN 10), contained a 5’ EcoRI site (blue), and the 
reverse primer, (PTEN 11), contained a 5’ Sail site (red). This should 
promote the ligation of double digested insert into pEGFP vector in one 
orientation only, and thus ensure that the correct strand of the cloned PTEN 
cDNA is transcribed. The overall cloning strategy is illustrated in Figure 9.
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PTEN PCR PRODUCT & pEGFP
i 1.£coRI/Sa/l digest
5’ EcoRI Sal I 3’ 5’ EcoRI Sal I 3’
PTEN ■  pEGFP
I
2. Ligation
EIEN
3. Recombinant pEGFPEcoRI Sal
containing PTEN with C-pEGFP
terminal EGFP moiety
(green oval)
Figure 9
Cloning strategy showing 1. Digestion of PTEN & pEGFP, 2. Ligation of cut 
fragments to produce 3. Recombinant directional clone
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2.3.2 Extraction of RNA from whole human blood
Fresh human venous blood was collected from four staff members into 
vacutubes containing EDTA and the tubes marked anonymously. 
Mononuclear cells were harvested using Histopaque (Sigma), according to 
the manufacturers’ guidelines. Briefly, 5 ml of Histopaque was added to four 
sterile 15 ml Falcon tubes and carefully overlayed with 5 ml of each blood 
sample, ensuring that the blood did not mix with the Histopaque. The blood 
samples were centrifuged at 19,000 rpm for 30 minutes at room temperature 
using a Sorvall RT7 Plus centrifuge, and the mononuclear cells carefully 
collected from the interface using a sterile Pasteur pipette into clean 15 ml 
Falcon tubes.
The mononuclear cells were washed by adding 10 ml of sterile 1x PBS 
(Appendix 1.3) followed by centrifugation at 2000 rpm for 5 minutes at room 
temperature using a Sorvall rotor. This step was repeated and the pelleted 
cells resuspended in 1 ml of cold TRI reagent for RNA isolation. Quantitation 
of the resulting RNA was performed as described in Section 2.2.3.
2.3.3 RT-PCR of Full Length Human PTEN for Cloning
2.3.3.1 Analytical Scale Digestion of cDNA With Restriction 
Endonucleases Mse I and Hha I
cDNA synthesis was performed using 5jug of total RNA isolated from each of 
the four members of staff, as described in 2.2.3.3 To verify that the cDNA 
produced was free of genomic DNA contamination, each cDNA sample was 
amplified by PCR with exonic primers PTEN 1 and 4, using the PTEN I PCR 
programme and conditions previously described in Chapter 2. These primers
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amplified the N-terminal region of PTEN, yielding a fragment of 450bp in 
length which could be cleaved by Mse I and Hha I restriction endonucleases 
to distinguish between PTEN from mRNA or contaminating genomic 'FPTEN 
pseudogene (Liu & Kagan, 1999).
PTEN derived from cDNA contains a unique Mse I site, and the pseudogene 
contains a unique Hha I site within the PCR fragment (Appendix III). Each of 
the PCR products were therefore subjected to a restriction digest with each 
enzyme in separate reactions. 5 pi of PCR product was mixed in a sterile 0.2 
ml Eppendorf tube with 1pl of the appropriate 10x restriction buffer, (supplied 
with each enzyme), and 3pl of sterile water. 1pl of the appropriate enzyme 
was added (10U of Mse I or 20U of Hha\) and mixed by gentle flicking prior to 
incubating at 37°C for 2 hours on a thermal cycler.
The digestion was terminated by the addition of 2pl of loading buffer 
(Appendix I.8) and the products analysed by agarose gel electrophoresis on 
a 2% gel as previously described in Section 2.2.3.5.
2.3.4 PCR amplification of PTEN with High Fidelity Pfx Polymerase
2.3.4.1 Optimisation of PCR using Platinum Pfx Polymerase
Full length PTEN was amplified from each of the four staff cDNA samples 
using 0.5pl of the high fidelity proofreading DNA polymerase Platinum Pfx 
(InvitrogenJ, exonic primers PTEN 10b and 11a, and 3mM magnesium on the 
Pfx3lx PCR programme (Appendix V), to yield a fragment of 1.2 Kb. 10pl of 
each PCR product was analysed by agarose gel electrophoresis on a 1% gel
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with 1pl of 1Kb molecular weight marker, as previously described. The PCR 
programme was modified to increase the yield of product (Appendix V).
2.3.4.2 Scaled-up PCR of PTEN
Four PCR reactions were performed simultaneously using the Pfx3lx2 PCR 
programme and conditions previously described in Section 2.3.4.1. They 
were pooled and a 10pl aliquot was analysed on a 1% agarose gel.
2.3.5 Preparation of the PTEN fragment for ligation
2.3.5.1 Gel purification of the PTEN fragment
Full length PTEN PCR product was separated by 1% agarose gel 
electrophoresis and the product band carefully excised from the gel with a 
sterile scalpel. DNA was purified from the agarose slices using two columns 
from a Qiagen Gel Extraction Kit, according to the manufacturers’ 
instructions. Sterile water (30pl) was used to elute the DNA from each 
column, and the eluates were pooled.
2.3.5.2 Small-Scale Digestion of the PTEN PCR Product with Restriction 
Endonucleases Eco Rl and Sal I
Restriction digestion was performed by mixing 28pl of gel purified PCR 
product with 4pl of 10x EcoRI buffer, 4pl of 1pg/ml BSA and 2pl each of 
EcoRI and Sa/I in a total volume of 40pl. The digest was incubated at 37°C 
for 2 hours.
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2.3.5.3 Purification of the Eco Rl-Sal I digested PTEN Fragment and 
assessment of yield
The digested PTEN fragment was purified directly from solution using a 
Qiagen Gel Extraction Kit, according to the manufacturers’ instructions for the 
clean-up of enzymatic reactions. 30pl of sterile water was used to elute the 
purified DNA from the spin column, and the elutate stored at -20°C. Yield 
was assessed as described in 2.3.7.3.
2.3.6 Transformation of E.coli with CMV-pEGFP-N1
2.3.6.1 Preparation of chemically competent JA221 cells by calcium 
chloride method
Aseptic technique was used for all bacterial manipulations, using a protocol 
modified from Maniatis, Sambrook & Fritsch, (1989). A 1ml aliquot of JA221 
cells stored as a 50% glycerol stock at -80°C was thawed on ice. The 1ml of 
cells was inoculated into 100ml of LB in a 1L sterile flask and incubated at 
37°C for 16 hours with shaking at 250 rpm. The following morning 10ml of the 
saturated culture was diluted into 90ml of LB and grown at 37°C and 250 rpm 
for approximately 2 hours, until and an absorbance (A650) of 0.5-0.6 was 
reached.
The culture was then transferred into sterile pre-chilled 50ml Falcon tubes 
and incubated on ice for 10 minutes to inhibit further growth. The cells were 
centrifuged at 3,500 rpm at 4°C for 5 minutes in a pre-chilled Sorvall Super 
T21 centrifuge and the medium carefully removed. The cell pellets were
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resuspended in 10ml of ice-cold 0.1M MgCfe, incubated on ice for 5 minutes, 
and then centrifuged at 3,500 rpm at 4°C for 5 minutes.
Following careful aspiration of the supernatant, the cell pellets were gently 
resuspended in 1.5ml of ice-cold 0.1M CaCh and held on ice in preparation 
for transformation. The cells were treated very carefully at this stage, as the 
cell membranes are highly permeable and easily ruptured if too much shear 
force is applied to the tube.
2.3.6.2 Transformation of Competent JA221 with CMV-pEGFP-N1
Using the competent JA221 described above, a 200pl aliquot of cells was 
added to a sterile thin-walled polypropylene culture tube for transformation 
using pre-chilled pipette tips, based on a protocol modified from Maniatis, 
Sambrook & Fritsch, (1989). 1pl of CMV-pEGFP-N1 was added to the cells 
and mixed by swirling gently with the pipette tip; the cells were then 
incubated on ice for 30 minutes to allow the plasmid DNA to bind to the 
bacterial cell wall.
To induce bacterial uptake of the DNA, the cells were heat-shocked by 
placing the tube in a water bath at exactly 42°C for 90 seconds, then 
transferred immediately to ice for 2 minutes. 800pl of room-temperature SOC 
medium (Appendix 1.4) was added to the cells, which were incubated at 37°C 
for 1 hour at 220 rpm to allow expression of the kanamycin resistance gene 
encoded by the plasmid.
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2.3.6.3 Plating out of the transformants
From the transformed cells prepared in Section 2.3.6.1, a 100pl aliquot was 
spread onto an L-Agar plate containing 50pg/ml kanamycin (Appendix 1.4) 
using a sterile spreader and the plate inverted and placed in an incubator at 
37°C overnight. The plate was inspected for colony formation the following 
morning and stored inverted in a refrigerator until required.
2.3.7 Preparation of CMV-pEGFP-N1 Plasmid for Cloning
2.3.7.1 Small Scale Isolation of CMV-pEGFP-N1 DNA by Alkaline Lysis
From the plate prepared as described in Section 2.3.6.3, a single colony was 
picked using a sterile inoculating loop into 5ml of LB with kanamycin, 
(Appendix I.4), and incubated at 37°C for 16 hours at 250 rpm (Maniatis, 
Sambrook & Fritsch, (1989). Culture (3ml in total) was microcentrifuged in a 
1.5ml Eppendorf tube at 13,000 rpm for 5 minutes, and the pellet 
resuspended by vortexing in 100pl of ice-cold Solution I (Appendix 1.5). 
Solution II (200pl, Appendix 1.5) was added to the cell suspension and the 
tube gently inverted 5 times to lyse the cells. After incubation on ice for 3 
minutes the lysate was observed to become clear, indicating complete lysis, 
and 150pl of ice-cold Solution III (Appendix 1.5) was then added.
The tube was inverted twice and incubated on ice for 5 mins, prior to 
microcentrifugation at 13,000 rpm for 5 minutes at 4°C. 400pl of supernatant 
was transferred to a fresh sterile tube, an equal volume of 
phenol:chloroform:isoamyl alcohol added and the solution vortexed for 10 
seconds. The phases were separated by centrifugation at 13,000 rpm for 2 
minutes and 350pl of the supernatant transferred to a fresh sterile tube. To
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precipitate the plasmid DNA 700pl of100% ice-cold ethanol was added to the 
tube, mixed by inversion and incubated at -20°C for 20 minutes.
The DNA was pelleted by centrifugation at 13,000 rpm for 5 minutes at 4°C 
and washed with 1 ml of ice-cold 70% ethanol. A final centrifugation at 
13,000rpm for 10 minutes at 4°C was used to bring the pellet back to the 
bottom of the tube and the ethanol carefully aspirated.
The pellet was air-dried on the bench for approximately 2 hours until the DNA 
appeared transparent and dry, then resuspended in 40pl of 5mg/ml RNase A 
solution. Presence of the plasmid was confirmed by 1% agarose gel 
electrophoresis using 1pl of stock plasmid and a 1Kb molecular weight 
marker for a size comparison and to give an estimation of yield. Plasmid DNA 
was stored at -20°C until required.
2.Z.7.2 Small-Scale Digestion of CMV-pEGFP-N1 with restriction 
endonucleases EcoRI and Sal I
Double digest of the plasmid was performed essentially as described in 
Section 2.3.5.2, using 5pl of plasmid DNA (extracted as described in Section 
2.3.7.1) in a 20pl digest with 2pl of EcoRI (40U) and Sail (40U).
2.3.7.3 Gel Extraction of the EcoRI-Sa/1 Linearised Plasmid
To remove the unwanted small fragment generated during the restriction 
digest, the digest was fractionated on a 1% agarose gel and the 4.7Kb band 
corresponding to linearised vector carefully excised using a sterile scalpel. 
The DNA was extracted using a Qiagen Gel Extraction Kit according to the 
manufacturers’ instructions into 30pl of sterile water. Yield was assessed by
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analysing 5pl of the purified digested vector and 5pl of purified digested 
PTEN on a 1% agarose gel. The purified plasmid was stored at -20°C until 
required.
2.3.8 Ligation
After assessing the yield of the double-digested PTEN fragment and plasmid, 
three ligation reactions were carried out at DNA molar ratios of approximately 
1:1, 1:3 and 1:5 of vector : insert. This ensured that one of the reactions 
would contain the optimal amounts of each digested DNA fragment for 
efficient ligation. Ligations were performed by adding to the appropriate 
volumes of DNA 2.5pl of ligase buffer and 1pl of T4 DNA Ligase (NEB), in a 
total volume of 25pl. The reactions were incubated at 10°C for 16 hours on 
the block of a thermal cycler according to the instructions provided with the 
ligase.. A control ligation was also performed using 1pl of 100bp molecular 
weight marker under the same conditions, or at room temperature. To 
determine whether ligation had occurred, 10 pi of the three ligations and 
control reaction were subjected to 1 % agarose gel analysis.
2.3.9 Introduction of Recombinant Plasmid DNA into E.coli cells
2.3.9.1 Transformation of Chemically Competent DH5a
Chemically competent DH5a (Invitrogen) were transformed with 5pl of each 
ligation reaction (Section 2.3.8), according to the manufacturers’ 
recommendations, essentially as described in 2.3.6.2.
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2.3.9.2 Plating Out and Analysis of the Transformants
LB-Agar plates containing 50pg/ml Kanamycin were prepared as described 
in Appendix 1.4. Volumes of 20 or 50pl of each of the three transformation 
reactions were pipetted onto an agar plate and spread over the surface using 
a sterile spreader. A control plate was included which contained no 
antibiotic, onto which 20jliI of DH5a was spread from the remainder of the 
stock competent cells. The plates (8 in total) were incubated at 37°C for 16 
hours to allow colony formation. The number of colonies on each plate was 
noted by counting.
2.3.9.3 Confirmation of the presence of full length PTEN in the 
recombinant plasmids
Two medium-sized colonies were selected from each plate and inoculated 
into 5 ml of LB with 50 jig/ml kanamycin using sterile toothpicks, and grown 
for 16 hours at 37°C with shaking at 250 rpm. Each culture, (3ml), was used 
to isolate plasmid DNA by the alkaline lysis method as described in Section 
2.3.7.1; to the remaining 2ml of culture an equal volume of sterile glycerol 
was added, shaken, and frozen at -70°C.
The extracted plasmid DNA was analysed by running 1pl of each plasmid 
preparation against 0.5pl of uncut pEGFP on a 1% agarose gel. A 1pl aliquot 
of each plasmid was then double-digested with 1pl each of EcoRI, Sail and 
BSA in a total volume of 20pl as described previously. 10pl of each digest 
were analyzed by 1% agarose gel electrophoresis against 0.5pl of 
undigested pEGFP and 1 pi of double-digested pEGFP.
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2.3.10 Preparation of pRC-2 (clone 6A) plasmid DNA for Sequencing
Upon careful analysis of the results of gel electrophoresis of the double­
digested plasmid samples, the clone 6A was selected and named pRC-2. To 
propagate the clone, the pRC-2 glycerol stock was thawed and 20pl spread 
onto an L-Agar/Kan selective plate, as described in Section 2.3.9.2. After 16 
hours of incubation at 37°C a single colony was picked for overnight growth 
in selective LB as described in 1.7.3. From this preparation a stab culture 
was taken by dipping a sterile inoculating loop into the culture and ‘stabbing’ 
it into a selective L-agar tube (Appendix 1.4). The tube was incubated at 37°C 
overnight then packaged on ice and sent for sequencing to Lark 
Technologies.
2.3.11 Subcellular Localisation and Distribution of PTEN
2.3.11.1 Preparation of Ultrapure Supercoiled Plasmid
To improve the transfection rate of pRC-2 into all the cell lines, the plasmid 
was prepared by an alternative technique to the one described in Section 
2.3.7.1. Fresh LB selective plate was streaked with pRC-2 glycerol stock. An 
overnight culture was grown from a single colony picked from the plate and 
the plasmid isolated using a GenElute Plasmid Miniprep Kit, according to the 
manufacturer’s instructions. Plasmid DNA was analysed by agarose gel 
electrophoresis, the concentration measured spectrophotometrically at 
260nm and a stock solution of 1pg/pl prepared.
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2.3.11.2 Transfection of cell lines with pRC-2 by Lipid-Mediated Transfer
Initial transfections were performed on the COS-7 and HEC-1B cell lines 
using the pRC-2 plasmid at a stock concentration of 1 pg/pl. Cells lines were 
seeded on 13mm round coverslips placed in the wells of 24 well culture 
plates and grown to 50% confluence 24 hours prior to transfection with 0.6, 
0.7, 0.8, 0.9 or 1.0pg of plasmid, as recommended by the manufacturers of 
the Lipofectamine reagents (Invitrogen).
Two commercial transfection reagents were tested; Lipofectamine and 
Lipofectamine 2000 (LF2K), using 2pl of each reagent combined with each 
concentration of plasmid. These cationic lipid reagents bind to DNA and 
permit transfer across the cell membrane, and are commonly used in place of 
electroporation or calcium phosphate methods (Maniatis, Sambrook & 
Fritsch, 1989). The lipid reagents were used to transfect the cells according 
to the manufacturer’s instructions and these cells were then maintained in 
culture for 24 hours post-transfection to allow expression of the fusion 
protein.
The cells were washed twice with PBS, fixed in 200pl of ice-cold methanol for 
10 minutes (Beppu, et al, 1994), and the nuclei stained with DAPI (1pg/ml) 
for 5 minutes. The stain was washed off twice with PBS and the coverslips 
mounted on microscope slides using a small drop of Fluoromount G aqueous 
mountant.
Slides were analysed by manual fluorescence microscopy using a U-V filter 
for DAPI and FITC filter for EGFP The microscope used was an Olympus 
BX60 microscope with a JVC 3-CCD digital camera and Image Grabber PC
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V1.2 (Neotech Ltd, 1995) software. Transfection efficiency using
Lipofectamine and LF2K was recorded for each cell line.
2.3.12 Optimisation of Transfection
Adherence of the cells during fixing was improved by seeding onto coverslips 
that had been treated with polylysine. Prior to adding the cells, the coverslips 
were submerged in 200pl of a 5pg/ml solution of polylysine (Sigma) in sterile 
PBS for 20 minutes, according to the manufacturers’ recommendations. The 
polylysine was aspirated, allowed to air dry for a few minutes and the cells 
pipetted into the wells of the culture plate. The experiment described above 
in 2.3.1.2 was repeated using polylysine-treated coverslips and HEC-1B and 
Ishikawa cell lines. Conditions resulting in the highest transfection rate and 
expression of EGFP were noted for each cell line.
2.3.13 Stimulation of Transfected Cell lines
The effect of TGF-&1 and estrogen on the localization of pRC-2 was 
investigated in the HEC-1B and Ishikawa cell lines. The cell lines were 
transfected with 0.8-1.Opg of pRC-2 using 2pl Lipofectamine prior to 
treatment with the relevant compound.
2.3.13.1 Oestrogen
Transfected cells were stimulated with 10 or 100nM B-Oestradiol (Appendix
1.6) for various periods of time, based on work by Campbell, et al (2001). The
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complete growth medium was replaced with reduced-serum medium 
(Appendix 1.1) and the appropriate volume of hormone from the stock 
solution. HEC-1B cells were stimulated for 30 minutes and 1, 2, 6, or 24 
hours. Ishikawa cells were stimulated for 24 or 48 hours using reduced- 
serum medium with and without phenol red, to ascertain whether this 
molecule (which has structural similarity to oestrogen) was affecting the 
results. After each time point the coverslips were washed, fixed, DAPI 
stained and mounted for microscopic analysis as described in Section 
2.3.11.2.
2.3.13.2 TGF-B1
Transfected cells were stimulated with 2 or 5ng/ml of TGF-B1 (Appendix 1.6) 
for 30 minutes, 1, 2 and 6 hours. After transfection the complete growth 
medium was replaced with reduced-serum medium (Appendix 1.1) and the 
appropriate volume of cytokine from the stock solution. When stimulation was 
complete the coverslips were prepared for microscopic analysis as previously 
described.
2.3.14 Localisation of pRC-2 to Subcellular Compartments
To determine the sequestration of pRC-2 to subcellular compartments, 
transfected HEC-1B and Ishikawa and were used in double-labelling 
experiments. Monoclonal antibodies to the ER protein Colligin (Stressgen), 
PTEN (BD) and B-Actin (Sigma), were used according to the manufacturers’ 
guidelines. A polyclonal antibody against the golgi protein Mannosidase II
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The supernatant was carefully removed and the pellet reuspended in 20 ml of 
Buffer A, prior to centrifugation at 3000 rpm for 15 minutes at room 
temperature. The supernatant was again discarded and the pellet 
reuspended in 1 ml of Buffer B (Appendix I.7), and transferred to a sterile 1.5 
ml Eppendorf tube.
5M Sodium perchlorate (300pl) was added to the samples, which were mixed 
end-over-end for 10 minutes at room temperature followed by 
microcentrifugation at 14,000 rpm for 10 minutes at 4°C in a Heraus 
Microcentaur. To fresh Eppendorf tubes 600 pi of supernatant was 
transferred and 700 pi of ice-cold chloroform added. The samples were 
mixed end-over-end for 3 minutes at 4°C and then centrifuged at 14,000 rpm 
for 10 minutes at 4°C.
The top layer of each sample was carefully transferred to a clean tube and 
two volumes of ice-cold ethanol added, with gentle mixing. A final 
centrifugation at 14,000 rpm for 15 minutes at 4°C was performed, and the 
supernatant aspirated from resulting DNA pellets, which were air dried for 10 
minutes. The dried pellets were reuspended in 200-500 ml of sterile distilled 
water and stored at -70°C.
2.4.1.2 Extraction of Patient DNA from archival material
DNA from archival material was extracted and made available for my use by 
kind permission of Dr Ken Feeley, University of Sheffield Medical School. 
The extractions were performed by a member of Dr Feeleys technical staff.
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was kindly donated by Prof David Parkinson, and used according to his 
recommendations. Cell lines transfected as described previously were fixed 
in methanol, blocked for 1 hour with normal goat serum (NGS, Appendix II.6) 
and incubated with a-Colligin (1:200), a-Mannosidase II (1:70), a-PTEN 
(1:200) and a-B-Actin (1:20,000) in NGS for 1 hour. The cells were washed 
twice with PBS and incubated with secondary a- mouse / rabbit Alexafluor 
594 (1:200) in NGS for 45 minutes according to the enclosed instructions; the 
cells were then washed, DAPI stained and mounted.
2.4 MUTATIONAL ANALYSIS OF PTEN EXONS 3 & 5 IN ENDOMETRIAL 
DNA SAMPLES BY SINGLE STRAND CONFORMATION 
POLYMORPHISM ANALYSIS (SSCP)
2.4.1 Preparation of DNA Samples for SSCP Analysis
2.4.1.1 Extraction of DNA from whole human blood
Fresh human venous blood was collected from staff members into vacutubes 
containing EDTA and the tubes marked anonymously for processing using a 
method modified from Maniatis, Sambrook & Fritsch, (1989). Each blood 
sample (10-20ml) was transferred to sterile universal tubes and Buffer A 
(Appendix 1.7) added to make a total volume of 50 ml. The samples were 
mixed end-over-end for 4 minutes at room temperature, followed by 
centrifugation at 3000 rpm for 15 minutes at room temperature in a Sorvall 
RT7 Plus centrifuge.
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2.4.2 PCR of Patient & Control DNA for SSCP Analysis
PCR was carried out on patient DNA samples extracted from paraffin 
embedded archival tissue, and on control DNA prepared as described in 
Section 2.4.1.1. Oligonucleotide primers designed to amplify PTEN Exons 5 
and 8, (Risinger et al, 1997), in two overlapping fragments of approximately 
200bp in length for each exon were used. Primers 5A/5B and 5C/5D (Section 
2.1.3) produced PCR products of 137bp and 186bp respectively, and 8A/8B 
and 8C/8D produced PCR products of 122bp and 245bp respectively.
PCR was performed using 1-5pl of patient DNA, 3mM magnesium chloride, 
0.2 mM dNTPs, 0.5jnl of RedHot Taq polymerase and 50pM of forward and 
reverse primer in 1 x reaction buffer, in a total volume of 25pl. Reactions 
were carried out using the PTEN I programme for all primer pairs 5C/D and 
8A/B or the RIS2-2 programme for primers 5A/B (Appendix V). The PCR 
products (10pl) were analysed by agarose gel electrophoresis.
2.4.3 Preparation of Control PCR products for sequencing
To verify that the PCR products amplified from the control DNA were wild- 
type, and therefore suitable for use as SSCP controls, PCR fragments for 
each primer pair were sequenced following the extraction from 2% agarose 
gels using a Qiagen Gel Extraction Kit. The purified fragments were vacuum 
desiccated and sent to Lark Technologies where they were automatically 
sequenced using the respective PCR primers.
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2.4.4 SSCP analysis
2.4.4.1 Large gel format, Hoefer 18 x 24cm
SSCP was performed essentially as described by Rhei, et al (1997) and 
Aveyard, et al (1999). A large format gel was used to enable the samples to 
be electrophoresed slowly overnight, (to minimize heat generation), and to 
give maximum separation of bands. The SSCP plates were cleaned 
thoroughly with ethanol and assembled using 1mm spacers. Gels were 
prepared at concentrations of either 0.5 x MDE, for exon sections 5CD and 
8AB, or 0.6 x MDE for exon sections 5AB and 8CD all with 5% or 10% 
glycerol (Appendix 1.9) and cast between the assembled glass plates.
Teflon combs (15 wells) were inserted into the gels, which were allowed to 
polymerize at room temperature for 3 hours. The polymerized gels were then 
chilled to 4°C for 2 hours, the combs were removed and the wells rinsed 
thoroughly with chilled 0.6 x TBE running buffer (Appendix 1.9). The gels 
were then clamped into the gel tank and submerged in running buffer.
PCR products were prepared for SSCP analysis by mixing 2-4pl of sample 
with an equal volume of formamide buffer (Appendix I.9) and sterile water to 
a total volume of 10pl. Samples were then heated at 95°C for 10 minutes on 
a thermal cycler before being transferred to ice for 2 minutes. 10pl of each 
sample were loaded into the wells of the gel using gel loading tips; 0.5jul of 
molecular weight marker was also included in one well of each gel. The 
samples were subjected to electrophoresis at 18W constant power for 16 
hours with an ambient temperature of 4°C.
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2.4A.2 Silver staining
Upon completion of electrophoresis the plates were removed from the tank 
and the gels developed initially using a silver staining protocol based on that 
of Merril, (1990). Briefly, the gels were fixed for 10 minutes, incubated with a 
silver solution for 15 minutes and washed with distilled water, prior to 
developing for 15 minutes. The gels were washed again and then a final fixer 
solution applied for 10 minutes (Appendix I.9).
To improve the sensitivity of detection a PlusOne DNA Silver Staining kit was 
later used for all gels, according to the manufacturer’s instructions. Stained 
bands were visualized on a visible light box and photographed using a Kodak 
DC120 digital camera before being sealed in BioDesign gel wrap and allowed 
to dehydrate at room temperature for 24 hours. Bands observed for each 
patient sample were compared to those corresponding to the control DNA 
samples on each gel, and samples exhibiting bandshifts or extra bands were 
subjected to a repeated gel run.
For samples with confirmed bandshifts, the remaining PCR product was 
packaged on ice with aliquots of the relevant primer pairs and sent to Lark 
Technologies for sequencing.
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CHAPTER 3 
RESULTS
3.1 ANALYSIS OF EXPRESSION OF PTEN AND SELECTED GENES IN 
HEC-1B AND ISHIKAWA CELL LINES STIMULATED WITH TGF-B1
The aim of this section was to evaluate the response of PTEN to stimulation 
by TGF-p1 in endometrial cell lines. Several studies of this nature have 
previously been published describing the response of PTEN to TGF-p1 in 
other cell lines, including keratinocytic and myeloid, but the data from these 
papers is conflicting and appears to be cell-line specific. Compounds which 
up-regulate PTEN expression may represent a useful therapeutic strategy in 
the non-surgical treatment of tumours.
To assess any biologically significant changes in PTEN expression, both 
mRNA and protein levels were studied in two epithelial cell lines of 
endometrial adenocarcinoma origin. The HEC-1B cell line, representing a 
moderately differentiated grade II carcinoma (Crescenzi & Palumbo, 2001), 
possesses wild-type PTEN (Yaginuma, et al 2000) and expresses the protein 
(Figure 10.1). Conversely, the Ishikawa cell line represents a well 
differentiated carcinoma, but has a frameshift deletion in exon 8 of PTEN 
(codon 289 deletion of A) which codes for a rapidly degraded protein 
truncated at codon 290 (Yaginuma, et al 2000).
For experimental control purposes RNA and protein expression of the 
housekeeping genes GAPDH and p-Actin were studied. Housekeeping 
genes, including those indicated, are constitutively expressed and necessary 
for cell survival, with highly stable expression levels that are unlikely to 
change under experimental conditions. The TGF-p1 responsive gene PAI-1
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was also analysed, as levels of this gene have been widely reported to 
increase during TGF-p1 stimulation in many cell lines (Keeton, et al 1991, 
Fujimoto, et al 1996 & Jiang, et al 2003). mRNA expression of the pro- 
apoptotic protein Bcl-2 in FIEC-1B was also analysed by RT-PCR, as this 
protein has been reported to be down-regulated in this cell line (Crescenzi, et 
al 2000). Levels of phospho-PTEN protein were also analysed using an 
antibody specific for phosphorylated Ser380, as phosphorylation of the PTEN 
tail influences stability, degradation and activity of the protein.
Stimulation with cytokine was performed in the presence of either 10% or 1% 
foetal calf serum, which contains varying amounts of TG F-p i The 10-fold 
reduction in serum concentration was therefore used to discount any effects 
of cytokine in the growth medium. Cellular morphology, density, and 
proliferation were also studied to further elucidate any correlation between 
TGF-p1 stimulation and PTEN expression.
3.1.1 Analysis of mRNA expression
Cells were grown under serum-starved and non-starved conditions in order to 
assess any differences in response to TGF-p1 under different growth 
conditions. The cells were then treated with either 2ng/ml or 5ng/ml TGF-p1, 
RNA was extracted and quantitation of the yield and purity of RNA from each 
sample was performed. These procedures are detailed in Chapter 2, 
Sections 2.2.1 to 2.2.3. The results shown in Appendix VII indicated a good 
yield of RNA, the quality of which would be shown by electrophoresis. All 
samples were diluted to 1 pg/pl prior to use in PCR.
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Semi-quantitative analysis of mRNA for PTEN, PAI-1 and GAPDH
RT-PCR was performed as described in Chapter 2 Section 2.2.3 and the 
products separated by agarose gel electrophoresis (Chapter 2, Section 
2.2.3.5). Results are displayed in Figures 10 to 14 as a time course (4 to 24 
hours) with TGF-R1 concentrations of 2ng/ml in red, 5ng/ml in blue and the 
control (no TGF-B1) in white. A Yellow line indicates PCR control minus 
cDNA template and duplicate sets of data are labelled A and B. A 100bp 
ladder was included on each gel. Densitometric analysis of PCR products 
was performed as described in Chapter 2 and shown in Tables 3 to 7. 
Results below the detection limit of the software are indicated by the notation 
“nd” (no data). Using Microsoft Excel, the overall results of PTEN mRNA 
expression for each experiment were expressed graphically by plotting the 
mean mass of DNA for each set of data points (Graphs 1 to 3). Error bars 
were added after calculating the standard error of the mean values.
Results for HEC-1B serum non-starved electrophoresis are shown in Figures
10.1 to 10.4, and densitometric analysis is shown in Table 3 and Graph 1. 
This experiment was performed once, in duplicate. Results for HEC-1B 
serum starved electrophoresis experiments 1 and 2 are shown in Figures
11.1 to 11.4 and Figures 12.1 to 12.4, respectively, and densitometric 
analysis is shown in Table 4 and Table 5 respectively. Overall results for both 
independent experiments (performed in duplicate) are illustrated in Graph 2. 
Results for Ishikawa serum non-starved electrophoresis are shown in Figures
13.1 to 14.4, and densitometric analysis is shown in Tables 6 and 7. This 
experiment was performed once in duplicate, and cDNA synthesis performed 
twice, in duplicate. Results for both experiments are illustrated in Graph 3.
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Serum non-starved HEC-1B
Ong
4 8  2 4
I
A  B
Fig 10.1 PTEN expression in non-starved HEC-1B with duplicates A and B. 
No TGF-pi control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml TGF-pi in 
blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
A  B
Fig 10.2 GAPDH expression in non-starved HEC-1B with duplicates A and B. 
No TGF-p1 control shown in white, 2ng/ml TGF-pi in red, 5ng/ml TGF-pi in 
blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
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A  B
Fig 10.3 PAI-1 expression in non-starved HEC-1B with duplicates A and B. 
No TGF-p1 control shown in white, 2ng/ml TGF-pi in red, 5ng/ml TGF-pi in 
blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
Ong/4
Fig 10.4 -R T controls for 
PTEN expression in non- 
starved HEC-1B, all 
samples and duplicates 
A/B. PCR control shown as 
yellow dash.
Fig 10.5 Expression of 
1: PTEN and 2: TPIP with PCR 
control (yellow dash) in HEC- 
1B.
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S e ru m  n o n -s ta rv e d  H E C -1B  s tim u la te d  w ith  T G F -p i
This experiment was performed once, with duplicate flasks A and B from 
which cDNA was prepared for RT-PCR using primers for PTEN, PAI-1 and 
GAPDH. The analysis of RT-PCR products shown in Figure 11.1 show a 
subtle time and dose-dependant increase in PTEN mRNA expression in 
samples stimulated with TGF-pi when compared to the controls. The 
response of PAI-1 in Figure 10.3 indicated a strong time and dose-dependant 
increase in expression (approximately four-fold) compared to the 
unstimulated controls, in a manner concurrent with published data (Lee, et al 
1999).
2ng/ml TGF-01
From Figure 10.1 it was seen that under stimulation with 2ng/ml of cytokine, 
no increase in PTEN expression was detected at 4 hours. An average 
increase in expression of ~1.5-times was observed at 8 hours but little 
change at 24 hours was observed compared to the controls.
Figure 10.3 shows PAI-1 mRNA expression in response to cytokine 
stimulation. At 4 hours, an increase of ~4-times compared to the controls was 
observed. At 8 and 24 hours an increase in PAI-1 expression of ~3.5-times 
and 3-times respectively was detected in comparison to the controls.
5ng/ml TGF- j31
Samples stimulated with 5ng/ml of TGF-p1 exhibited an increase in PTEN 
expression at 4 hours of ~1.4 times. At 8 hours the average increase in
131
expression was ~2-times that of the controls and at 24 hours a small 
increase of ~1.2-times was observed:
Figure 10.3 shows PAI-1 mRNA expression in response to cytokine 
stimulation. At 4 hours, an increase of ~5-times compared to the controls was 
observed. At 8 and 24 hours an increase in PAI-1 expression of ~4-times and 
3-times respectively was detected in comparison to the controls.
Expression levels of GAPDH shown in Figure 10.2 remained constant in all 
samples, indicating that TGF-p1 had no discernable effect on this 
housekeeping gene.
Figure 10.4 shows RT-PCR of reverse transcription controls using the PTEN 
primers 2a and 3. All samples are free of PCR product and therefore the 
cDNA samples prepared were free of DNA contamination. The results 
observed in Figures 10.1 to 10.3 were also shown by densitometric analysis 
of band intensities in Table 3.
The additional PCR shown in Figure 10.5 was performed using 4 hour control 
cDNA and primers for PTEN (2a & 3) and TPIP (TPTE and PTEN 
homologous inositol lipid phosphatase). Sequences of the primers are listed 
in Chapter 2, Section 2.1.3. This PCR was included to demonstrate that 
amplification of TPIP, a PTEN homologue, had not occurred and therefore all 
such PCR reactions were specific for PTEN only.
Expression of Bcl-2 mRNA was undetectable in the 1:4 dilutions of cDNA 
used to perform RT-PCR. Feint bands were visible in all samples when 
undiluted cDNA was used, indicating that this cell line expressed very little 
Bcl-2 mRNA, and stimulation with TGF-p1 did not noticeably alter expression 
levels. The results are not shown due to the feint bands being very difficult to
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photograph. Very low expression of Bcl-2 protein has previously been 
reported in the HEC-1B cell line, and is indicative of malignant change from 
hyperplasia to carcinoma (Crescenzi & Palumbo, 2001).
Summary of Results
A modest up-regulation of PTEN mRNA was observed in cells stimulated 
with TGF-pi compared to the controls. The increase in transcripts was more 
strongly observed in cells stimulated with 5ng/ml of cytokine, which was seen 
to be approximately double after 8 hours compared to the unstimulated 
controls.
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Table 3 H E C - 1 B  S e r u m  non-starved P C R  Densitometry
P T E N  P C R  A P T E N  P C R  B
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
O D
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
O D
Ong/4 41.15 161 Ong/4 59.49 161
8 114 187 8 123.6 194
24 199.7 194 24 224.4 220
2ng/4 28.31 91 2ng/4 45.43 91
8 169.6 194 8 224.4 224
24 209.6 210 24 253.3 224
5ng/4 63.45 142 5ng/4 74.3 139
8 194.8 207 8 254.6 227
24 237.5 210 24 280.2 251
G A P D H  P C R  A G A P D H  P C R  B
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
O D
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
O D
Ong/4 332.11 252 Ong/4 321.9 251
8 330.31 252 8 320.64 253
24 332.13 252 24 321.71 253
2ng/4 330.4 251 2ng/4 313.2 250
8 332 253 8 319.81 253
24 334.2 254 24 320.21 254
5ng/4 331.16 253 5ng/4 320.3 252
8 332.11 254 8 320.6 254
24 333.5 254 24 321 252
PAI-1 P C R  A PAI-1 P C R  B
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
O D
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
O D
Ong/4 40.93 89 0ng/4 41.45 91
8 70.12 117 8 70.55 117
24 110.67 117 24 114.4 118
2ng/4 176.3 218 2ng/4 179.4 218
8 261.5 245 8 261.3 245
24 295.1 254 24 293.2 252
5ng/4 200 220 5ng/4 196.6 220
8 285.64 254 8 287.3 238
24 294.4 254 24 296.8 238
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Serum starved HEC-1B, Experiment 1
A B
Fig 11.1 PTEN expression in serum-starved HEC-1B with duplicates A and 
B. No TGF-(31 control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml TGF-p1 
in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
Ong
_J0%4 a 24
A B
Figure 11.2 PAI-1 expression in serum-starved FIEC-1B with duplicates A 
and B. No TGF-P1 control shown in white, 2ng/ml TGF-pi in red, 5ng/ml 
TGF-pi in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
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Fig 11.3 GAPDH expression in serum-starved HEC-1B with 
duplicates A and B. All samples from TGF-(31 (white) to 
5ng/ml TGF-(31 (red) and duplicates A/B. PCR control shown
as yellow dash
Fig 11.4 -RT controls for PTEN expression in serum starved 
HEC-1B. All samples from TGF-(31 (white) to 5ng/ml TGF-(31 
(red) and duplicates A/B. PCR control shown as yellow dash.
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S e ru m -s ta rv e d  H E C -1B  s tim u la te d  w ith  TGF-J31
This experiment was performed twice, with duplicate flasks A and B from 
which cDNA was prepared for RT-PCR using primers for PTEN, PAI-1 and 
GAPDH. The two experiments were performed independently and were 
donated experiments 1 and 2 respectively.
Experiment 1
The analysis of RT-PCR products shown in Figure 11.1 show a subtle time 
and dose-dependant increase in PTEN mRNA expression in samples 
stimulated with TGF-p1 when compared to the controls, with a slightly 
different response pattern to that observed in the non-starved experiments. 
Reduction of serum initiated a 2-fold increase in expression, as observed 
between the 10% serum controls and 4 hour serum-starved controls. 
Modulation of PTEN expression during serum starvation has been reported 
previously in neuronal cells (Kyrylenko, et al 1999). The response of PAI-1 in 
Figure 11.3 indicated a strong time and dose-dependant increase in 
expression (approximately three-fold) compared to the unstimulated controls.
2ng/ml TGF-p1
From Figure 11.1 it was seen that under stimulation with 2ng/ml of cytokine, 
no increase in PTEN expression was detected at 4 hours. An average 
increase in expression of ~2-times was observed at 8 hours and maintained 
over 24 hours compared to the controls.
Figure 11.2 shows PAI-1 mRNA expression in response to cytokine 
stimulation. At 4 hours, negligible increase of expression compared to the
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controls was observed. At 8 and 24 hours an increase in PAI-1 expression of 
~2-times and 3-times respectively was detected in comparison to the 
controls.
5ng/ml TGF- (31
Samples stimulated with 5ng/ml of TGF-p1 exhibited an increase in PTEN 
expression at 4 hours of ~2-times. At 8 hours the average increase in 
expression was ~2-times, which was again maintained over the 24 hour 
period when compared to the controls.
Figure 11.2 shows PAI-1 mRNA expression. At 4 hours, very little increase of 
expression compared to the controls was observed. At 8 and 24 hours an 
increase in PAI-1 expression of ~2-times and 3-times respectively was 
detected in comparison to the controls.
Expression levels of GAPDH shown in Figure 11.3 remained constant in all 
samples, indicating that TGF-p1 had no detectable effect on this 
housekeeping gene.
Again, Bcl-2 levels were undetectable in diluted cDNA samples but feint 
bands were detected using undiluted cDNA as observed for serum non­
starved HEC-1B. TGF-01 did not appear to alter expression of Bcl-2 mRNA 
from the slight bands seen in the controls (data not shown).
Figure 11.4 shows RT-PCR of reverse transcription controls using the PTEN 
primers 2a and 3. All samples are free of PCR product and therefore the 
cDNA samples prepared were free of DNA contamination. The results 
observed in Figures 11.1 to 11.3 were also shown by densitometric analysis 
of band intensities in Table 4.
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Table 4 HEC-1B Serum-Starved Experiment 1 PCR Densitometry
PTEN PCR A PTEN PCR B
TGF-pi (ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pi (ng) 
/Time (hrs)
Mass
ng Peak OD
10% 82.76 175 10% 63.6 128
Ong/4 124.4 205 Ong/4 122.63 206
8 115.6 208 8 116 214
24 69.99 156 24 68.91 158
2ng/4 141.5 192 2ng/4 143.2 205
8 264.7 250 8 264 250
24 130.7 196 24 126.4 193
5ng/4 149 215 5ng/4 149 214
8 254.7 247 8 255.1 246
24 132 212 24 130.2 202
GAPDH PCR A GAPDH PCR B
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pl(ng) 
/Time (hrs)
Mass
ng Peak OD
10% 332.4 255 10% 330.2 247
4 333.1 254 4 331.11 252
8 333 255 8 331 252
24 331.64 254 24 333.7 252
2ng/4 331.11 254 2ng/4 329.6 252
8 330.16 254 8 334.3 251
24 330.9 255 24 332 251
5ng/4 330 253 5ng/4 321.9 250
8 332 253 8 332 253
24 334.2 255 24 331.8 254
PAI-1 PCR A PAI-1 PCR B
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pi (ng) 
/Time (hrs)
Mass
ng Peak OD
10% 47.3 92 10% 60 146
Ong/4 54 102 Ong/4 61.4 143
8 56.4 122 8 61.1 147
24 40.2 87 24 47.5 96
2ng/4 60.8 147 2ng/4 76 151
8 89.6 174 8 113.3 196
24 110.3 193 24 176 219
5ng/4 61 149 5ng/4 64 155
8 92.5 188 8 120.7 204
24 121 201 24 200.6 241
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Serum starved HEC-1B, Experiment 2
A B
Fig 12.1 Expression of PTEN in serum-starved HEC-1B with duplicates A 
and B. No TGF-|31 control shown in white, 2ng/ml TGF-pi in red, 5ng/ml 
TGF-pi in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
A B
Figure 12.2 Expression of GAPDFI in serum-starved FIEC-1B with duplicates 
A and B. No TGF-pi control shown in white, 2ng/ml TGF-pi in red, 5ng/ml 
TGF-pi in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
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A B
Fig 12.3 Expression of PAI-1 in serum-starved HEC-1B with duplicates A 
and B. No TGF-p1 control shown in white, 2ng/ml TGF-pi in red, 5ng/ml 
TGF-p1 in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash
Fig 12.4 -RT controls for PTEN expression in serum-starved HEC-1B with 
duplicates A and B in green No TGF-pi control (white), to 5ng/ml TGF- 
pi (red) over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash
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Experiment 2
The analysis of RT-PCR products shown in Figure 12.1 again show a subtle 
overall increase in PTEN mRNA expression in samples stimulated with TGF- 
p i, with a two-fold peak at 8 hours as observed in serum-starved Experiment 
1. This increase was again maintained over 24 hours as seen in Experiment 
1 (Figure 11.1), with the exception of the 5ng/ml sample at 24 hours from 
flask A. This sample did not show the 2-fold increase in PTEN expression 
and was most likely due to experimental error.
Expression levels of GAPDH shown in figure 12.2 were constant, and PAI-1 
in Figure 12.3 showed the same 3-fold increase in expression as seen in 
Experiment 1. Results for Bcl-2 were as described for serum-starved 
experiment 1, with only feint bands detected in RT-PCR with undiluted cDNA 
and no change in expression under TGF-pi stimulation (data not shown). All 
RT-PCR controls were free of contamination as shown in Figure 12.4 and the 
results observed in Figures 12.1 to 12.3 were additionally shown by 
densitometric analysis of band intensities (Table 5).
Summary of Results for Experiments 1 & 2
A modest up-regulation of PTEN mRNA was observed in cells stimulated 
with TGF-p1 compared to the controls. The increase in transcripts was more 
strongly observed in cells stimulated with 5ng/ml of cytokine, which was seen 
to be approximately double after 4 hours compared to the unstimulated 
controls, and was maintained over the 24 hour period.
In both serum non-starved and serum-starved HEC-1B cells treated with 
TGF-pi, a modest time and dose-dependant increase in PTEN mRNA
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expression was observed. This change in expression was quite similar 
regardless of serum levels, although serum-starvation did appear to yield a 
stronger induction of PTEN mRNA at 8 hours of stimulation with both 
concentrations of cytokine.
Notable, the response appeared to differ slightly between the controls for 
these experiments which were not treated with cytokine, indicating the 
presence of serum may alter PTEN mRNA levels. For example, PTEN 
expression in serum non-starved HEC-1B controls increases slightly in a 
linear manner over the 24 period of incubation. Cells which were serum- 
starved, however, demonstrated a gradual reduction in PTEN transcript 
levels in a linear manner over the 24 hour period. The significance of this is 
not clear from these results, but as a decrease in PTEN mRNA levels was 
observed in the controls in reduced serum medium this could be due to lower 
level of cytokines in the medium, including TGF-pi, reducing overall PTEN 
levels.
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Table 5 HEC-1B serum-starved experiment 2 PCR densitometry
PTEN PCR A PTEN PCR B
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
10% 149.7 200 10% 139 191
Ong/4 163.8 204 Ong/4 164.1 201
8 133.2 204 8 167.5 203
24 59.28 157 24 167.3 210
2ng/4 70.1 173 2ng/4 143.7 209
8 187.4 252 8 176.4 225
24 149.3 165 24 170 224
5ng/4 147.3 220 5ng/4 151.8 207
8 187.6 257 8 188.4 236
24 57.9 150 24 165.2 205
GAPDH PCR A GAPDH PCR A
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
OD
10% 329.3 249 10% 334.7 245
Ong/4 329 241 Ong/4 332.6 244
8 329.11 241 8 334.4 245
24 323.21 241 24 333.28 243
2ng/4 330 247 2ng/4 329.8 244
8 330.4 246 8 333.71 246
24 333 246 24 334.67 247
5ng/4 332 244 5ng/4 330.5 241
8 334.2 245 8 333.5 243
24 332.5 245 24 333.2 245
PAI-1 PCR A PAI-1 PCR B
TGF-p1 (ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-p1 (ng) 
/Time (hrs)
Mass
ng
Peak
OD
10% 63 147 10% 50 103
Ong/4 64 149 Ong/4 51.1 110
8 66.4 149 8 51 114
24 65 134 24 53.3 125
2ng/4 74 153 2ng/4 74.9 158
8 115.1 189 8 112.4 195
24 174.6 217 24 147 210
5ng/4 66 152 5ng/4 80 156
8 117.2 200 8 123.6 202
24 197 237 24 205 240
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Serum non-starved Ishikawa cells, Experiment 1
A B
Fig 13.1 Expression of PTEN in non-starved Ishikawa with duplicates A and 
B. No TGF-(31 control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml TGF-pi 
in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash
A B
Fig 13.2 Expression of GAPDH in non-starved Ishikawa with duplicates A 
and B. No TGF-(31 control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml 
TGF-01 in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
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A B
Fig 13.3 Expression of PAI-1 in non-starved Ishikawa with duplicates A and 
B. No TGF-(31 control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml TGF-pi 
in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash
Ong
A B
Fig 13.4-RT controls for PTEN expression in non-starved Ishikawa with 
duplicates A and B. No TGF-(31 control shown in white, 2ng/ml TGF-01 in 
red, 5ng/ml TGF-p1 in blue over 4, 8 & 24 hours. PCR control (no DNA) is a
yellow dash
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This experiment was performed once, with duplicate flasks A and B. From 
these duplicate flask, cDNA was prepared twice on separate occasions for 
RT-PCR using primers for PTEN, PAI-1 and GAPDH. The two individual 
batches of cDNA were designated as experiments 1 and 2 respectively.
Experiment 1
The analysis of RT-PCR products shown in figure 13.1 show a modest time 
and dose-dependant two-fold increase in PTEN mRNA expression in 
samples stimulated with TGF-p1 at 8 hours, similar to that observed in serum 
non-starved HEC-1B. This cell line, which has a mutant copy of PTEN, also 
responded to cytokine stimulation by up-regulating expression of the TGF-pi- 
responsive gene PAI-1,but the expression pattern was different from that 
observed for HEC-1B. In ISK cells, induction of mRNA for PAI-1 was rapid 
and maximal at 4 hours, declining thereafter. This pattern of expression has 
also been described in A594 (Keska-Oja, et al 1988) and rat mesangial cells 
(Jiang, et al 2003).
2ng/ml TGF-pi
From Figure 13.1 it was seen that under stimulation with 2ng/ml of cytokine, 
no increase in PTEN expression was detected at 4 hours. An average 
increase in expression of ~2-times was observed at 8 hours and maintained 
over 24 hours compared to the controls.
Figure 13.3 shows PAI-1 mRNA expression in response to cytokine 
stimulation is essentially the reverse of that observed in HEC-1B. At 4 hours,
149
a ~2-fold increase in expression compared to the controls was observed. At 8 
and 24 hours the levels of PAI-1 expression slowly diminished but was still 
detectable after 24 hours, whereas no bands were observed in the 
unstimulated controls.
5ng/ml TGF-/31
Figure 13.1 shows that under stimulation with 5ng/ml of cytokine, no increase 
in PTEN expression was detected at 4 hours. An average increase in 
expression of ~2-times was observed at 8 hours and maintained over 24 
hours compared to the controls.
Figure 13.3 shows PAI-1 mRNA expression in response to cytokine 
stimulation. At 4 hours, a ~3-fold increase in expression compared to the 
controls was observed. At 8 and 24 hours the levels of PAI-1 expression 
diminished but was still detectable after 24 hours, with -2-times the level of 
expression remaining at 24 hours compared to samples stimulated with 
2mg/ml of cytokine.
Expression levels of GAPDH shown in Figure 13.2 are constant throughout, 
and all RT-PCR controls were free of contamination as shown in Figure 13.4. 
The results observed in Figures 13.1 to 13.3 were again shown by 
densitometric analysis of band intensities (Table 6).
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Table 6 Ishikawa Serum Non-starved, Experiment 1 PCR Densitometry
PTEN PCR A PTEN PCR B
TGF-pl(ng) Mass Peak TGF-pi (ng) Mass Peak
/Time (hrs) ng OD /Time (hrs) ng OD
Ong/4 59.86 141 Ong/4 57.3 121
8 52.73 113 8 62 148
24 49.9 92 24 61.52 154
2ng/4 42.85 89 2ng/4 43.7 81
8 120.04 198 8 114.9 193
24 63.7 150 24 93.8 172
5ng/4 51.4 113 5ng/4 66 115
8 118 195 8 120.1 197
24 114.1 186 24 121 196
GAPDH PCR A GAPDH PCR B
TGF-pl(ng) Mass Peak TGF-pi (ng) Mass Peak
/Time (hrs) ng OD /Time (hrs) ng OD
4 326.3 255 4 333.4 254
8 330 255 8 334 254
24 331.5 254 24 334 255
2ng/4 330.04 255 2ng/4 335.1 256
8 330 256 8 334.21 255
24 333.1 254 24 335 255
5ng/4 329 254 5ng/4 335.3 253
8 334.3 255 8 334 254
24 332 255 24 334.6 255
PAI-1 PCR A PAI-1 PCR B
TGF-pl(ng) Mass Peak TGF-pi (ng) Mass Peak
/Time (hrs) ng OD /Time (hrs) ng OD
Ong/4 40.56 89 0ng/4 43.12 96
8 43.15 95 8 45.5 99
24 nd nd 24 nd nd
2ng/4 71.8 159 2ng/4 94.33 176
8 62.71 147 8 70.4 155
24 25.4 58 24 24.91 57
5ng/4 124 192 5ng/4 121.3 192
8 64.1 142 8 69.7 157
24 41.51 94 24 41.6 93
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Serum non-starved Ishikawa cells, Experiment 2
Ong 
S  4 8 24
2 n g  
4 8 24
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A B
Fig 14.1 Expression of PTEN in non-starved Ishikawa with duplicates A and 
B. No TGF-pi control shown in white, 2ng/ml TGF-pi in red, 5ng/ml TGF-p1 
in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
A B
Fig 14.2 Expression of GAPDH in non-starved Ishikawa with duplicates A 
and B. No TGF-pi control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml 
TGF-pi in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash.
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A B
Fig 14.3 Expression of PAI-1 in non-starved Ishikawa with duplicates A and 
B. No TGF-p1 control shown in white, 2ng/ml TGF-p1 in red, 5ng/ml TGF-p1 
in blue over 4, 8 & 24 hours. PCR control (no DNA) is a yellow dash
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This experiment was performed once, with duplicate flasks A and B. From 
these duplicate flask, cDNA was prepared twice on separate occasions for 
RT-PCR using primers for PTEN, PAI-1 and GAPDH. The two individual 
batches of cDNA were designated as experiments 1 and 2 respectively.
Experiment 2
Analysis of RT-PCR products shown in Figure 14.1 show the same time and 
dose-dependant two-fold increase in PTEN mRNA expression in samples 
stimulated with TGF-p1 after 8 hours to Ishikawa non-starved Experiment 
1 (Figure 13.1). This confirmed that the original RT-PCR results in Experiment 
1 were correct, as the fresh cDNA used in Experiment 2 gave very similar 
results. Expression levels of GAPDH shown in Figure 14.2 and PAI-1 in 
Figure 14.3 are also similar to Ishikawa Experiment 1, with the results for 
PAI-1 showing a three-fold increase with both concentrations of TGF-p1.
As PAI-1 expression in Ishikawa Experiment 1 was only induced 2-fold by 
2ng/ml cytokine, this difference may be due to the use of a new batch of RT 
enzyme used in the cDNA synthesis for Ishikawa Experiment 2, causing 
slight variations in the cDNA. Band intensities from Figures 14.1 to 14.3 
were again also shown by densitometric analysis (Table 7).
Summary of Results for Experiments 1 & 2
A modest up-regulation of PTEN mRNA was observed in cells stimulated 
with TGF-pi compared to the controls. The increase in transcripts was 
observed to be comparable in cells stimulated with 2ng/ml or 5ng/ml of
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cytokine, which was seen to be approximately double after 8 hours compared 
to the unstimulated controls, and was maintained over the 24 hour period.
The results obtained for serum non-starved Ishikawa and serum non-starved 
HEC-1B were very similar, with a time and dose-dependant increase in 
PTEN mRNA observed in response to cytokine stimulation. With regard to 
the control samples, the Ishikawa cell line did not appear to exhibit the slight 
up-regulation of PTEN over 24 hours in the absence of TGF-pi that was 
seen in HEC-1B cells. This may indicate variation in the sensitivity of these 
two cell lines to serum components, or may be due to experimental 
difference, such as the source of serum used, which contains variable 
amounts of cytokines and other factors.
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Table 7 Ishikawa Serum Non-Starved, Experiment 2 PCR Densitometry
PTEN PCR A PTEN PCR B
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
OD
Ong/4 61 146 0ng/4 62.4 150
8 59.32 142 8 61.73 150
24 59.4 145 24 61.8 152
2ng/4 64.03 153 2ng/4 60.11 155
8 120.6 201 8 125.7 207
24 127.61 205 24 122.96 206
5ng/4 65 151 5ng/4 61.3 150
8 129.01 209 8 126.2 210
24 126.95 205 24 125.58 207
GAPDH PCR A GAPDH PCR B
TGF-p1 (ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
4 331.2 254 4 327 253
8 330 254 8 331.5 254
24 330.4 253 24 332 254
2ng/4 333.02 256 2ng/4 330 255
8 329.7 255 8 330.81 256
24 330.1 253 24 328.97 255
5ng/4 327 254 5ng/4 330 254
8 331.3 255 8 330.6 253
24 329 254 24 331.72 254
PAI-1 PCR A PAI-1 PCR B
TGF-pi(ng) 
/Time (hrs)
Mass
ng
Peak
OD
TGF-pl(ng) 
/Time (hrs)
Mass
ng
Peak
OD
Ong/4 54.8 99 Ong/4 55 96
8 57.2 98 8 50.3 97
24 43.01 51 24 45.42 53
2ng/4 196 239 2ng/4 199.12 242
8 112.1 190 8 114 187
24 40.37 88 24 43.6 92
5ng/4 197.5 238 5ng/4 201.81 240
8 113.9 189 8 118 197
24 64.04 152 24 69.11 154
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3.1.2 Analysis of PTEN, Phospho-PTEN, p-Actin and PAI-1 protein levels 
in HEC-1B and Ishikawa cell lines stimulated with TGF-B1
To determine whether changes in mRNA expression elicited any modification 
of protein expression in response to TGF-p1 stimulation, total protein was 
extracted from HEC-1B and Ishikawa cells which had been treated with no 
cytokine or 2 and 5ng/ml TGF-p1, again under either serum-starved or non- 
starved conditions (Chapter 2, Section 2.2.4.1), and levels of specific proteins 
(PTEN, PAI-1, phospho-PTEN [P-PTEN] and p-Actin) determined by Western 
blotting. Determination of levels of PTEN and P-PTEN were required to 
ascertain any biological significance of PTEN mRNA up-regulation by TGF- 
P1.
3.1.2.1 Determination of protein concentration by the Bradford assay 
To determine the concentration of protein in each sample obtained from 
stimulation with TGF-p1, a BSA standard curve was first prepared according 
to the instructions supplied with the Bradford reagent. Quantitation of the 
protein was necessary to enable the equal loading of 10pg onto the SDS- 
PAGE gel from each sample, so that expression levels could be compared. 
Briefly, serial dilutions of BSA were made in triplicate and the absorbance 
recorded at 595nm using disposable cuvettes after incubation with the 
reagent. The readings for each dilution were averaged and the results plotted 
as shown in Appendix IV.
Samples obtained from the stimulation experiments were measured in 
duplicate as described in Chapter 2, Section 2.2.4.2 and the average values 
shown in Table 8 with the volumes required for 10pg of protein.
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Table 8 Protein Concentrations from HEC-1B & Ishikawa Stimulated with TGF-p1
Ishikawa Non-Starved
For 10|jg 
(Ml)X
X
5.81T“CT> r-00
7.46
7.46
5.49COCO00
6.94COCO00
6.94LO00CD
6.94
6.67
7.14
7.93
7.14COCO
5.32
ZLZL
X
X
CMIs-
1.14CO
1.34CM00 CMT-
1.44
1.2
1.44CO
1.44lOT— M;
1.26
1.4COCO 0000
HEC-1B Serum-Starved 
2
For 10|jg 
(Ml)CO
22 S‘8
CM
11.76h-T“
OCM
CMT“
COh-
CO00
CO
12.81^
COCM
ZL'a)ZL
CDCOO
0.29
0.45
1.17CMo
0.85COo SO
0.74
0.700o 9Z0
90
CMh-o
0.74COr-o
0.7
0.7890
COCOo’
HEC-1B Serum Starved 
1
For 10|jg 
(Ml) .CO
CO
o
00
CO
lO
5.95CD 00
6.5CD
CM
CO
8.3T“CO
O)LO
5.8
6.5VL
oT—
zl*0)ZL
0.75■M’CO-
COX—
LO
1.7800CO
1.66
1.28
1.54CDCD
1.41
1.67
1.27
1.24
1.69
1.72
1.52COCO 00O)o’
HEC-1B Non-Starved
O)H.
o
 ^
 
n.
L. '---'
oLi­
X
X
00O)
9.6COo
12.2CD00
CO00
9.8
9.8
11.9OD
10.6
12.800o>
CDCT>
CT>
CT>
9.1
0.7
'S.O)ZL
X
X
CMO
1.04
0.94CM00O
CO
CO
1.02
1.02■M-00O
1.1
0.9400Is-o
CMO
1.04
1.1
0.7
ccu C00
10% ACO
0/4 ADQ
<00o
DQ
0/24 ADQ
2/4 ADQ
2/8 ADQ<■M-CMCM DQ
5/4 ADQ
5/8 ADQ
5/24 ADQ
Os
3.1.2.3 Detection of proteins by Western blot with enhanced 
chemiluminesence (ECL) and densitometry.
Western blotting and detection by ECL were performed as described in 
Chapter 2, Section 2.2.4 for HEC-1B and Ishikawa cell lines, after 
fractionation of 10pg of each protein sample by 8% SDS-PAGE against a 
broad-range biotinylated molecular weight marker (Appendix 1.4). Antibodies 
were used to detect PTEN, phospho-PTEN Ser380 (P-PTEN), p-Actin and 
PAI-1 as described in Chapter 2.
Both PTEN and phospho-PTEN (Ser380) levels were analysed using two 
separate antibodies (anti-PTEN from BD Biosciences and anti-P-PTEN 
Ser380 from NEB). This was performed only on the HEC-1B cell line which 
expresses wild-type PTEN, as the Ishikawa cell line does not express PTEN 
protein (Figure 18.1) due to a mutation of PTEN in this cell line (Yaginuma, et 
al, 2000). This was to determine if TGF-p1 was capable of modifying overall 
PTEN protein levels, which could indicate a potential use as an anti-tumour 
therapy, and also if the amount of phospho-PTEN was also changed. As 
phosphorylation of PTEN prevents degradation, but also inhibits catalytic 
activity (Vazquez, et al 2000), assessing the phosphorylation status under 
cytokine stimulus may aid in the elucidation of mechanisms of PTEN protein 
regulation by TGF-p1.
Scanned images of the developed films are shown in Figures 15 to 18 The 
intensity of each specific band, indicated by an arrow, was analysed (Chapter 
2, Section 2.2.4.5.1) and displayed in Tables 9 to 12.
Results for HEC-1B serum non-starved are shown in Figures 15.1 to 15.4 and 
Table 9.
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Results for HEC-1B serum-starved Experiments 1 and 2 are shown in Figures
16.1 to 16.2, Table 10 and Figures 17.1 to 17.4 and Table 11, respectively. 
The results for non-serum starved Ishikawa cells are presented in Figures
18.1 to 18.3 and Table 12.
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HEC-1B Serum non-starved
Figure 15.1 Anti-PTEN western blot for non-starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-p1 
in red,5ng/ml TGF-p1 in blue over 4, 8 & 24 hours Arrow indicates specific
band at ~55KDa
m
«*sfr m
4NPi f  nBP 
mm 24 4 8 24 V  2ng 5ng •
Figure 15.2 Anti-P Actin western blot for non-starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-p1 
in red,5ng/ml TGF-p1 in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~43KDa.
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Fig 15.3 Anti-phospho-PTEN (Ser380) western blot for Non-starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-pi 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~55KDa.
u p
Fig 15.4 Anti-PAI-1 western blot for non-starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-pi 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~47KDa.
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Non-specific band 
^  PTEN
Fig 15.5 Anti-PTEN blot to show the source of the high molecular weight 
non-specific band with (+ 1°Ab) or without (-1° Ab) primary anti-PTEN
antibody.
M= protein marker.
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This experiment was performed once, with duplicate flasks A and B from 
which total protein was prepared for Western blotting using antibodies 
against for PTEN, phospho-PTEN(Ser380), PAM and p-actin.
As can be seen in Figure 15.1, expression of PTEN protein in HEC-1B (band 
in A and B samples at ~55KDa with respect to the marker) changes little 
between the samples, with only a very minor decrease after 24 hours with 
5ng/ml of cytokine, and does not exhibit the increase observed in mRNA 
(Figure 10.1). Expression of PTEN protein was not assessed in the 
publications describing modulation of PTEN mRNA by TGF-pi(Lee, et al 
1999 and Li and Sun, 1997), but PTEN protein was decreased in pancreatic 
cells after 24 hours of treatment with 10ng/ml of cytokine (Ebert, et al 2002). 
Levels of p-Actin in Figure 15.2 and phospho-PTEN in Figure 15.3 are also 
fairly constant.
It should be noted that the phospho-PTEN antibody used here is specific to 
Ser380. A new phospho-PTEN antibody is now available which recognises 
phosphorylated Ser380 and Thr382/383, and therefore could be used to 
detect changes at all three residues unlike the Ser380-specific antibody. The 
expression of PAI-1 protein (Fig 15.4) shows a similar pattern as for PAI-1 
mRNA (Figure 10.3), with a time and dose-dependant increase of ~4-fold at 4 
hours rising to ~5-fold at 24 hours for both concentrations of TGF-p1. Band 
intensities were also shown by densitometric analysis (Table 9).
The high molecular weight band of >90KDa observed in variable amounts in 
all the blots was due to non-specific binding by the ABC/secondary antibody 
complex. This band was present even in the absence of primary anti-PTEN
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antibody (Figure 15.5), and therefore was not an artefact of non-specific 
binding by the primary antibody.
Summary of Results
Expression of PTEN and P-PTEN did not appear to undergo any detectable 
change in levels in cells stimulated with TGF-pi compared to the controls. 
This would indicate that although the cytokine was capable of up-regulating 
PTEN mRNA, no change in protein levels were observed suggesting that 
TGF-p1 does not represent a novel anti-tumour therapy in the HEC-1B cell 
line.
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Table 9 HEC-1B Serum non-starved Western blot Densitometry
HEC-1B Serum-starved, Experiment 1
   - ^
4 8 24 4 8 24
5n9 A
Fig 16.1 Anti-PTEN western blot for serum starved HEC-1B 
with duplicates A and B. No TGF-pi control shown in white, 2ng/ml TGF-p1 
in red,5ng/ml TGF-(31 in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~55KDa.
Fig 16.2 Anti-|B actin western blot for serum starved HEC-1B with 
duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-pi in 
red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~43KDa.
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Table 10 HEC-1B Serum Starved Experiment 1
Western blot Densitometry
Anti-PTEN A Anti-PTEN B
TGF-pl(ng) Ave Peak TGF-1(ng) Ave Peak
/Time (hrs) OD OD /Time (hrs) OD OD
10% 0.18 0.23 10% 0.26 0.34
Ong/4 0.22 0.33 Ong/4 0.24 0.35
8 0.24 0.35 8 0.24 0.35
24 0.23 0.35 24 0.24 0.35
2ng/4 0.28 0.37 2ng/4 0.4 0.52
8 0.35 0.47 8 0.44 0.59
24 0.32 0.44 24 0.4 0.55
5ng/4 0.31 0.45 5ng/4 0.4 0.56
8 0.33 0.48 8 0.43 0.6
24 0.25 0.36 24 0.39 0.54
Anti-p Actin A Anti-p Actin B
TGF-pl(ng) Ave Peak TGF-pi(ng) Ave Peak
/Time (hrs) OD OD /Time (hrs) OD OD
10% 0.45 0.68 10% 0.5 0.77
Ong/4 0.53 0.75 Ong/4 0.51 0.74
8 0.55 0.79 8 0.46 0.7
24 0.63 0.86 24 0.58 0.89
2ng/4 0.52 0.77 2ng/4 0.6 0.86
8 0.49 0.76 8 0.65 0.91
24 0.5 0.74 24 0.65 0.91
5ng/4 0.54 0.82 5ng/4 0.62 0.9
8 0.54 0.83 8 0.48 0.71
24 0.53 0.78 24 0.45 0.68
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HEC-1B Serum-starved experiment 2
Fig 17.1 Anti-PTEN western blot for serum starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-p1 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~55KDa.
Fig 17.2 Anti-p actin western blot for serum starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-pi 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~43KDa.
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Fig 17.3 Anti-phospho-PTEN (Ser 380) western blot for serum starved 
HEC-1B with duplicates A and B. No TGF-pi control shown in white, 2ng/ml 
TGF-pi in red,5ng/ml TGF-(31 in blue over 4, 8 & 24 hours. Arrow indicates
specific band at --55KDa.
* 2ng 5ng
t ii. mm
f
• 4 8 24 4 8 24 A
% 2ng 5ng
IN’ m m m  — 1 1
t 4 8 24 4 8 24
Fig 17.4 Anti-PAI-1 western blot serum starved HEC-1B 
with duplicates A and B. No TGF-p1 control shown in white, 2ng/ml TGF-p1 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~47KDa
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S e ru m  s ta rv e d  H E C -1B  s tim u la te d  w ith  T G F -p i
This experiment was performed twice in duplicate flasks A and B from which 
total protein was prepared for Western blotting using antibodies against for 
PTEN, phospho-PTEN(Ser380), PAI-1 and p-actin. Proteins extracted in 
experiment 1 were scraped into cold Tris, and therefore P-PTEN could not be 
detected in these samples. Proteins extracted in experiment 2 were isolated 
using a phosphoprotein lysis buffer (Appendix I.3) and could therefore by 
probed for P-PTEN.
Experiments 1 & 2
The results of both serum-starved HEC-1B experiments (Figures 16.1 and 
17.1) show little change in PTEN expression levels, and again p-Actin 
remained constant (Figures 16.2 and 17.2). A slight decrease in phospho- 
PTEN levels was observed in a time and dose-dependant manner (Figure 
17.3), but this decrease was very small and not completely consistent 
between duplicate samples. A strong response was observed for PAI-1 
(Figure 17.4) which was undetectable in the controls. A continuous increase 
from 4 to 24 hours of stimulation was seen, giving approximately double the 
band intensity after 24 hours, with the strongest response from the 5ng/ml 
samples. These observations were reflected in the densitometry results 
shown in Tables 10 and 11.
Experiment 1 only included blots for PTEN and p-Actin due to the protein 
extraction method used (scraping into ice-cold Tris). The cell lysates initially 
prepared in this manner were very viscous, which gave difficulty loading onto 
the gels, and upon probing for phospho-PTEN were seen to have degraded
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substantially. Phosphoprotein lysis buffer (protocol courtesy of Mr Mike 
Sharrard, University of York), was later employed to overcome this problem.
Summary of Results for experiments 1 & 2
Expression of PTEN and P-PTEN did not appear to undergo any detectable 
change in cells stimulated with TGF-pi compared to the controls. This would 
indicate that although the cytokine was capable of up-regulating PTEN 
mRNA, no change in protein levels was observed. Reduction of foetal calf 
serum from 10% to 1% in these experiments also appear to have very little 
effect on PTEN and P-PTEN expression, even though reduction of serum 
was observed to mildly induce expression of PTEN mRNA (Figures 11 and 
12, Section 3.1.1).
Again, as PTEN and P-PTEN levels remained unchanged with cytokine 
stimulation, TGF-p1 does not appear to represent an anti-tumour agent in 
this cell line.
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Table 11 HEC-1B Serum starved Experiment 2
Western blot Densitometry
Anti-PTEN A Anti-PTEN B
TGF-pi (ng) Ave Peak TGF-p1 (ng) Ave Peak
/Time (hrs) OD OD /Time (hrs) OD OD
10% 0.29 0.37 10% 0.17 0.21
Ong/4 0.44 0.63 Ong/4 0.35 0.49
8 0.42 0.59 8 0.37 0.52
24 0.54 0.75 24 0.45 0.65
2ng/4 0.58 0.8 2ng/4 0.43 0.61
8 0.49 0.69 8 0.41 0.61
24 0.48 0.62 24 0.4 0.55
5ng/4 0.45 0.56 5ng/4 0.38 0.52
8 0.56 0.74 8 0.37 0.53
24 0.48 0.71 24 0.42 0.49
Anti-p Actin A Anti-p Actin B
TGF-pi (ng) Ave Peak TGF-pl(ng) Ave Peak
/Time (hrs) OD OD /Time (hrs) OD OD
10% 0.7 0.94 10% 0.52 0.75
Ong/4 0.74 0.96 0ng/4 0.53 0.69
8 0.75 1.01 8 0.61 0.81
24 0.78 1.04 24 0.60 0.65
2ng/4 0.61 0.85 2ng/4 0.63 0.67
8 0.64 0.84 8 0.69 0.79
24 0.65 0.82 24 0.63 0.83
5ng/4 0.6 0.76 5ng/4 0.65 0.80
8 0.56 0.71 8 0.6 0.75
24 0.48 0.68 24 0.62 0.72
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Anti-P-PTEN A Anti-P-PTEN B
TGF-pl(ng) 
/Time (hrs)
Ave
OD
Peak
OD
TGF-p1 (ng) 
/Time (hrs)
Ave
OD
Peak
OD
10% 0.23 0.31 10% 0.22 0.27
Ong/4 0.35 0.51 Ong/4 0.28 0.38
8 0.36 0.53 8 0.27 0.37
24 0.37 0.58 24 0.34 0.44
2ng/4 0.36 0.55 2ng/4 0.33 0.43
8 0.29 0.46 8 0.3 0.38
24 0.25 0.41 24 0.24 0.31
5ng/4 0.25 0.39 5ng/4 0.24 0.31
8 0.25 0.39 8 0.27 0.35
24 0.21 0.33 24 0.29 0.37
Anti-PAI-1 A Anti-PAI-1 B
TGF-pi(ng) 
/Time (hrs)
Ave
OD
Peak
OD
TGF-pl(ng) 
/Time (hrs)
Ave
OD
Peak
OD
Ong/4 nd nd 0ng/4 nd nd
8 nd nd 8 nd nd
24 nd nd 24 nd nd
2ng/4 0.29 0.39 2ng/4 0.38 0.46
8 0.49 0.65 8 0.5 0.6
24 0.65 0.93 24 0.69 0.91
5ng/4 0.37 0.47 5ng/4 0.42 0.48
8 0.58 0.71 8 0.65 0.78
24 0.72 0.99 24 0.83 1.0
Table 11 (Continued)
HEC-1B Serum starved Experiment 2 Western blot Densitometry
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Ishikawa Serum Non-Starved
Fig 18.1 Anti-PTEN Western blot for non-starved Ishikawa & HEC-1B 
H=HEC-1B, l=lshikawa, arrow indicates specific band at ~54KDa
m  2ng 5ng
*  4 8 24 4 8 24
Fig 18.2 Anti-PAI-1 western blot for non-starved Ishikawa 
with duplicates A and B. No TGF-pi control shown in white, 2ng/ml TGF-pi 
in red,5ng/ml TGF-pi in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~47KDa
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W  24 4 8 24
2ng 5ng g
Fig 18.3 Anti-p actin western blot for non-starved Ishikawa 
with duplicates A and B. No TGF-(31 control shown in white, 2ng/ml TGF-pi 
in red,5ng/ml TGF-p1 in blue over 4, 8 & 24 hours. Arrow indicates specific
band at ~43KDa
S e ru m  n o n -s ta rv e d  Is h ik a w a  s tim u la te d  w ith  TGF-J31
This experiment was performed once in duplicate flasks A and B from which 
total protein was prepared for Western blotting using antibodies against for 
PTEN, phospho-PTEN(Ser380), PAI-1 and p-actin.
The absence of PTEN protein in the Ishikawa cell line was confirmed by anti- 
PTEN Western blot using 10pg of protein from HEC-1B as a positive control 
and an equivalent amount of protein from Ishikawa cells. The blot shown in 
Figure 18.1 demonstrates the lack of detectable PTEN protein in the 
Ishikawa cell lysate, whilst the 54KDa band (black arrow) is visible in the 
HEC-1B cell lysate, and confirms previous reports (Guzeloglu-Kayishli, et al 
2003).
The results of the Ishikawa serum non-starved experiment showed a more 
moderate response for PAI-1 (Figure 18.2), but with an inverse pattern 
compared to HEC-1B serum non-starved (Figure 15.4). For the Ishikawa cell 
line, PAI-1 induction by TGF-p1 occurred rapidly after 4 hours, then showed 
a steady decline up to 24 hours, where the signal is no longer detectable. 
This pattern of expression was also observed for mRNA expression levels 
shown in Figures 13 and 14, Section 3.1.1. Levels of p-actin protein 
remained constant throughout (Figure 18.3). These observations were 
verified by the densitometric analysis shown in Table 12.
Summary of Results
Expression of PTEN protein was absent in this cell line, in agreement with 
published material. A strong response to TGF-pi was observed as a robust 
up-regulation of PAI-1 protein, reflecting the mRNA response previously
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observed in Section 3.1.1, indicating a functional signalling pathway through 
the TGF-pi receptor. The results for PAI-1 mRNA and protein up-regulation 
in both HEC-1B and Ishikawa cell lines indicates that the cytokine is capable 
of affecting PTEN mRNA expression regardless of whether PTEN is wild-type 
(HEC-1 B) or mutated (Ishikawa).
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Table 12 Ishikawa Non-serum starved
Western blot Densitometry
Anti-PAI-1 A Anti-PAI-1 B
TGF-b1(ng)/Time Ave Peak TGF-b1(ng)/Time Ave Peak
(hrs) OD OD (hrs) OD OD
Ong/4 0.19 0.23 0ng/4 0.23 0.26
8 0.16 0.2 8 0.18 0.22
24 nd nd 24 nd nd
2ng/4 0.31 0.47 2ng/4 0.39 0.58
8 0.24 0.36 8 0.30 0.49
24 nd nd 24 nd nd
5ng/4 0.3 0.41 5ng/4 0.4 0.55
8 0.24 0.38 8 0.33 0.4
24 nd nd 24 nd nd
Anti-p-Actin A Anti-p-Actin B
TGF-b1(ng)/Time Ave Peak TGF-b1(ng)/Time Ave Peak
(hrs) OD OD (hrs) OD OD
Ong/4 0.59 0.74 0ng/4 0.72 1.01
8 0.63 0.88 8 0.7 0.98
24 0.61 0.83 24 0.67 0.91
2ng/4 0.63 0.79 2ng/4 0.71 0.99
8 0.65 0.8 8 0.7 0.95
24 0.68 0.84 24 0.69 0.9
5ng/4 0.58 0.79 5ng/4 0.73 0.97
8 0.6 0.81 8 0.68 0.94
24 0.59 0.7 24 0.71 0.96
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3.1.3 HEC-1 B cell proliferation assay
From the results obtained in Section 3.1.1, further investigations were carried 
out to ascertain the relationship between changes in PTEN mRNA levels 
observed in the HEC-1 B cell line and the growth of the cells under TGF-p1 
stimulation. To determine the effect of TGF-p1 on the ability of HEC-1 B cells 
to proliferate a simple, non-radioactive commercial cell proliferation assay 
was performed. This assay measures cellular reduction of the CellTitre 
reagent by the mitochondria of living cells to a coloured compound which can 
be measured using a standard plate reader. This method is an alternative to 
established techniques for measuring DNA synthesis such as 3H-thymidine 
and 5-bromo-2-deoxyuracil (Brdu) incorporation.
HEC-1 B cells were cultured on the wells of 24-well tissue culture plates in 
complete medium prior to serum starvation for 24 hours in reduced serum 
medium. The cells were stimulated with 1 to 10ng/ml of TGF-p1 for 4, 8 and 
24 hours prior to addition of the assay reagent as described in Chapter 2, 
Section 2.2.5. Controls included no TGF-p1 and no cells (media only) and all 
readings were taken in quadruple from this experiment, which was performed 
once. Mean values for the quadruple readings were subtracted from the ‘no 
cells’ control and shown in bold, (Table 13); the results were also shown 
graphically (Graph 4).
The cell proliferation assay for HEC-1 B cells stimulated with 1-10ng/ml TGF- 
pi indicate no significant change in proliferation levels compared to the 
controls. Using this assay, TGF-p1 appeared to have no positive or negative 
effects on proliferation levels of HEC-1 B over the time course and 
concentration of cytokine used.
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Table 13 HEC-1 B Cell Proliferation Assay Results
Time
(hours)
Ave no 
cells 
(n=4)
TGF-31 concentration (ng/ml)
0 1 2 4 5 7 10
4 0.134
1.15 1.07 1.16 1.00 0.92 1.05 0.94
1.11 1.12 0.99 0.97 0.94 1.07 0.99
1.10 1.15 0.92 0.92 1.10 1.09 0.99
0.96 1.17 1.01 1.01 0.92 0.96 0.94
Average A490 
nm (n=4) 1.08 1.1 0.83 0.98 0.97 1.04 0.97
Average - no 
cells A490 nm 0.95 0.97 0.70 0.84 0.84 0.91 0.83
8 0.1437
1.18 1.04 1.03 1.26 1.07 1.06 1.42
1.25 1.11 1.12 1.05 1.14 1.33 1.04
1.28 1.28 1.16 1.02 1.19 1.05 1.10
1.27 1.27 1.23 1.06 1.25 1.28 1.0
Average A490 
nm (n=4) 1.26 1.17 1.13 1.1 1.16 1.18 1.16
Average - no 
cells A490 nm 1.12 1.03 0.99 0.95 1.02 1.04 1.02
24 0.1387
1.57 1.38 1.39 1.28 1.41 1.40 1.53
1.75 1.62 1.18 1.52 1.65 1.37 1.68
1.49 1.81 1.68 1.49 1.32 1.25 1.31
1.67 1.53 1.46 1.47 1.61 1.65 1.48
Average A490 
nm (n=4) 1.62 1.58 1.43 1.44 1.50 1.42 1.50
Average - no 
cells A490 nm 1.48 1.44 1.29 1.30 1.36 1.28 1.36
182
00 CM
HEE
T=H
00 CO M; CNI oGO CO CM
LO
CM
O)c
02.iLL
O
O
co■ HMI
ss
£0)o£O
o
iuuQ6t7 eo u eq josq  v
00
liT
0-Q0_3
_q
0
0  LU1M—o
£
3 0) 
0 a:rj-
JZQ.0k.O
0oc000 s_Q .
0
M-CNI
M" -t-
0 .E >o —"O0E
£
0Q.
0i_0
</) Co'-4->_g
E -#—■ co
_re3E
0
CO. .EI S—LL 0O >
coo>»0 CO CO 0c0’>3 
0
1 Iok .Q.
D)Co
0S_
0_Q
0 O
DO 0^>
0s_3OJZ
NfCMo*5
Hf0JD
0
Q.i_3CL
"O 0 
0 0
D)Co
Eo»_M—
0c
o>o
0co'■+-<
0
-i— ic0ocoo
03o
0E
T>0 -t—< 
0 g
T3c
0
0
_0
0o
0
X50"O■a0
00
_0
o+Jcoo
0
o
0 ~a
0s_
0Q.Eo0
_0
0>0
cg-4—'0
1  o
CL
c
.1 a  
1  so _c
U i o>%0000
0
0o
E3
TD
0E
E3
00
TO0O3"O
0
E3i—
00
0O
0■*->0o
c
0g
‘cD)0
OC
00 -#—<0gT3_c
0
0Q
Ecoo>
4-»0
-o0 !_3000E
0Oc0JOl_o0-Q0 ho
urs
. 
The
 
stim
ula
tion
 
exp
eri
me
nt 
was
 
per
for
me
d 
on
ce,
 i
n 
trip
lica
te 
(ov
era
ll 
n=
3).
 D
ata
 
is 
pre
sen
ted
 
as 
me
an 
+ 
SE
M.
3.1.4 Assessment of the effect of cell density on PTEN expression in 
HEC-1B cells.
To determine whether the minor increase in PTEN mRNA expression 
observed in the HEC-1B cell line in the absence of cytokine stimulation 
(Figures 10, 11 and 12) could be due to increasing cell density and contact 
inhibition, rather than TGF-pi, cells were cultured at low or high initial 
densities for several days. The effect of increasing cell density on PTEN 
expression was performed as described in Chapter 2, Section 2.2.6. Briefly, 
HEC-1B cells seeded at 4x105 or 9x105 cells per flask were cultured for 4 
days in CM, or for 4 days with a media change on day 3. The media change 
was included to show the effects of replenishment of fresh CM, containing 
unknown quantites of cytokines, on PTEN expression. RNA was extracted for 
RT-PCR as previously detailed in Chapter 2, Section 2.2.3. Results are 
shown in Appendix VIII and Figures 19 to 21.
The expression of PTEN mRNA shown by RT-PCR in Figure 19 
demonstrates a steady increase of PCR product over days 1 to 4, with the 
highest expression levels observed for the samples which received a media 
change on day 3 (MC). The increase in PTEN expression in day 3 MC 
samples may be due to renewal of stimulating factors, such as TGF-p1 in the 
fresh medium. No difference was discernable between cells seeded at 4x105 
or 9x105 cells per flask, therefore initial density had no effect on PTEN 
expression levels, which increased in a linear manner for both densities, with 
comparable band intensities. Figure 20 shows that no changes in expression 
of the internal control GAPDH occurred over the course of the experiment, 
and Figure 21 indicates that no DNA was present as a contaminant in the 
cDNA.
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3.1.5 Morphological changes in HEC-1B and Ishikawa cell lines in 
response to TGF-B1
As cell density alone did not appear to affect PTEN expression levels 
(Section 3.1.4), the effects of TGF-pi on the morphology of both Ishikawa 
and HEC-1B cell lines was evaluated. Although the cytokine did not modify 
PTEN protein levels in the experiments described previously, decreased 
proliferation and increased cell volume has been described in HEC-1B 
stimulated with TGF-pi(Boyd & Kaufman, 1990). This may involve changes 
in phospho-PTEN levels which could possibly be detected with the new 
commercial anti-phospho-PTEN (Ser380/Thr383/384) antibody. A decrease 
in P-PTEN levels may indicate increased PTEN protein activity and 
degradation and a decrease in Akt-mediated proliferation.
HEC-1B and Ishikawa cell lines were cultured in medium containing 10% 
foetal calf serum, then cultured for a further 48 hours in medium containing 
1% serum to reduce any effects of TGF-p1 in the medium. Cells were then 
cultured in reduced-serum medium in the absence or presence of TGF-01 at 
a concentration of 10ng/ml for 48 and 72 hours as described in Chapter 2, 
Section 2.2.7. This experiment was performed once, with triplicate wells. The 
live cells were photographed under phase contrast using Polaroid film 
(Figures 22 to 25). The cells were trypsinised and counted using a 
haemocytometer and the average figures from the triplicate wells are shown 
in Graphs 5 and 6.
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HEC-1B Morphological Changes
Fig 22 Morphological changes in HEC-1B under reduced-serum conditions 
with no TGF-(31 at A: 48 hours and B: 72 hours Live cells visualised after 48 
& 72 hours using phase contrast microscopy. Magnification x20
Fig 23 Morphological changes in HEC-1B with 10ng/ml TGF-(31 at A: 48 
hours and B: 72 hours Live cells visualised after 48 & 72 hours using phase 
contrast microscopy. Magnification x200
Table 14 HEC-1B cell count x 104
48 hours 72 hours
No TGF-pi
13.5 28.5
12 36.5
11.5 26
Average 12.3 30
10ng/ml TGF-01
8 17
8.5 15
7 14.5
Average 7.8 15.5
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By comparing Figure 22 and 23, it can be seen that treatment of HEC-1B 
cells with TGF-p1 had the effect of increasing cell volume. Untreated cells 
were small and rounded, with a characteristic “cobblestone” appearance. 
After 48 hours of stimulation the cells were significantly larger, and after 72 
hours had assumed a flattened profile. After performing cell counts of the 
stimulated and unstimulated HEC-1B cells (Table 14), the results were 
expressed in Graph 5.
After both 48 and 72 hours there was almost twice the number of untreated 
cells to treated cells. Untreated control cell numbers increased approximately
2.5 times between the 48 and 72 hour time points, whereas the TGF-p1 
treated cells increased by 2 times. In this experiment using HEC-1B cells, 
TGF-p1 had the overall effect of increasing cell volume and decreasing 
proliferation. This effect of TGF- p1 on HEC-1B morphology and growth has 
previously been reported by Boyd & Kaufman, 1990.
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Ishikawa morphological changes
Fig 24 Morphological changes in Ishikawa under reduced-serum conditions 
with no TGF-p1 at A: 48 hours and B: 72 hours Live cells visualised after 48 
& 72 hours using phase contrast microscopy. Magnification x200
Fig 25 Morphological changes in Ishikawa with 10ng/ml TGF-pi at A: 48 
hours and B: 72 hours Live cells visualised after 48 & 72 hours using phase 
contrast microscopy. Magnification x200
Table 15 Ishikawa cell count x 104
48 hours 72 hours
No TGF-pi
14 16.5
12 18
13.5 19.5
Average 13.2 18
10ng/ml TGF-pi
12 17.5
10.5 18
10.5 13.5
Average 11 16.3
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By comparing Figure 24 and 25, it can be seen that treatment with TGF-pi 
had little effect on Ishikawa cell volume, but after 48 hours of stimulation 
small patches of cells appeared to have detached from the flask, leaving 
areas free of cell growth.
After performing cell counts of the stimulated and unstimulated Ishikawa cells 
(Table 15), the results were expressed in Graph 6. After both 48 and 72 
hours there was only a very slight increase in the number of untreated cells 
to treated cells. Additionally, little change was observed between the 48 and 
72 hour time points for both treated and untreated cells. This suggests that 
TGF-p1 has significantly less effect on the morphology and proliferation of 
Ishikawa cells compared to HEC-1B cells under the conditions used. ISK 
cells have previously been reported to show inhibition of proliferation in 
response to TGF-p1 (Anzai, et al 1992).
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3.2 CLONING OF FULL LENGTH HUMAN PTEN INTO CMV-pEGFP-N1 
AND SUBCELLULAR LOCALISATION OF PTEN PROTEIN
The localisation of P T E N  has been described as mainly cytoplasmic but has 
also been reported as nuclear in s o m e  cells, and its localisation has not 
previously been described in H E C - 1 B  or Ishikawa endometrial cell lines. 
Changes in the localisation of P T E N  in the cell are a possible mechanism of 
regulating its function.
To  enable the rapid study of P T E N  localisation in various cell lines, full length 
h u m a n  P T E N  w a s  cloned into a G F P  plasmid vector to create a C-terminal 
fusion protein which can be detected by fluorescent microscopy using a 
standard FITC filter. The production of G F P - P T E N  permitted the transfection 
of cultured cells, regardless of the state of endogenous PTEN, and the 
subsequent ability to add stimulating compounds to these transiently 
transfected cells. The fusion protein could be rapidly visualised without the 
need for detection using antibodies, which m a y  be difficult to detect if cellular 
levels of P T E N  are very low.
The overall cloning strategy is outlined in Chapter 2, Section 2.3.1. Briefly, 
full-length P T E N  amplified by P C R  and the C M V - P E G F P - N 1  vector were 
subjected to double-digestion with two restriction enzymes, EcoRI and Sa/I, 
to create a single cohesive end from each enzyme on both D N A  sources. 
Subsequent ligation of the cut fragments to form a E G F P - P T E N  chimera can 
only occur in one direction, thus ensuring that the P T E N  fragment is inserted 
into the vector and later transcribed and translated in the correct orientation 
(5’->3’).
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The detection of other cellular compartments, proteins or organelles could 
also be accomplished in transfected cells using a primary antibody bound by 
a secondary antibody linked to a fluorescent moiety that is not green, eg red, 
cyan or magenta. This would enable the study of the localisation of GFP- 
P T E N  to such cellular compartments by overlapping the two differently 
coloured images and noting areas of co-localisation, indicated by a colour 
change (eg an overlap of green and red is seen as yellow).
3.2.1 Extraction of RNA from whole human blood
Total R N A  w a s  extracted from the whole blood of four m e m b e r s  of staff using 
TRI Reagent. The yield and purity of each sample w a s  assessed by reading 
the absorbance at 260 and 2 8 0 n m  and the results shown in Table 16. 
Peripheral blood w as chosen because P T E N  mutations in lymphocytes are 
very rare even in haematological malignancies, therefore cells from healthy 
individuals w as most likely to be wild-type for PTEN.
Table 16 Staff total R N A  yield and purity
Staff Number A260nm A280nm ratio pg/pi
1 0.065 0.033 1.74 0.52
2 0.101 0.059 1.84 0.81
3 0.085 0.046 1.816 0.68
4 0.082 0.044 1.832 0.66
3.2.2 RT-PCR of full-length human PTEN for cloning
3.2.2.1 Analytical scale preparation of cDNA and digestion with
restriction endonucleases Mse I and Hha I
c D N A  w a s  synthesised as described in Chapter 2, Section 2.3.3 from each of 
the four staff members and amplified using P T E N  primers 1 and 4 to yield a
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450bp fragment, shown in Figure 26. This fragment can be used in an 
analytical digest with Mse I and Hha I to distinguish between P T E N  derived 
from pure RNA, (contains an Mse I site only), or from genomic contamination, 
(contains a Hha I site only). The P C R  products were therefore digested with 
Mse I and Hha I (Figure 27). From this gel it can be clearly observed that all 
four P C R  products were only digested with Mse I, and were therefore derived 
from P T E N  c D N A  and not genomic M^PTEN. Staff c D N A  number 4 w a s  
selected for cloning as it gave a good yield of P C R  product and the R N A  from 
which it w as derived had a high purity ratio (260/280nm).
3.2.2.2 P C R  amplification of P T E N  with high fidelity Pfx polymerase
c D N A  w a s  used in the amplification of full-length P T E N  as described in 
Section 2.3.4 using the Pfx3lx P C R  programme (Appendix V), and the 
reactions analysed by agarose gel electrophoresis (see Figure 28). To  
improve the yield of P C R  product, which w a s  poor, a modified version of the 
programme (Pfx3lx2) w a s  then used which included a 20 minute final 
extension (Appendix V). The products were again analysed on an agarose 
gel as shown in Figure 29, and a significant improvement in yield w a s  
observed. Several P C R  reactions were performed, pooled, and separated on 
an agarose gel to provide adequate D N A  for cloning. The 1.2Kb band w a s  
carefully excised from the gel and purified as described in Chapter 2, Section 
2.3.5.
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Analytical RT-PCRs & Analytical Digests of Staff PTEN cDNA Samples
M -RT-RNA 1 4 M
Figure 26
PCR of staff cDNAs (1 - 4) with PTEN primers 1&4 to 
amplify a 450bp fragment. RT-PCR controls (-RT & - 
RNA), are shown with the four staff samples. M= 100bp
ladder.
M 4 3 2 1 4 3 2 1
Figure 27
Aliquots of staff PCR samples 1-4 digested with 
Mse I (red) and Hha I (blue). M =  100bp ladder. The 
products were cleaved by Mse I to yield two distinct
bands.
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PCR Amplification of Full-Length Human PTEN cDNA
M -  Pfx3lx 
Figure 28
Electrophoresis of Staff number 4 full-length PTEN 
PCR product (1.2Kb), using Pfx3lx PCR cycle. PCR 
Control shown as a dash, M =  1Kb ladder.
M -  Pfx3lx2
Figure 29
Electrophoresis of Staff number 4 full-length 
PTEN PCR product (1.2Kb), using Pfx3lx2 cycle. 
PCR Control shown as a dash, M =  1Kb ladder.
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3.2.3 Digestion and purification of the PTEN fragment for ligation
To  create the restriction fragment sites for ligation into the vector, the purified 
P T E N  fragment w a s  digested with EcoRI and Sal I as described in Chapter 2, 
Section 2.3.5 and cleaned up as described in the s a m e  section. To assess 
yield a 5pl aliquot w a s  separated on an agarose gel alongside 5pl of double 
digested and purified p E G F P  as shown in Figure 31. From this gel a good 
yield of both plasmid and insert w a s  observed, with no extraneous bands in 
either sample (shown in Section 3.2.5).
3.2.5 Preparation of CMV-pEGFP-N1 plasmid for cloning
The C M V - p E F P  family of plasmids are widely used for the fluorescentj
tagging of proteins to be expressed in mammalian cells, and are available fpr 
either N  or C-terminal fusions. They also include a range of colours^sijbfnas 
E C F P  (cyan) and E Y F P  (yellow) which are point m u j a n i s o M h e  standard
E G F P  (green) fluorescent protein. The vecjdrs are suitable for mammalian
/
expression due to the presence of the ^ strong cytomegalovirus (CMV) 
promoter. The EG F P - N 1  version of the plasmid w a s  chosen for cloning as 
this w a s  readily available and would attach the G F P  moiety to the C-terminus 
of the mature P T E N  protein. As  it has been postulated that degradation of 
P T E N  is controlled via the C-terminus, the generation of this clone m a y  yield 
s o m e  insight into the cellular effects of interfering with this process.
//
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3.2.5.1 Transformation of E.coli with CMV-pEGFP-N1 and plasmid DNA 
isolation by Alkaline Lysis
Chemically competent JA221 cells were prepared and transformed with 
C M V - p EGFP-N1, as described in Chapter 2, Section 2.3.6. Numerous 
colonies were observed on the selective plate. Plasmid D N A  extracted from a 
single colony by the method described in Chapter 2, Section 2.3.7 w as 
analysed on a 1 %  agarose gel. 1pl of plasmid w a s  run with a 1Kb marker as 
illustrated in Figure 30. The preparation wa s  seen to consist of two bands; 
the upper of these being the open circular form of the plasmid and the lower 
being the supercoiled form. 5pl of plasmid (~10pg) w as used in double 
restriction digest and purification as described in Chapter 2, Section 2.3.7.
3.2.5.2 Comparison of yield of PTEN and linearised pEGFP after 
digestion.
To give an estimation of yield of the double digested P T E N  and p E G F P  after 
purification, 5pl of each sample w as separated on an agarose gel, as shown 
in Figure 31. The concentration of the P T E N  fragment w as estimated to be 
approximately 2.5 times that of the p E G F P  fragment. The relative amount of 
D N A  in each sample w as used to determine the amount required to perform 
three ligations with different ratios of vector to insert DNA.
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3.2.6 Ligation
Ligations were performed at 1:1, 1:3, and 1:5 ratios of vector: insert (Table 
17) based on the P T E N  fragment having 2.5 times the concentration of D N A  
as the vector, and 10pl analysed on an agarose gel (Figure 32). A  control 
ligation w a s  performed using a 100bp marker (Chapter 2, Section 2.3.8), and 
is shown as an inverted image in Figure 33.
Table 17 Ligation Reactions for p E G F P  &  
P T E N
Ligation Number Ratio V:l V:l (pi)
1 1:1 6.5:2.5
2 1:3 6.5:7.5
3 1:5 6.5:12.5
Table 17 Ligation ratios and volumes of vector (v) and insert (I).
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Preparation of p E G F P  &  Comparison of yield of Digested
P T E N  &  p E G F P
M pEGFP
Fig 30
Agarose gel 
electrophoresis of 1 pi 
pEGFP. M =  1Kb 
marker.
M 1 2
Fig 31
Comparison of yield of 
double digested 
products 5pl each of 1: 
PTEN, and 2: pEGFP. 
M =  100bp marker.
Ligation &  Ligation Control
M 1 2 3
Fig 32
Agarose gel 
electrophoresis of 
ligations 1, 2 &  3 M= 
1 Kb ladder.
M 1 2 M
Fig 33
Control ligations of 
10Obp ladder at 1: 4°C 
and 2: 24°C shown as 
an inverted image. M =  
100bp ladder
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From Figure 33 it w a s  observed that the ligation of the 100bp ladder w as 
most successful at 4°C, as this gave the highest yield of ligated product. The 
lower temperature w a s  therefore used in ligations involving P T E N  and 
pEGFP. Figure 32 shows the three ligation reactions and as expected all 
contain multiple bands, indicating that the ligation w a s  successful insofar that 
the D N A  fragments had been randomly joined.
3.2.7 Introduction of Recombinant Plasmid DNA into E.coli cells
3.2.7.1 Plating out and analysis of the transformants
The three ligation reactions were used to transform chemically competent 
D H 5 a  cells which were plated onto selective L-agar as described in Chapter 
2, Section 2.3.9. Chemically competent cells are available commercially and 
avoid the need for preparing competent cell stocks. Following overnight 
incubation the number of colonies on each control or ligation plate w a s  noted 
and shown in Table 18. From the results tabulated it w a s  observed that 
plates 1 and 5 gave the highest colony numbers. These plates correspond to 
the ligation ratio of 1:1.
3.2.7.2 Confirmation of the presence of full length PTEN in the 
recombinant (pRC-2) plasmids
To confirm that the cloning had been successful, two colonies were picked 
from each ligation plate (with the exception of plate 5 which contained too 
m a n y  colonies) into selective LB for overnight growth. Plasmids were labelled 
A  and B for each plate. The following day plasmids were extracted as 
previously described in Chapter 2, Section 2.3.7. Each plasmid w a s  digested 
and aliquots of cut and uncut plasmid analysed on a 1 %  agarose gel. Gels
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with uncut plasmid (Figure 34), and double digested plasmid (Figure 35) are 
shown overleaf.
Table 18 Results of Transformation
Plate number Ligation pi cells spread Colonies Formed
1 1 20 71
2 2 20 49
3 3 20 43
4 control 20 130
5 1 50 370
6 2 50 170
7 3 50 108
8 control 20 122
Confirmation of the presence of Recombinant Plasmids 
Containing Full-Length P T E N
Fig 34
Electrophoresis of uncut 
plasmids derived from clones 
1A to 7B. C =  uncut pEGFP, 
M= 1 Kb marker.
Fig 35
Electrophoresis of EcoRI / Sal I 
double digested plasmids derived 
from clones 1A to 7B. C =  uncut 
pEGFP, D =  linear pEGFP, M= 
1 Kb marker.
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All the cultures gave a high yield of plasmid D N A  of approximately 1-1.5Kb 
higher in size w hen compared to the p E G F P  control and 1Kb marker. Upon 
digestion, all plasmids yielded two bands of approximately 4.7Kb and 1.2Kb. 
These bands corresponded to linear p E G F P  and PTEN, respectively.
3.2.7.3 Preparation of pRC-2 (Clone 6A) plasmid DNA for Sequencing
From Figure 35 it wa s  observed that clone number 6 A  had the cleanest 
digest, as the presence of an extra band at approximately 2.5Kb w a s  not 
detected. In addition, Figure 34 shows that this clone had a high proportion of 
supercoiled D N A  (lower band) to the open circular form upper band), 
indicating that little d a m a g e  to the plasmid D N A  had occurred during 
preparation. T o  confirm the P T E N  insert sequence, and to verify that the 
clone w as in-frame with respect to the E G F P  tag, the plasmid w a s  
propagated and sent for automated sequencing (Chapter 2, Section 2.3.10). 
The sequencing data is shown in Figure 36 and includes a single strand read 
with standard E G F P  and C M V  primers. The read confirmed that pRC-2 
contained wild-type PTEN.
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Date sent f i t  28 Jun 200211:47:32 +0100 ,
Subject; LARK TECHNOLOGIES EGFP DrimGrFrom: Stephen Foster <stephen@!3rtoiR.co.uk> r
To; Eric Blair <g.e.blair@ieeds.ac.uk>
CGGTAdCGTb
GAcioGACftr
TGtCAGAATA
GACGGCTCCTCTACTGTTTTTGTGAAGTACAGGTTCACCTTAAAATTTGGAGAAAAGTATCGGTTGGCTTTGTCTTTATT 
TGCTTTGTCAAGATCATTTTTTGTTAAAGTAAGTACTAGATATTCCTTGTCATTATCTGCACGCTCTATACT GCAAATGC
TATCGATTTC _______TTGATCAGATAGACinCCATTTTCTAGTTTTTOTGAGGTTTCCTCTGGTCGTGGTATGAAGAATGTATTT 
ACCCAAAAGTGAMCATTTTGTCCTTTTTTAGCATCTTGTTCTGTTTGTGGAAGAACTCTAGTTTGATATCACCACAGAC
AGGTAACGGCTGAGGGAACTCAAAGTACATGAACTTGTCTTCCCGTCGTGTGGGTCCTGAATTGGAGGAATATATCTTCA 
CCT'iTAGCTGGCAGACCACAAACTGAGGATTGCAAGTTCGGCCACTGAACATTGGAATAGTTTCAAACATCATCTTGTGA 
AACANCAGTG 
GCCAGTGGTC;
GGGAAfAGTTACTCCCTTTTTGGNCTCTGGCGGTTACTTCCGCATANAAATCTANGGCCCTNTTGGCCCTTTAAAANTTN
NCCCCGANGTAATAATTTGCCCATTTCNTTNNCCCAGTTNGTCCCTrrCCAGTTTTCNNGGNAATGGCNGCACATGATNG
GCCTCNNCCTNTACCCNNGGGCAAAANCTNCCAAANGGGTTGGAAAANNNCNACCGGGGGGGGNNANGMCCCCAAAGNAT
TT
Date sent: Fri, 28 Jun 200211:47:32 +0100
Subject: LARK TECHNOLOGIES /s* M\ i
From: Stephen Foster <stepben@larkuk.co.tj|<> C/MV DrilTlSr
To: Eric Qlafr <g.e.blair@leeds.ac.uk> *
GNNGGGCCGCNCTATATAAGCAGNAGGTGTCTGGGTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGA
CTCACTATAGGGAGACCCAAGCTTCGAATTCAGCATGACAGCCATCATGAAAGAGATCGTTAGCAGAAACAAAAG8AGAT
ATCAAGAGGATGGATTCGACTTAGACTTGACCTATATFTATCCAAACATTATTGCTATGGGATTTCCTGC
AGAAAGACTT
GAAGGCGTATACAGGAACAATATTGATGATGTAGTAAGGTTTTTGGATTCAAAGCATAAAAACCATTACA
AGATATAGAA
TCTTTGTGCTGAAAGACATTATGACACCGCCAAATTTAATTGCAGAGTTGCACAATATCCTTTTGAAGAC
CATAACCGAC
CACAGGTAGAAGTTATCAAACCCTTTTGTGAAGATGTTGACCAATGGCTAAGTGAAGATGACAATCATGT
TGCAGGAATT
TAAAGGCACA
AGAGGCGCTAGATTTCTATGGGGAAGTAAGGACCAGAGAGAAAAAGGGAGTAACTATTCCCAGTCAGAGGGGCTATGTGT
atta ttatag cta cctg ttaaa g a atcatc tg g attatag acc ag tg g ca ctg ttg tttcac aag atg at
6TTTGAAACT
tcc tccantt
ca g g a c c c a c a c g a c g g g n a g a c a a g ttc a tg tn c tttg a n ttc c c tc a a c c g tta c c tg g g tg tg g g g a
attnaaaana
Im n ttn ttc c n c a a c a a a a n a g a g c ta a a a a g g n c a a a tg t tc n c tttn g g g n a a n a a ttc ttn n n c c n g[ACCGGGGAAC
Ic tn a a a a a ntnaa ang g g g ttttg g g ncca aaanc ctag ccttg g cn atna an cg ncna aanan nag naa
fTTT
Figure 36
pRC-2 Clone 6 A  Sequence data acquired using C M V  &  E G F P  primers.
3.2.8 Sub-cellular distribution and localisation of pRC-2
Although it has been widely reported that PTEN is mainly a cytoplasmic 
protein, evidence exists that it can localise to the plasma membrane and the 
nucleus in a manner which may be cell-line specific (Ginn-Pease & Eng, 
2003). The observation of PTEN in the nucleus suggests that it may interact 
with an as yet unidentified protein to modulate transcription, but as yet there 
is no direct evidence to support this. In this section, the localisation and 
distribution of PTEN was studied in endometrial cell lines by transfection with 
pRC-2. The monkey cell line COS-7 was also used in initial transfections as 
this cell line has a very flat morphology which is easy to visualise using 
fluorescent microscopy. A commercial lipid-based transfection reagent was 
chosen to deliver pRC-2 into COS-7, HEC-1B and Ishikawa cell lines. These 
cationic lipid reagents bind to DNA and permit transfer across the cell 
membrane, and are a less time-consuming alternative methods, such as 
calcium phosphate.
3.2.8.1 Preparation of Ultrapure Supercoiled Plasmid D N A
Preparation of high quality, supercoiled pRC-2 plasmid 
DNA was performed using a Sigma miniprep kit according 
to the manufacturer’s guidelines (Chapter 2, section 
2.3.11). To assess the quality of the plasmid, a 1pl aliquot 
was analysed by agarose gel electrophoresis, as shown in 
Figure 37. Samples of plasmid (5pl) were diluted 1:200 in 
sterile water to measure absorbance at 260nm. A stock 
solution of 1pg/pl was prepared and small aliquots frozen.
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M 1
Figure 37
Electrophoresis 
of 1: pRC-2, 1pl. 
M = 1Kb ladder
Initial transfections were performed with 0.6-1 .Opg of pRC-2 or p E G F P  and 
2pl of Lipofectamine (LF) or Lipofectamine 2000 (LF2K), as described in 
Chapter 2 Section 2.3.11. Transfection into both the C O S - 7  and H E C - 1 B  cell 
lines w a s  highly inefficient in all conditions, with less than 1 0 %  transfectants 
visible on each coverslip. M a n y  of the cells were observed to have detached 
from the coverslips during the fixing process of submerging in cold methanol, 
indicating poor adherence to the glass surface. Additionally, the presence of 
the fusion protein did not appear to be toxic as the nuclei of transfected cells 
were visibly normal and several could be seen in a state of mitosis. This 
experiment was performed several times in triplicate and on several separate 
occasions. Images were captured from wells transfected with 0.8pg of 
plasmid, (see Figures 38 and 39), and are representative of the distribution 
observed in all transfection conditions in each individual experiment.
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Transfection of COS-7 Cell Line with pRC-2
a 0.8pg pRC-2 and 2pl LF■1 iT j
b 0.8(jg pRC-2 and 2pl LF2K 
Figure 38
Transfection of COS-7 cell line with a 0.8pg pRC-2, and 2pl LF and b 0.8pg 
pRC-2 and 2pl LF2K. Filters used were 1 DAPI for the nucleus and 2 FITC 
for EGFP. Composite images are shown in 3. Magnification x400.
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Transfection of HEC-1B with pRC-2
a 0.8pg pRC-2 and 2pl LF
b 0.8pg pRC-2 and 2pl LF2KKMuM i
c 0.8|jg pEGFP and 2pl LF2K 
Figure 39
Transfection of HEC-1B cell line with a 0.8|jg pRC-2 and 2pl LF and b 0.8pg 
pRC-2 and 2pl LF2K. Filters used were 1 DAPI for the nucleus and 2 FITC 
for EGFP. Composite images are shown in 3. Magnification x400.
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From the previous images it w a s  noted that the green pRC-2 signals showed 
a distinctly cytoplasmic distribution in both cell lines, with prominant 
delineation around the nuclear m e m b r a n e  or perinuclear region. Cytoplasmic 
localisation of P T E N  has been reported in endometrial stromal cells, whilst P- 
P T E N  w a s  observed in the nucleus (Guzeloglu-Kayisli, et al 2003). Varying 
amounts of protein and ‘speckles’ appeared in the approximate location as 
the nucleus, as described in neuronal cells by Lachyankar, et al (2000). 
Overall expression levels varied widely within the visible cells. The patterns 
of distribution and expression levels were comparable between pRC-2 and 
pEGFP. Of the two transfection reagents used, Lipofectamine 2000 (LF2K) 
gave a higher yield of transfected cells (Figure 38b &  39b) and w a s  therefore 
selected to perform further investigation.
3.2.9.3 Optimisation of Transfection
H E C - 1 B  and Ishikawa cells were seeded onto coverslips coated in 
polylysine, (Chapter 2, Section 2.3.12), and were observed to exhibit greater 
adherence as fewer cells beca m e  detached during the fixing process. 
Transfection rates were scored visually from several experiments performed 
independently with duplicate samples. Figures 40 to 43 s how transfection 
levels using 2pl LF2K, and 0.6-1 .Opg of pRC-2 for these cell lines at 200- and 
400-times magnification.
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Optimisation of HEC-1B Cell Line Transfection
a 0.6pg pRC-2 and 2pl LF2k x200B l
ai 0.6pg pRC-2 and 2pl LF2k x400
b 0.7pg pRC-2 and 2pl LF2k x200
mm
bi 0.7(jg pRC-2 and 2pl LF2k x400
Figure 40
Transfection of HEC-1B cell line grown on polylysine with 0.6 to 1.0pg pRC-2 
and 2pl LF2K, a-d. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200 & x400.
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c 0.8pg pRC-2 and 2pl LF2k x200
ci 0.8pg pRC-2 and 2pl LF2k x400
m m
d 1.0|jg pRC-2 and 2pl LF2k x200
Figure 40 (Continued)
Transfection of HEC-1B cell line grown on polylysine with 0.6 to 1.0pg pRC-2 
and 2pl LF2K, a-d. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200 & x400.
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Figure 41
High power images of HEC-1B cell line grown on polylysine with 0.8 pg pRC- 
2 and 2pl LF2K. Magnification x1000.
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1Optimisation of Ishikawa Cell Line Transfection
2 3
a 0.6pg pRC-2 and 2pl LF2k x200
ai 0.6|jg pRC-2 and 2pl LF2k x400
b 0.7pg pRC-2 and 2pl LF2k x200
c 0.8pg pRC-2 and 2pl LF2k x200
ci 0.8pg pRC-2 and 2pl LF2k x400
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wm
d 0.9pg pRC-2 and 2pl LF2k x200
e 1 .Opg pRC-2 and 2pl LF2k x200
H k  w t  1
■  i " 7  b i J
ei 1.Opg pRC-2 and 2pl LF2k x400 
Figure 42
Transfection of Ishikawa cell line grown on polylysine with 0.6 to 1 .Opg pRC- 
2 and 2pl LF2K, a-ei. Filters used were 1 DAPI for the nucleus and 2 FITC 
for EGFP. Composite images are shown in 3. Magnification x200 & x400.
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Figure 43
High power image of Ishikawa cell line grown on polylysine with 0.8 pg pRC- 
2 and 2pl LF2K. Magnification x1000.
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The results for H E C - 1 B  indicated that the best transfection rates of 50-70% 
were obtained using 0.8-1.Opg of pRC-2 (Fig 40 c-d). The majority of the 
transfected cells were seen to be expressing the P T E N  protein at low levels, 
but a greater number of cells expressed the protein highly in proportion to 
increasing the amount of pRC-2 used.
The data obtained for Ishikawa cells showed that the best transfection rates 
of 30-50% were again obtained using 0.8-1 .Opg of pRC-2 (Fig 42 c-ei). The 
majority of the transfected Ishikawa cells were seen to be expressing the 
G F P  protein at low levels, but as observed with H E C - 1 B  a greater number of 
cells expressed the protein highly in proportion to increasing the amount of 
pRC-2 used. Although Ishikawa cells do not express P T E N  protein, the nuclei 
of transfected cells were observed undergoing division, and reconstitution of 
P T E N  did not appear to cause apoptosis as nuclear fragmentation w a s  not 
observed.
3.2.9.4 Stimulation of Transfected Cell Lines
Localisation of P T E N  in H E C - 1 B  and Ishikawa cell lines w a s  investigated 
under stimulation using TGF-p1 or oestrogen, a hormone which influences 
cellular conditions in the endometrium. Oestrogen plays a major role in 
regulating the architecture of the endometrium during the menstrual cycle, 
and m a y  therefore cause morphological changes in endometrial cells which 
could be linked to a change in P T E N  protein localisation. Although TGF-p1 
did not appear to modify P T E N  protein levels in the experiments previously 
described here, it is worthwhile investigating whether the cytokine can 
change the localisation of the protein. Such changes in location within the cell 
m a y  indicate sequestration to specific compartments which m a y  have an
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impact on the cellular function of P T E N  in attenuating PI3K, and therefore 
growth regulation.
Briefly, cells were transfected with 0.8pg pRC-2 in the presence of 2pl LF2 K  
and stimulated with the relevant compound as described in Chapter 2, 
Section 2.3.13. A s  cellular response to hormones and cytokines can be rapid, 
short incubation times of 1-2 hours were used. Longer incubations of up to 24 
hours were employed to detect any delayed or long-lasting response.
3.2.9.4.1 Oestrogen stimulation of HEC-1B and Ishikawa cell lines
Concentrations of oestrogen (10 and 100nM) were chosen on the basis of 
published work (Campbell, et al 2001). Transiently transfected cells were 
stimulated with hormone and fixed for fluorescent microscopy after 2, 6 or 24 
hours. These experiments were performed in triplicate on several separate 
occasions. Results for oestrogen stimulation of Ishikawa and H E C - 1 B  cells 
lines are shown in Figures 44 to 47 and are representative of all the 
experiments.
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Oestrogen Stimulation of Transfected Ishikawa Cell Line■
a 10nM oestrogen, 2 hrs x200
b 10nM oestrogen, 24 hrs x200
c 100nM oestrogen, 2 hrs x200H jL jpLJI
d 100nm oestrogen, 24hrs x200 
Figure 44
Stimulation of transfected Ishikawa cell line with 10-100nM oestrogen for 2 
and 24 hours a-d. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200
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1 2 3
100nm oestrogen, 24hrs 
Figure 45
High power image of transfected Ishikawa cell stimulated with 100nM 
oestrogen for 24 hrs. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x1000.
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Oestrogen Stimulation of Transfected HEC-1B Cell Line
a 10nM oestrogen, 2hrs x200
b 10nM oestrogen, 6hrs x200
I J
c 10nM oestrogen, 24hrs x200 
Figure 46
Stimulation of transfected HEC-1B cell line with 10-100nM oestrogen for 2 
and 24 hours a-c. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200
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d 100nM oestrogen, 2hrs x200
E i
e 100nM oestrogen, 6 hrs x200! ■ ■
f 100nM oestrogen, 24hrs x200 
Figure 46 (Continued)
Stimulation of transfected HEC-1B cell line with 10-100nM oestrogen for 2,6 
and 24 hours d-f. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200.
224
The results shown in Figure 44 and 45 indicated no discernable change in 
the distribution of PTEN in Ishikawa cells with the concentrations of hormone 
and incubation times used. Ishikawa cells are known to express functional 
oestrogen receptors (Nishida, 2002), but stimulation with this hormone 
appeared to have little effect on PTEN localisation. Cells from this experiment 
were very difficult to photograph compared to HEC-1B due to cloudiness on 
the coverslips which prevented good focussing of the microscope. This may 
represent morphological changes, eg rounding of the cells, but this 
experiment would need to be repeated using confocal microscopy to fully 
assess this observation.
The images presented in Figure 46 indicated no change in the overall 
distribution of PTEN in HEC-1B with the concentrations of hormone and 
incubation times used. As with the Ishikawa cell line, stimulation of transiently 
transfected HEC-1B cells appears to have little or no effect on the localisation 
of PTEN protein contributed by pRC-2.
3.2.9.4.2 TGF-P1 Stimulation of HEC-1B cell line
Transiently transfected HEC-1B cells were stimulated with either 2ng/ml or 
5ng/ml of cytokine, as these concentrations were previously used in the 
investigation of PTEN mRNA and protein expression. As for oestrogen, short 
incubation times of 1, 2 and 6 hours were used as cellular responses to 
cytokines can be rapid. Results for TGF-p1 stimulation of the HEC-1B cells 
line are shown in Figure 47.
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TGF-P1 Stimulation of Transfected HEC-1B Cell Line
a 2ng TGF-pi, 1 hr x200
b 2ng TGF-p1, 2hr x200
B j
c 2ng TGF-p1,6hrs x200
Figure 47
Stimulation of transfected HEC-1B cell line with 2 and 5ng/ml TGF-p1 for 1,2 
and 6 hours a-c. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200.
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M i
d 5ng TGF-p1, 1 hr x200
%  >
e 5ng TGF-p1, 2hrs x200
T  A
f 5ng TGF-p1, 6hrs x200
Figure 47 (Continued)
Stimulation of transfected HEC-1B cell line with 2 and 5ng/ml TGF-p1 for 1,2 
and 6 hours d-f. Filters used were 1 DAPI for the nucleus and 2 FITC for 
EGFP. Composite images are shown in 3. Magnification x200.
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Figure 47 shows the results of stimulating transiently transfected HEC-1B 
cells with TGF-p1. No discernable change in the localisation of PTEN 
encoded by pRC-2 was observed with the concentrations of hormone and 
incubation times used.
Although no changes in the distribution of PTEN were detected in the 
stimulation experiments performed, it is possible that if any response 
occurred it was too rapid for observation or so slow that it occurred outside of 
the 24 hour maximum incubation time used.
3.2.9.5 Localisation of pRC-2 to Subcellular compartments
A comparison of the localisation of PTEN encoded by pRC-2 with colligin (ER 
marker) and mannosidase II (golgi marker) was performed to determine any 
co-localisation of PTEN to the ER or golgi. Localisation to specific regions of 
the cell may indicate partitioning of PTEN and have implications for the 
phosphatases’ ability to gain access to its substrates. Additionally, close 
association with the ER may be important for the nuclear translocation of 
PTEN, the mechanism of which has not yet been described.
As described in Chapter 2, Section 2.3.14, transiently transfected HEC-1B 
and Ishikawa cell lines were probed with antibodies against colligin (Hsp47), 
an ER-resident protein, or golgi-specific anti-mannosidase II. Any overlap 
between the green signal from pRC-2 and the red signal from colligin or 
mannosidase II show as a yellow colour on the merged images.
Results for localisation with colligin are presented in Figures 48a/b and 49a/b 
for HEC-1B and Ishikawa cell lines respectively. Localisation studies with 
mannosidase II are shown in Figures 50 a/b and 51a/b for HEC-1B and 
Ishikawa cell lines respectively, and represent several separate experiments.
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Localisation of Colligin & pRC-2 in HEC-1B Cell Line
»
Figure 48a
Anti-colligin staining of HEC-1B transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (Colligin),3 DAPI 
for the nucleus. Composite image shown in 4.
Magnification x400.
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Figure 48b
Anti-colligin staining of HEC-1B transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (Colligin),3 DAPI 
for the nucleus. Composite image shown in 4.
Magnification x400.
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Localisation of Colligin & pRC-2 in Ishikawa Cell Line
3
Figure 49a
Anti-colligin staining of Ishikawa transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (Colligin),3 DAPI 
for the nucleus. Composite images are shown in 4. Magnification x400.
Localisation of Colligin & pRC-2 in Ishikawa Cell Line
3
Figure 49a
Anti-colligin staining of Ishikawa transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (Colligin),3 DAPI 
for the nucleus. Composite images are shown in 4. Magnification x400.
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Figure 49b
Anti-colligin staining of Ishikawa transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (Colligin),3 DAPI 
for the nucleus. Composite images are shown in 4. Magnification x400.
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Localisation of Mannosidase II & pRC-2 in HEC-1B Cell Line
2
3
Figure 50a
Anti-Mannosidase II staining of HEC-1B transiently transfected with pRC-2.
Filters used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 
(Mannosidase II),3 DAPI for the nucleus. Composite images are shown in 4.
Magnification x400.
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Figure 50b
Anti-Mannosidase II staining of HEC-1B transiently transfected with pRC-2.
Filters used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 
(Mannosidase II),3 DAPI for the nucleus. Composite images are shown in 4.
Magnification x400.
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Localisation of Mannosidase II & pRC-2 in Ishikawa Cell Line
3
Figure 51a
Anti-Mannosidase II staining of Ishikawa transiently transfected with pRC-2.
Filters used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 
(Mannosidase II),3 DAPI for the nucleus. Composite images are shown in 4.
Magnification x400.
235
1 2
Figure 51b
Anti-Mannosidase II staining of Ishikawa transiently transfected with pRC-2.
Filters used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 
(Mannosidase II),3 DAPI for the nucleus. Composite images are shown in 4.
Magnification x400.
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As the images in Figures 48a and b show, there was some degree of overlap 
between PTEN and colligin giving a yellow colour on the composite images. 
This suggests that a proportion of the PTEN fusion protein was present in the 
ER, and that the presence of the GFP moiety did not prevent entry into this 
compartment. Additional signals derived from the FITC filter once 
demonstrate the presence of a small amount of exogenous PTEN in the 
cytoplasm and nuclear region.
Figures 50a and b show that there was no discernable overlap between 
pRC-2-derived PTEN and the golgi marker Mannosidase II in HEC-1B cells. 
The fusion protein was therefore not specifically localised to the golgi. 
However, the staining of the golgi was indistinct and diffuse particularly in 
transfected cells. The poor definition was possibly due to the polyclonal 
nature of the anti-Mannosidase antibody, which could be less specific than a 
monoclonal.
Figures 49a & b show there was some degree of overlap between pRC-2 and 
Colligin in Ishikawa cells, giving a yellow colour on the composite images. 
This suggests that at least some of the PTEN fusion protein was present in 
the ER, and that as observed in HEC-1B cells the presence of the GFP 
moiety did not exclude entry into this compartment. Additional signals derived 
from the FITC filter once again demonstrated the presence of exogenous 
PTEN in the cytoplasm and nuclear region.
Figures 51a and b show that there was very little overlap between pRC-2- 
derived PTEN and the golgi marker Mannosidase II in Ishikawa cells. The 
fusion protein was therefore not specifically localised to the golgi, as there 
was a partial overlap of colours in only a small proportion of cells. The
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staining of the golgi was again indistinct and diffuse particularly in transfected 
cells, although somewhat clearer definition of the golgi was observed in the 
Ishikawa cell line.
3.2.9.6 Co-localisation of exogenous PTEN to endogenous PTEN in 
HEC-1B
To determine whether endogenous PTEN in transfected cells would 
demonstrate a different staining pattern to exogenous PTEN-EGFP, 
transfected HEC-1B cells were incubated with anti-PTEN primary (BD 
Biosciences) and AlexaFluor 594-labelled secondary antibodies (Chapter 2, 
Section 2.3.14). The images obtained are presented in Figures 52 a and b. In 
Figure 52 a low expression level of endogenous PTEN can be observed in 
non-transfected cells which has been detected by the anti-PTEN antibody 
and visualised under a Texas red filter. In contrast, the level of exogenous 
PTEN in transfected cells is significantly increased, suggesting that the 
endogenous cellular level of PTEN protein is fairly low.
From these images, a total overlap between the red and green images was 
observed, suggesting that both sources of PTEN localise to the same cellular 
regions. It should be noted, however, that if the anti-PTEN antibody is 
capable of binding to PTEN-GFP, then this experiment would not 
discriminated between the endogenous and exogenous forms of PTEN. The 
antibody’s ability to bind to PTEN-GFP could be tested by Western blot 
against protein lysates from transfected Ishikawa cells which contain no 
endogenous PTEN protein.
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Co-Localisation of PTEN and PTEN-EGFP in HEC-1B Cell Line
2
Figure 52a
Anti-PTEN staining of HEC-1B transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (PTEN),3 DAPI 
for the nucleus. Composite images are shown in 4. Magnification x400.
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Figure 52b
Anti-PTEN staining of HEC-1B transiently transfected with pRC-2. Filters 
used were 1 FITC for EGFP,2 Texas red for AlexaFluor 594 (PTEN),3 DAPI 
for the nucleus. Composite images are shown in 4. Magnification x1000
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3.3 MUTATIONAL ANALYSIS OF PTEN EXONS 5 & 8 IN ENDOMETRIAL 
DNA SAMPLES BY SINGLE STRAND CONFORMATIONAL 
POLYMORPHISM ANALYSIS (SSCP)
Various studies have been conducted into the mutation status of genomic 
PTEN in fresh tumour tissue of diverse origin, but little work has been 
published using archival material (paraffin fixed and frozen samples which 
may have been stored for several years). This is mainly due to technical 
difficulties associated with retrieving DNA from paraffin embedded tissue 
sections. Extracted DNA can be highly fragmented and overall yields low, 
and the isolation of DNA from only one cell type is difficult if the section 
contains a mixture of cells.
Due to the availability of a large repository of archival endometrial 
carcinomas, complete with histologically normal cervical sections, a study of 
PTEN mutations was performed for the 43 patients available (a total of 127 
samples). Because a histologically normal sample was available for each 
accompanying tumour specimen, any mutations in PTEN could be compared 
between normal and tumour DNA, thus such changes could be described as 
early or late events. Published results for fresh tumours described a range of 
mutations which were mainly clustered in exons 5 and 8 of PTEN, and 
therefore prompted my focus on these two exons. The electrophoretic 
technique of SSCP was chosen as a relatively simple and rapid method of 
analyzing the 127 samples for both exons, a total of 508 PCR samples.
SSCP is an electrophoretic method which is capable of detecting single base 
changes in a population of small DNA strands which are otherwise identical 
in sequence to a known sequenced control. Single stranded DNA forms
241
stable intramolecular secondary structures in solution, therefore differences 
in base sequence will manifest as differences in single-strand conformations. 
This technique distinguishes between these conformations by virtue of 
differences in DNA mobility through the gel. When compared to the control, 
sequence variations can be observed as ‘bandshifts’ which display a change 
in migration pattern. Controls used in SSCP analysis were derived from 
peripheral blood lymphocytes, in which mutations in PTEN are uncommon 
(Dahia, et al 1999). These samples were donated by members of staff and 
denoted as rDNA, gDNA, C1 and SJ1. Sequencing of these controls was 
peformed to verify a wild-type PTEN sequence.
Small PCR fragments of <250bp in length are required for a good detection 
rate using this method. For this reason, Exons 5 and 8 were ‘split’ into two 
overlapping PCR reactions using primer pairs AB and CD, which contain a 
small region of overlap to amplify the entirety of each exon in these two 
reactions.
3.3.1 Preparation of DNA Samples for SSCP Analysis
3.3.1.1 Extraction of human DNA from whole blood and archival 
material
Extraction of DNA from whole blood and archival material was performed as 
described in Chapter 2, Section 2.3.2 and stored at -70°C prior to use in PCR 
reactions.
242
3.3.1.2 PCR amplification of Patient & Control DNA samples for SSCP 
Analysis
3.3.1.2.1 PCR amplification of samples for Exon 5
PCR products for Exons 5AB and 5CD were obtained for each patient 
sample from Dr K Feeley, University of Sheffield UK. PCR was performed 
using the conditions described in Chapter 2, Section 2.4.2 using the PTEN I 
programme (Appendix V). The presence of PCR products for 5AB (137bp) 
and 5CD (186bp) were confirmed by 15% PAGE.
Due to a very low yield of product amplified for 5AB in the PCRs sent to me, 
aliquots of all remaining patient DNA samples were requested from Dr 
Feeley. All patient DNA samples available, and controls, were therefore 
subjected to repeated PCR for 5AB using the RIS2-2 cycle (Appendix III) with 
the conditions described previously. PCRs were analysed by agarose gel 
electrophoresis, and the majority of samples exhibited an improved yield of 
the 5AB fragment when compared to PCR products generated by the PTEN I 
programme. Examples of these PCRs are illustrated in Figure 53 which 
shows the typical yield of some of the original samples, and Figure 54 which 
shows the improved yield using the RIS2-2 PCR cycle.
PCR samples provided for exon 5CD showed good amplification in the 
majority of patient DNA samples; an example is shown in Figure 55. Control 
5CD DNA (RDNA) is shown in Figure 56.
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PCR of Patient and Control samples for Exon 5AB
Figure 53 15% PAGE of 5AB patient samples 92- 
222, 10pl/ lane, PTEN I cycle.
M - 1 2 3
Figure 54 5AB PCR of 1: control rDNA 2: patient 49 
3: patient 52x, 10pl/lane, RIS2.2 cycle. Dash 
indicates PCR control, M: 100bp ladder.
92 93 227 228 229 224 225 226 220 222
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PCR of Patient and Control samples for Exon 5CD
Figure 55 15% PAGE of 5CD PCR for patient 
samples 84-93, 10pl/ lane, PTEN I cycle.
M - 1
Figure 56 5CD PCR of 1: control rDNA, 10pl per 
lane, PTEN I cycle. Dash indicates PCR control. 
M:100bp ladder.
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3.3.1.2.2 PCR amplification of samples for Exon 8
PCR products for Exons 8AB were obtained for each patient sample from Dr 
K Feeley, as described, and the presence of the 8AB fragment (188bp) 
confirmed by 15% PAGE. For Exon 8CD, PCR was performed on available 
patient DNA using the PTEN I cycle (Chapter 2, Section 2.4.2). The presence 
of the 8CD (245bp) fragment was confirmed by agarose gel electrophoresis. 
For exon 8AB, all patient DNA samples showed good amplification; an 
example is shown in Figure 57. Control DNA amplified using PTEN I cycle is 
shown in Figure 58. PCR of all patient DNA samples available for exon 8CD 
was performed as previously described. Control DNA is shown in Figure 59.
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PCR of Patient and Control samples for Exon 8 AB
Figure 57 15% PAGE of 8AB PCR for patient samples 
84-92, 10pl/ lane, PTEN I cycle. M= 100bp ladder.
M - 1 2
Figure 58 8AB PCR of controls 1: RDNA, 2: 
gDNA, 10jlx ! per lane. Dash indicates PCR 
control
PCR of Control samples for Exon 8 CD
M 1
Figure 59 8CD PCR of 1: Control gDNA, 
10pl. Dash indicates PCR control M= 100bp
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3.3.2 Preparation of Control PCR products for sequencing
To provide normal sequence controls for SSCP, PCR was performed using 
DNA derived from peripheral blood donated by four staff members. PTEN 
mutations are very rare in white blood cells, so these samples were likely to 
have normal sequences from which to compare patient DNA. Staff control 
DNA (rDNA, gDNA, C1 and SJ1) to be used as controls was purified as 
described in Chapter 2, Section 2.4.3, following PCR with AB and CD primer 
pairs for both exons as previously described for patient DNA (Section 2.4.2). 
Sequence information was obtained from Lark as electropherograms (see 
Figures 60 to 68). Adequate sequences were obtained for exon 5AB, 5CD 
and 8AB, for either g- or r-DNA, C1 and SJ1 control samples. The sequences 
showed a high degree of sequence homology to PTEN cDNA with few 
ambiguous bases. These samples were regarded as suitable controls for 
these exon fragments. Sequence data for the 8CD control was not obtained 
due to poor read quality after several attempts, but was still used on the 
relevant gels.
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3.3.3 SSCP Analysis
PCR products were initially separated using a minigel ( 8 x 1 0  cm) system. 
This method, however, was revised due to poor band migration. Increased 
band separation and detection sensitivity was observed using an 18x24 cm 
large gel format, therefore this method was selected to analyse the PCR 
products for all exon fragments. SSCP was performed as described in 
Chapter 2, Section 2.4.4 using 0.5 - 0.6% MDE/10% glycerol gels running 
overnight at 4°C to avoid heat generation. Bands were detected initially by 
manual silver staining (Section 3.3.3.2), which gave a high background and 
poor band definition, and later with a silver staining kit as described in 
Chapter 2, Section 2.4.4.2.
Results of SSCP are shown in Figures 69 and 70, for exon 5 (Section 
3.3.3.1-2) and Figures 76 and 77 for exon 8 (Section 3.3.3.3-4). Samples 
were carefully compared to the band migration pattern of one or more of the 
controls (rDNA, gDNA, C1 or SJ1). Samples showing band shifts were noted 
and re-run on separate gels to confirm the presence of the aberrant bands 
(highlighted in red), where sufficient sample was available. The results for 
each exon were tabulated to include histological details for each sample, 
where available (Tables 19 to 22).
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3.3.3.1 Exon 5AB SSCP Results 
Fig 69a
•
4mMI
4*
rDNA 24 25 27 28 30x 30y 31 35 36 45 46x
Fig 69b
#.•* *
1
4
gDNA 46y 47 48 49 51 52x 52y 61x 102 112 113
Fig 69c1*
rDNA 18 68x 69 73 74 75 76 
Fig 69d
77 78 79 80
*
*
rDNA 81 82 83x 83y 84 88 89 90 92 93
Figure 69 a-d SSCP results for exon 5ABSamples with bandshifts are
numbered in red. Controls rDNA and/or gDNA are included with 100bp
marker on each gel (lane 1).
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Fig 69e
rDNA 114 134 135 137 138 151 152 153 159 160 gDNA
rDNA 161 162 219 220 222 224 226 227 228 229 gDNA
Fig 69g
rDNA 207 208 209 210 211 212 214x 216 217 218 gDNA
Fig 69 e-g SSCP results for exon 5AB 
Samples with bandshifts are numbered in red. Controls rDNA and/or gDNA 
are included with 100bp marker on each gel (Lane 1).
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Table 19 Bandshift Summary 
Exon 5AB
Sample ID Tissue Histology
18 95/23231 e Endometrium AH?
51 94/18507c Endometrium AH?
74 97/12804 In Endometrium Com H
83x 97/21010 jx Endometrium AdCa 2 & AH
83y 97/2101 Ojy Endometrium AdCa 2 & AH
84 97/21010 a Cervix Normal
88 98/4189 2a Cervix Normal
89 98/4189 2d Endometrium AdCa 2
90 98/4189 2c Endometrium AdCa 2 & AH
92 98/11642 h Endometrium AdCa 3
93 98/11642 g Endometrium AH?
152 94/11672 c Endometrium H
153 94/11672 b Cervix Normal
159 94/20749 c Endometrium H
160 95/6941 c Endometrium H
208 97/3404 f Endometrium Marginal
209 94/4094 f Endometrium -
Table 19 Bandshift Summary for Exon 5AB showing samples in which 
aberrant bands were detected. Where available, tissue and histological 
description are included. H: hyperplasia, AH: atypical hyperplasia, Com H: 
complex hyperplasia, AdCa (x): adenocarcinoma (grade), ?: histological
grouping unclear.
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3.3.3.2 Exon 5CD SSCP Results 
Fig 70a
rDNA 18 18a 20 21 22 24 25 27 28 134 135
rDNA 30x 30y 31 67 68x 68y 69 112 113 114
rDNA 35 36 45
Fig 70d
rDNA 35 36 45 - 46x 46y 47 48 49 C1
Figure 60 a-d SSCP results for exon 5CD. Samples with bandshifts are 
numbered in red. Controls rDNA and/or gDNA are included with 100bp
marker on each gel.
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Fig 70e
rDNA 50 60 61x 61 y 195 196 C1
Fig 70f
73 74 75 76 77 78 79 80 81 82
rDNA 83x 83y 87 88 89 90 91 92 93 rDNA
70h
Figure 60 e-h SSCP results for exon 5CD. Samples with bandshifts are
numbered in red. Controls rDNA and/or gDNA are included with 100bp
marker on each gel (lane 1).
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rDNA 160 161 162 163 166 167 168 169 170 171 rDNA
rDNA 205 206 207 208 209 210 211 212 214 215 rDNA
rDNA 216 217 218 219 220 221 222 rDNA (8AB)
rDNA 224 225 226 227 228 229 rDNA (8AB)
Figure 60 i-l SSCP results for exon 5CD. Samples with bandshifts are
numbered in red. Controls rDNA and/or gDNA are included with 100bp
marker on each gel (lane 1).
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rDNA 153 154 172 173 174 175 176 177 178 rDNA
Fig 70n
rDNA 179 180 185 186 189 190 191 192 rDNA
Fig 70o
rDNA 20 21 22 67 68x 68y 69 164 165 191 192
Fig 60 m-o SSCP results for exon 5CD. Samples with bandshifts are 
numbered in red. Controls rDNA and/or gDNA are included with 100bp
marker on each gel (lane 1).
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Table 20 Bandshift Summary Exon 5CD
Sample ID Tissue Histology
22 96/11307 h Endometrium -
46x 94/5212 Ibx Endometrium AdCa 3 + AH?
61x 95/22466 5fx Endometrium lECa/SevAH
61y 95/22466 5fy Endometrium lECa/Sev AH
67 97/9145 3b Cervix Normal
68y 97/9145 32y Endometrium AdCa 2
69 97/9145 Ib3 Endometrium AH / lECa
165 94/21552 3a Cervix Normal
192 97/3362 e Endometrium -
Table 22 Bandshift Summary for Exon 5CD showing samples in which 
aberrant bands were detected. Where available, tissue and histological 
description are included. AH: atypical hyperplasia, Com H: complex 
hyperplasia, Sev AH: severe atypical hyperplasia, AdCa (x): 
adenocarcinoma (grade), lECa: intraepithelial carcinoma, ?: histological
grouping unclear.
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Exon 5 Summary
SSCP separation for the 5AB exon fragment was good, however 
interpretation of the bands was difficult due to multiple additional bands 
observed in each sample. Patient samples could not be sequenced due to 
inadequate read quality after several attempts.
Figures 70a-j show gels developed by manual silver staining. Sensitivity was 
very low and background staining high for the majority of gels. Figures 70k-o 
demonstrate the improvement of gels stained with the PlusOne silver 
staining kit (Chapter 2, Section 2.4.4.2).
With regard to exon 5CD, sequencing was performed on sample 46x, which 
exhibited a bandshift, and also samples 45, 46y and 47 obtained from the 
same patient. Sequence data was successfully obtained (Figures 71 to 74) 
but the readings were incomplete, containing ambiguous bases and low 
signal strength, especially with the 5C primer.
The readable portions of data were aligned with the PTEN cDNA sequence 
for comparison (Figure 75). No conclusions as to the success of bandshift 
detection could be made from the sequence data obtained, due to the high 
number of ambiguous bases or base changes.
Overall figures for the incidence of bandshifts in exon 5 were as follows. For 
exon 5AB, 26% (11/43) of patients demonstrated bandshifts from a 
corresponding total of 13% (17/127) of all samples. For exon 5CD, 14% 
(6/43) of patients demonstrated bandshifts from a corresponding total of 7% 
(9/127) of all samples. The total bandshift detection rate for exon 5 was 40% 
(17/43) of patients, from 20% (26/127) of the samples used.
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3.3.3.3 Exon 8AB SSCP Results 
Fig 76a
rDNA 30x 30y 31 35 36 45 46x 46y 47 rDNA
Fig 76b
f A
mm
rDNA 48 49 50 51 52 60 61 x 61 y rDNA
Fig 76c
* * • m
rDNA 67 68x 68y 73 74 75 76 SJ1 C1
Fig 76d
rDNA 77 78 79 80 81 82 83x 83y 84 SJ1
Figure 76 a-d SSCP results for exon 8AB Samples with bandshifts are 
numbered in red. Controls rDNA and/or C1 and SJ1 are included with 100bp
marker on each gel (lane 1).
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Fig 76e
% m m m m  m
t
m m m/ /
rDNA 88 89 90 91 92 93 101 102 C1 rDNA
Fig 76f
rDNA 112 113 114 134 135 136 137 138 SJ1 rDNA
Fig 76g
rDNA 151 152 153 154 158 159 160 161 162 163 C1
Fig 76h
« *
rDNA 164 165 166 167 168 169 170 171 172 173 SJ1
Figure 76 e-h SSCP results for exon 8AB Samples with bandshifts are
numbered in red. Controls rDNA and/or C1 and SJ1 are included with 100bp
marker on each gel (lane 1).
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Fig 76i
rDNA 174 175 176 177 178 179 180 185 186 C1
Fig 76j
rDNA 187 188 189 190 191 192 193 194 195 196 SJ1
Fig 76k
rDNA 200 201 202 203 204 205 206 207 - 208 C1
Fig 76I
■vmm
rDNA 209 210 211 212 214 215 216 217 218 219 SJ1
Fig 76m
rDNA 220 221 222 224 225 226 227 228 229 C1
Figure 76 i-m SSCP results for exon 8AB Samples with bandshifts are
numbered in red. Controls rDNA and/or C1 and SJ1 are included with 100bp
marker on each gel (lane 1).
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Fig 76n
rDNA 18 18a 24 25 50 51 52 60 61 x 61 y SJ1
Fig 76o
mmm
rDNA 35 36 45 46x 46y 47 151 152 166 167
Figure 76 n-o SSCP results for exon 8AB. Samples with bandshifts are 
numbered in red. Controls rDNA and/or C1 and SJ1 are included with 100bp
marker on each gel (lane 1).
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Table 21 Bandshift Summary Exon 8AB
Sample ID Tissue Histology
25 96/17667 c Endometrium Com H
35 97/23720 1a Cervix Normal
36 97/23720 1p Endometrium AH (B'gr)
47 94/5212 1j Cervix -
48 98/1372 la Cervix Normal
49 98/1372 Id Endometrium AH
50 94/18507 a Cervix Normal
51 94/18507 c Endometrium AH?
52 94/18507 f Endometrium AdCa 3
60 95/22466 5c Cervix Normal
61x 95/22466 5fx Endometrium IE Ca / Sev AH
61y 95/22466 5fy Endometrium IE Ca/SevAH
83y 97/21010 j Endometrium AdCa2 + Ah
84 97/21010 a Cervix Normal
92 98/11642 h Endometrium AdCa 3
194 98/10452 j Endometrium -
Table 21 Bandshift Summary for Exon 8 AB showing samples in which 
aberrant bands were detected. Where available, tissue and histological 
description are included. AH: atypical hyperplasia, Com H: complex 
hyperplasia, Sev AH: severe atypical hyperplasia, lECa: intraepithelial 
carcinoma, AdCa (x): adenocarcinoma (grade), ?: histological grouping
unclear.
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3.3.3.4 Exon 8CD SSCP Results
Fig 77a
x \  ■ ' i l l l l i
' .i:- i l  |
| w mm pm -  m *
a ‘-: ■ JH R  •«*“:gDNA 80 81 82 83y 84 88 89 90 92 101 102
Fig 77b 
*
gDNA 20 21 27 28 48 49 81 82 83y 84 88
Fig 77c
4
~~ s —
gDNA 89 90 92 112 113 114 135 137 138 151 152
Fig 77d
gDNA 153 159 160 161 162 168 169 174 175 176 177
Fig 77e___
gDNA 167 171 172 179 180 185 186 188
Figure 77 a-e SSCP results for exon 8CD. Samples with bandshifts are 
numbered in red. Control gDNA is included with 100bp marker on each gel
(lane 1).
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Fig 77f
b Sf |Ml$$ -s  ‘ 4
gDNA 189 190 192 193 194 195 196 202 52y 61 x 61 y 
Fig 77g
♦
gDNA 67 68x 73 75 79 80 81 102 134 165 166
Figure 77 f-g SSCP results for exon 8CD. Samples with bandshifts are 
numbered in red. Control gDNA is included with 100bp marker on each gel
(lane 1).
Table 22 Bandshift Summary Exon 8CD
Sample ID Tissue Histology
89 98/4189 2d Endometrium AdCa 2
90 98/4189 2c Endometrium AdCa 2 & AH
Table 22 Bandshift Summary for Exon 8 CD showing samples in which 
aberrant bands were detected. Where available, tissue and histological 
description are included. AH: atypical hyperplasia, AdCa (x): 
adenocarcinoma (grade).
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Exon 8 Summary
Exon 8AB generated very good SSCP gels with clean, well-separated bands 
and very little background (Figures 76a-o). Sequences for patient samples 
sent for contained many ambiguous bases (data not shown) and were 
difficult to interpret. SSCP for exon 8CD fragments demonstrated much lower 
separation than for 8AB, and altering the gel composition had little effect in 
improving this (data not shown). Again, sequencing of patient samples 89 
and 90 in which aberrant bands were detected contained many ambiguous 
bases (data not shown).
Figures for the incidence of bandshifts in exon 8 were as follows. For exon 
8AB, 21% (9/43) of patients demonstrated bandshifts from a corresponding 
total of 12% (16/127) of all samples. For exon 8CD, 2% (1/43) of patients 
demonstrated bandshifts from a corresponding total of 2% (2/127) of all 
samples. The total bandshift detection rate for exon 8 was 23% (10/43) of 
patients, from 14% (18/127) of the samples used.
3.3.3.5 Patients with multiple bandshifts
Eight samples corresponding to five patients displaying bandshifts in more 
than one exon are shown in Table 23. Six samples carry an exon 5 AB or 
8AB bandshift, with 4 samples carrying changes in both of these exon 
portions. This may reflect the sensitivity of the SSCP technique for the 
different exon portions. It is interesting to note that 6 out of the 8 samples 
(75%) displaying aberrations in two exons are histologically advanced lesions 
(adenocarcinomas). The higher grade of the samples (2 and 3) denotes 
increasing depth of invasion into the tissue underlying the endometrium.
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Table 23 Samples with Bandshifts in Multiple exons
Sample Histology Exons
51 AH? 5AB & 8AB
61x* lECa/SevAH 5CD & 8AB
61 y* lECa / Sev AH 5CD & 8AB>*CO00 AdCa2 + AH 5AB & 8AB
84t Normal 5AB & 8AB
89s AdCa2 5AB & 8CD
90s AdCa2 + AH 5AB & 8CD
92 AdCa3 5AB + 8AB
Table 23 Samples displaying bandshifts in multiple exons, with histological 
descriptions. Symbols indicate samples belonging to the same patient. 
AH: atypical hyperplasia, Sev AH: severe atypical hyperplasia, lECa: 
intraepithelial carcinoma, AdCa (x): adenocarcinoma (grade), ?: histological
grouping unclear.
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CHAPTER 4 
DISCUSSION
4.1 Discussion of Results
Understanding the molecular mechanisms which underlie the initiation and 
progression of cancer is central to the development of novel therapeutic 
strategies. Since its discovery in 1997, the PTEN tumour suppressor has 
proven to be the first of an emerging species of lipid phosphatase involved in 
multiple cellular processes, which now includes SHIP and myotubularin 
phosphatase (Wishart & Dixon, 2002). The existence of PTEN and its several 
homologues, such as PTEN 2, TPTE and TPIP across the spectrum of 
eukaryotic organisms highlights the evolutionary importance of this enzyme. 
The central role of PTEN in the control of multiple signalling pathways, and 
its interaction with other cell-cycle proteins, have placed it amongst the 
hierarchy of tumour suppressor genes including pRb and p53. Recently, 
PTEN has proven to be much more that just a tumour suppressor by 
exhibiting a fundamental role in the development and organisation of tissues 
as diverse as neurones and immune cells.
Significantly, the high occurrence of PTEN mutation or loss of expression is a 
feature of certain cancers, including endometrial and prostate carcinomas, 
although the reasons for such tissue specificity are not yet fully understood. 
The exceptionally high incidence of PTEN aberrations in endometrial 
carcinomas (~80%) has provoked many studies, and unlike other somatic 
cancers, loss of PTEN is an early event in the development of EC. Clearly, 
PTEN has a fundamental role in endometrial pathology, and it is hoped that
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by dissecting this role advances will eventually be m a d e  in the diagnosis and 
treatment of endometrial carcinoma.
The aims of this thesis were therefore to investigate the role of P T E N  in 
endometrial carcinoma by three distinct approaches. These included analysis 
of the effect of TGF-pi on P T E N  expression in E C  cell lines, cloning of 
h u m a n  P T E N  c D N A  and assessing sub-cellular localisation of the protein 
under various conditions, and the detection of novel mutations in E C  archival 
DNA.
The effect of TGF-J31 on PTEN expression in EC cell lines 
TGF-pi has previously been shown to both up- and down-regulate P T E N  
m R N A  or protein levels in various cell lines, in a manner which m a y  indicate 
cell-line specificity, but this has not been previously reported in cells of 
endometrial origin. C o m p o u n d s  which up-regulate P T E N  m a y  represent 
future anti-cancer therapies, and therefore merit investigation.
For this study, cell lines were chosen which expressed wild-type (HEC-1B) or 
mutant (Ishikawa) P T E N  protein. This permitted the study of the effects of 
the cytokine on growth and cellular morphology in the presence or absence 
of endogenous P T E N  protein, in addition to modulation of P T E N  m R N A  and 
protein levels.
The results presented in Chapter 3, Section 1 indicated a modest up- 
regulation of P T E N  m R N A  expression in both H E C - 1 B  and Ishikawa cell lines 
in response to TGF-pi. Similar results have been reported by Lee, et al 
(1999) in the h u m a n  monocytic leukaemia cell line U937, but this group did 
not describe a possible pathway for the data described. Serum deprivation
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also appeared to have a small up-regulatory effect on P T E N  m R N A  
expression. This could be accounted for by the lack of growth factors, which 
w h e n  present in the medium could suppress P T E N  protein function, and 
possibly m R N A  expression. Functionality of the TGF-p1 receptor signalling to 
S m a d s  in H E C - 1 B  and ISK cell lines w a s  confirmed by the time and dose- 
dependant up-regulation of the classically TGF-pi-responsive gene PAI-1. 
Additionally, the effects of high cell density on increasing P T E N  m R N A  
expression were ruled out, as plating H E C - 1 B  cells at high density displayed 
no difference in P T E N  expression to cells grown at a lower density (Chapter 
3.1.5)
Analysis of P T E N  and P - P T E N  protein levels indicated very little change from 
the controls which were not stimulated with cytokine. This suggests that the 
effects of TGF-p1 occurred mainly at the transcriptional level, or that the 
protein analysis methods used were not sensitive enough to detect subtle 
post-translational changes. It remains unclear, however, which of the three 
putative P T E N  phosphorylation sites in the C-terminus (Ser380 and 
Thr382/383) are phosphorylated under differing cellular conditions. At the 
time that the work described here w a s  performed, only an anti-P-PTEN 
(Ser380) antibody w a s  commercially available. T he use of a n e w  anti-P- 
P T E N  antibody (CST, UK), which detects phosphorylation of all three C- 
terminal sites (Ser380 and Thr382/383), m a y  increase the sensitivity of the 
Western blot for P-PTEN.
Effects of TGF-pi on endometrial cell morphology agree with published data 
(Boyd &  Kaufman, 1990 &  Anzai, et al 1992) in that the cytokine increases 
cell volume and/or decreases proliferation of the H E C - 1 B  and ISK cell lines.
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The mechanisms underlying the regulatory effects of TGF-p1 on P T E N  are 
yet to be described. TGF-pi m a y  exert growth suppression on these cell 
lines via several mechanisms described in Chapter 1. These m a y  include cell 
cycle restriction via the transcription factor Sp1 which increases expression 
of the cyclin inhibitor p15INK, increased F O X O  activity, or by inhibition of c- 
myc. The presence of a Sp1 consensus site in the promoter region of P T E N  
has been noted by Sheng, et al (2002), and this m a y  represent a pathway of 
transcriptional modulation by TGF-p1.
Cloning of Human Full-Length PTEN and localisation of Transfected PTEN 
protein in Endometrial cell lines.
P T E N  has been described as a cytoplasmic protein in the majority of cell 
lines and tissues, which would appear to correlate with a lack of nuclear 
location signal (NLS). However, nuclear P T E N  has been reported in a 
number of studies and it is likely that other proteins are involved in its 
transport both to the nucleus and to various cellular compartments.
Other phosphatases have been observed to be shuttled between the nucleus 
and cytoplasm in synchrony with the cell cycle, including C D C 2 5 B  (Davezac, 
et al 2000) and C D C 1 4  (Li, et al 1997b). The discovery of a nuclear PI3,4,5P3 
cycle, which is still poorly understood, supports the theory that P T E N  m a y  
have a role in the nucleus (Lachyankar, et al 2000). The extent to which 
nuclear P T E N  responds to modulation by external stimuli, such as growth 
factors and hormones, is also not fully understood.
The results of transfection of pRC-2 into H E C - 1 B  and Ishikawa cell lines are 
partially consistent with a recently published report by Ginn-Pease &  Eng
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(2003). This group used full-length P T E N  cloned into both a vector without a 
fluorescent tag and also into the pE G F P - C 1  vector, to transiently transfect 
the M C F - 7  breast cancer cell line. The paper reported accumulation of 
transfected P T E N  around the nuclear m e m b r a n e  and in the general location 
of the nucleus, which increased at Go -Gi and decreased during S-phase. 
Co-localisation of P T E N  with the nuclear protein C D K 2  during G1 w as also 
observed. Additionally, the presence of P T E N  in the nucleus w a s  confirmed 
by Western blot of nuclear and cytoplasmic extracts prepared from the 
transfected cells. T he presence of the N-terminal E G F P  moiety did not 
reportedly affect P T E N  entry into the nucleus or the cell cycle. The results 
shown in Chapter 3, Section 2 are strikingly similar to those of Ginn-Pease &  
Eng (2003) in that strong staining in the perinuclear and nuclear regions, but 
also ubiquitous cytoplasmic localisation, were observed in the endometrial 
cell lines. S o m e  vault proteins can accumulate at the nuclear m e m b r a n e  
adjacent to nuclear pores, and as P T E N  can bind the major vault protein via 
its C 2  domain (Yu, et al 2002) this m a y  be a mechanism of transport into the 
nucleus. Other proteins, such as p-catenin, m a y  bind directly to the nuclear 
pore to mediate their o wn transport, but in this case the mechanism is 
unknown (Suh &  Gumbiner, 2003).
A  further possibility proposed by Ginn-Pease and Eng is that P T E N  m a y  
have a more rare form of N L S  called a nuclear-cytoplasmic shuttling 
sequence, or a bipartite NLS. Such bipartite sequences have previously been 
reported in p53 (Liang &  Clarke, 1999), and the C D K  inhibitor p27KIP1 has 
been shown to require an interaction with Jab1/CSN5 for CRM1-mediated 
nuclear export (Tomoda, et al 2002).
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A  lack of detectable change in subcellular localisation of P T E N  encoded by 
pRC-2 in endometrial cell lines in response to stimulation by oestrogen and 
TGF-pi w a s  observed (Chapter 3, Section 2). With respect to oestrogen, 
Mutter, et al (2000) has described ubiquitous expression of P T E N  in both the 
nucleus and cytoplasm of oestrogen-exposed dividing endometrial glandular 
and stromal cells. A  further study by Guzeloglu-Kayisli, et al (2003) 
demonstrated a rapid and short-lived increase in total P T E N  and nuclear P- 
P T E N  in endometrial cells in response to oestrogen. This increase declined 
after 15 minutes and w a s  absent in cells treated over longer periods (3 to 24 
hours), suggesting that any increase in P T E N  is extremely rapid and 
transitory. A s  the unstimulated distribution of P T E N - E G F P  w a s  observed to 
be both perinuclear/nuclear and cytoplasmic, oestrogen m a y  not affect 
localisation of P T E N  under the experimental conditions used. Cells 
stimulated with TGF-p1 also demonstrated no change in exogenous P T E N  
localisation, suggesting that with consideration to the lack of endogenous 
P T E N  increase shown by Western blot in Chapter 3, the cytokine does not 
modify levels of the protein.
Co-localisation of P T E N  in endometrial cell lines with markers for the E R  and 
Golgi shown in Chapter 3, Section 2 has not previously been described. 
Localisation of the murine testis-specific homologue of PTEN, called PTEN-2, 
to the golgi in transfected C O S - 7  cells has been demonstrated by W u ,  et al 
(2001), w h o  cloned PTEN-2 into pEGFP-N3. This localisation w a s  shown to 
require the N-terminal domain of PTEN-2 containing four potential 
transmembrane domains, which m a y  play a role in vesicular trafficking 
through the golgi network.
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In the H E C - 1 B  and ISK cell lines used in this study, very little co-localisation 
w a s  observed between the golgi protein mannosidase II and PTEN. Although 
detection of the golgi with the non-commercial polyclonal antibody did not 
appear to be very specific, it is more likely that P T E N  simply does not 
associate with the golgi in the s a m e  manner as testis-specific PTEN-2. C o ­
localisation of P T E N  with the endoplasmic reticulum resident chaperone 
protein colligin (Hsp47) w a s  detected in both endometrial cell lines as 
illustrated in Chapter 3, Section 2. As  the E R  is continuous with the outer 
nuclear membrane, it is possible that P T E N  localises with colligin if it has 
been localised to the perinuclear region perhaps via one of the theoretical 
mechanisms previously described.
Recently, P T E N  has been detected in lipid rafts within intestinal cells, which 
m a y  affect PTEN-mediated attenuation of PI3K by specific localisation of the 
protein (Li, et al 2004). Lipid rafts and their stabilising caveolin proteins, are 
distinct micromembrane domains which have been implicated in signal 
transduction and can associate with m a n y  transduction elements, including 
receptor tyrosine kinases, PKC, G-proteins and R a s - M A P K  components 
(Pike, L. J., 2003 &  Smart, et al 1999). P T E N  and other protein tyrosine 
phosphatases have previously been shown to form complexes with caveolin- 
1, which m a y  regulate the function of these proteins (Caselli, et al 2002).
Mutation Analysis of PTEN Exons 5 & 8 in Archival Endometrial DNA by 
SSCP
A  large variety of P T E N  mutations have n o w  been described in E C  and other 
cancers. The S S C P  technique used in this thesis w as  based on previous
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reports (Rhei, et al 1997, Aveyard, et al 1999 &  Cinti, et al 2000) in which a 
commercial mutation detection gel solution and silver staining kit were used 
to give superior separation and detection of bands. The results of S S C P  
analysis shown in Chapter 3, Section 3 indicate that excellent separation and 
staining w a s  achieved for all samples with the exception of exon 8 C D  P C R  
products. From the total of total of 43 patients, 27 (63%) were found to have 
at least one sample containing a bandshift. This figure is in agreement with 
the published P T E N  mutation rate in E C  of 20-85%, which includes the 
earliest hyperplasias to the highest grade adenocarcinomas.
The S S C P  technique, whilst being relatively simple, rapid, and up to 9 5 %  
effective for s o m e  genes, is also extremely sensitive to changes in 
temperature and primer concentration (Hennessy, Teare &  Ko, 1998). The 
latter of these variables m a y  account in part for the poor separation of 8 C D  
products. A s  stated in Chapter 3, sequencing data w as difficult to obtain for 
the great majority of samples exhibiting bandshifts. T he quality of D N A  
derived from archival material is notoriously fragile, and can generate not 
only low yields of P C R  product but also reduce the specificity of the reaction 
and lead to spurious amplification. This is the main reason w h y  archival D N A  
is not commonly used in such studies, where fresh tissue is preferred.
The P C R  products for all samples appeared to consist of a single clean band, 
but insufficient P C R  product w as problematic in s o m e  samples, particularly in 
exon 5AB. Although non-specific amplicons were visually undetectable on 
the agarose gel, the presence of very small amounts of extraneous P C R  
product could be a cause for interference in sequencing as the technique is 
very sensitive to contamination.
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A  further explanation for the sequencing difficulties encountered is that more 
than one cell type w a s  present in the tissue samples w h e n  D N A  was 
extracted. Potentially, strands of D N A  with slightly different sequences could 
therefore have been present in the samples prior to PCR, causing multiple 
amplicons of the s a m e  apparent size to be generated. A s  the tissue handling 
and D N A  extraction were performed by our collaborators, this element of the 
study w a s  essentially beyond m y  control.
Despite the associated technical hurdles, S S C P  is still being used to 
effectively detect P T E N  mutations and thereby increase our understanding of 
this gene in disease. O n e  recent study has discovered three polymorphisms 
in P T E N  from Japanese patients with type-2 diabetes, these being c.-9C->G 
in the 5’ U T R  of exon 1, IVS5-11T->G in intron 4 and c.859T->C in exon 8 
(Ishihara, et al (2003). The most c o m m o n  polymorphism in the 5 ’ U T R  of 
exon 1 wa s  shown to cause increased P T E N  expression w h e n  cloned and 
expressed in two cell lines. Exposure of the transfected cells to insulin 
showed a significant reduction in P-Akt/PKB compared to a control of wild- 
type PTEN, and this polymorphism m a y  therefore contribute to insulin 
resistance in type-2 diabetes in this population.
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4.2 Future Work
Although several compounds have been shown to positively affect P T E N  
m R N A  expression including progesterone, TGF-p1, and NGF, or protein 
levels, (vitamin D 3  analogues, B D N F  and BMP), few studies have proposed 
mechanisms which m a y  underlie these observations. Additionally, few groups 
have analysed both m R N A  and protein expression of P T E N  in response to 
stimulation. It is not clear, therefore, h o w  m a n y  studies in which increased 
P T E N  m R N A  w as detected would also demonstrate a change in protein 
levels. A s  the regulation of P T E N  m a y  involve both transcriptional and post- 
translational events which m a y  be further complicated by cell-type specificity, 
it is worthwhile investigating both levels of response for a complete picture. 
The fundamental question still remains as to h o w  constitutive expression of 
P T E N  is maintained, and h o w  the compounds mentioned above actually 
affect changes in m R N A  expression.
Recently, a study by Han, et al 2003 on m o u s e  P T E N  revealed a strong 
promoter in the 5’ U T R  at -551 to -220 upstream of the translation start 
codon. This promoter drives the production of an m R N A  transcript with a 
shorter 5’ U T R  which w as translated at 100-fold higher efficiency that the full- 
length 5’ U T R  transcript. The group also demonstrated constitutive activation 
of the promoter via Sp1. It would be of interest to determine whether this is 
also the case for the constitutive expression of h u m a n  PTEN. For this 
purpose, the entire h u m a n  5’U T R  upstream of exon 1 would be cloned into a 
reporter vector containing the luciferase gene, such as pGL-2-Basic 
(Promega). A  range of clones with successively smaller portions of 5’U T R  
would also be created, and the clones transfected into a suitable mammalian
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cell line. Degree of promoter activity would be assessed after 24-48 hours by 
fluorescence of cell extracts in the luciferase assay, in which luciferin is 
added to the extracts and light levels determined by scintillation counter. To  
assess the ability of Sp1 to initiate transcription, the transcription factor would 
be cloned into a Drosophila expression vector containing a strong promoter, 
such as pAC5.1 (Invitrogen) which is driven by the actin 5 C  promoter. C o ­
transfection of the Sp1 and P T E N  5’U T R  clones into Drosophila SL2 cells 
(which contain no Sp factors) followed by the luciferase assay would be used 
to determine the degree of promoter activity in each P T E N  clone. Clones 
exhibiting significantly higher levels of promoter activity would then be 
sequenced to determine whether one or more transcripts are present. A s  
TGF-pi m a y  affect P T E N  transcription via Sp1, it would be interesting to 
stimulate co-transfected cells with the cytokine to ascertain whether 
treatment enhances promoter activity.
To  further investigate the presence of nuclear P T E N  in endometrial cell lines, 
the following approach could be taken. Firstly, transfected cells would be 
imaged using a confocal microscope with the ability to scan and create 3-D 
images to more accurately assess the location of P T E N - E G F P .  Secondly, 
nuclear and cytoplasmic protein extracts would be prepared from transfected 
cells using a commercially available kit such as N E - P E R  (Pierce-Endogen). 
The two fractions would be used in Western blot and probed with an anti- 
P T E N  antibody, with anti-p-actin as a control to demonstrate the purity of the 
nuclear fraction. A s  a lack of nuclear P T E N  has been associated with s o m e  
high-grade tumours, a cell line in which nuclear P T E N  has been reported, 
such as M C F - 7  breast cancer cells, would be used as a control.
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APPENDIX I 
MEDIA AND BUFFER COMPOSITION
1. Cell Culture Media Composition 
HEC-1B Cell Line
McCoy’s 5A Modified Medium
For Complete Medium (CM) add the following to 500ml of McCoy’s:
1% L-Glutamine 
1 % Penicillin-Streptomycin 
10% Foetal Calf Serum
For Reduced-Serum Medium (RSM) add the following to 500ml McCoy’s: 
1 % L-Glutamine 
1% Penicillin-Streptomycin 
1 % Foetal Calf Serum
Ishikawa Cell Line
Minimal Essential Medium Eagle
For Complete medium (CM) add the following to 500ml of MEME: 
1 % L-Glutamine 
1% Penicillin-Streptomycin 
1 % non-essential amino acids 
5% Foetal Calf Serum
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COS-7 Cell Line
Dulbecco’s Modified Eagles Medium (DMEM) with Glutamax
For complete medium (CM) add the following to 500ml of DMEM: 
1% Penicillin-Streptomycin 
10% Foetal Calf Serum
2. Agarose Gel Electrophoresis 
10x TAE Buffer:
Tris 32.3 g
EDTA 2.48 g
Glacial Acetic Acid 11.7 ml
Make up to 1 L with distilled water. 
Loading Buffer
Sucrose-------------------------------25%.
Xylene Cyanol FF 
Bromophenol Blue
0.02%
0.05%
Base Pafes OKA fclass
m  ■ i 'sr7 (r<8)45
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3. Protein Extraction
Activation of Sodium orthovanadate
Prepare a 200 mM solution of sodium orthovanadate. Adjust the pH to 10.0 
to give a yellow solution. Boil the solution until it turns colorless and cool to 
room temperature. Readjust the pH to 10.0 and repeat the boiling and pH 
adjustment until the solution remains colorless and the pH stabilises at 10.0. 
Aliquot and store at -20°C.
Protein Lysis Buffer
Glycerol 5ml
SDS 0.5g
DTT 0.5g
1M Sodium fluoride 5ml
2M Na4P20 7 0.5ml
1M Na3V 0 4 (activated) 0.05ml
0.1MPMSF 0.5ml
Protease inhibitor Cocktail 300pl
1M Tris pH 6.8 3.125ml
Add distilled water to 50ml, aliquot and store at -20°C.
4. SDS-PAGE & Western Blotting 
Resolving Buffer
1.5M Tris/HCI pH 8.8
Stacking Buffer
0.5M Tris/HCI pH 6.8
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10x Running Buffer
0.25M Tris/HCI 
2M glycine 
1% SDS (w/v)
Adjust to pH 8.3
Resolving Gel, 8% (2x minigels of 0.75mm thickness)
Resolving Buffer 3.0ml
Acrylamide 1.6ml
dH20 3.2ml
10% SDS 80jil
Mix by inverting three times and add:
10% APS lOOjul
-TEMED---------------------------- 40jil____________________
Stacking gel, 4% (2x minigels of 0.75mm thickness)
Stacking Buffer 1.25ml
Acrylamide 0.5ml
dH20  3.1ml
10% SDS 20jul
Mix by inverting three times and add:
10% APS lOOjul
TEMED 40pl
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Towbin Buffer
Tris 4.84 g
Glycine 21.62 g
Methanol 150 ml
Dissolve in 1L of distilled water.
Chill for 2 hours at -20°C
10x TBS/T
20mM Tris
0.9% Sodium Chloride
Adjust the pH to 7.5 and make up to 1L with distilled water 
Add 0.1% TWEEN-20
10x PBS/T
Sodium Chloride 80 g
Potassium Chloride 2 g
Disodium hydrogen orthophosphate 26.8 g
Potassium dihydrogen orthophosphate 2.4 g
Adjust the pH to 7.4 and make up to 1L with distilled water 
Add 0.1% TWEEN-20
Coomassie Stain
Dissolve Coomassie R250 in destain to 0.25%
Store at 4°C.
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Destain
Methanol 45ml
Acetic acid 5mI
Make up to 100ml with distilled water.
Protein Markers
208KDa
116
66
97.4KDa
58.1
45
29
38.8
29
20.1
14.3
High Range Colour Marker Biotinylated Marker
5. Bacterial Culture 
L-Broth
Tryptone 10g
Yeast Extract 5g
Sodium Chloride 5g
Add 900 ml of ultrapure water, adjust pH to 7.5, make up to a final volume of 
1L.
Autoclave to sterilise.
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L-Agar Selective Plates & Stabs
Add kanamycin to cooled molten L-Agar to final concentration of 50pg/ml. 
Pour 30ml per Petri dish and allow to set. For stabs pour 15ml into a sterile 
50ml Falcon and allow to set at a 45° angle. Store at 4°C for up to 2 weeks.
RNase A Stock Solution
Dissolve 10 mg of RNase A in 1 ml of sterile water. Filter sterilise and store at 
-20°C.
6. Plasmid Isolation 
Alkaline lysis solutions
Solution I
Glucose 50 mM
EDTA 10 mM
Tris-HCI (pH 8.0) 25 mM
Add ultrapure water to a final volume of 100 ml. 
Autoclave to sterilise and store at 4°C.
Solution II (Prepared fresh just prior to use):
2M Sodium Hydroxide 100 pi
10% SDS 100 pi
Water 800 pi
Solution III
5M Potassium Acetate 14.7 g
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Acetic Acid 5.75 ml
Add distilled water to 50 ml and store at 4°C.
7. Stimulation Stock Compounds 
P-17-Estradiol (20pg/ml)
Dissolve the contents of the bottle in 1 ml of ethanol and add 49ml of 
McCoy’s 5A medium. Store at 4°C.
TGFB-1 (2pg/ml)
Dissolve the contents of the vial (2 pg) in 1 ml of sterile 4mM HCI containing 
1% BSA. Store aliquots at -70°C.
Normal goat serum
Dilute in PBS to final concentration of 10% with 0.05% Sodium azide.
Aliquot and store at -20°C.
8. Extraction of Human DNA from Whole Blood 
BufferA
Tris 1.2g
Sucrose 108.5g
Magnesium chloride 1g
Make up to 990ml with distilled water and adjust pH to 8.0.
Autoclave to sterilize. Add 10ml of TritonX-100 and store at 4°C.
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Buffer B
Tris 48.44g
EDTA 22.33g
Sodium chloride 8.766g
Make up to 900ml with distilled water and adjust pH to 8.0.
Autoclave to sterilize. Add 100ml of a 10% SDS solution and store at 4°C.
9. SSCP
Formamide Buffer
Formamide 9.5 ml
10mM EDTA in 10mM NaOH 0.5 ml
Blue / orange dye (Promega) 200 pi
10x TBE Buffer
Tris 112g
Boric Acid 55g
1MEDTA 20ml
Make up to 1 L with distilled water.
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SSCP Gel Mix, 80ml
0.5x MDE with 5% glycerol
glycerol
2x MDE 20ml
10x TBE 4.8ml
50% glycerol 8ml
Water 47.2ml
0.6x MDE with 10%
2x MDE 
10x TBE 
50% glycerol 
Water
25ml
4.8ml
16ml
34.2ml
Mix by inverting three times.
Add 800|il of freshly prepared 25% Ammonium Persulphate and 80pl of 
TEMED.
Invert three times, pour between the glass plates and insert the teflon combs.
Manual Silver staining 
Gel Fix
Ethanol 100ml
Glacial acetic acid 5ml
Add distilled water to 1L.
Silver stain
0.001% Silver nitrate in distilled water. Store in the dark.
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Developer
5M Sodium hydroxide 30ml 
Formaldehyde 1.5ml
Make up to 500ml with distilled water. Store in the dark. 
Final fix
Sodium carbonate 3.75g 
Make up to 500ml with distilled water.
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APPENDIX II
PTEN Sequence Data
1. PTEN cDNA Sequence
1 ATG ACA GCC ATC ATC AAA GAG ATC GTT AGC AGA AAC AAA AGG AGA 15
16 TAT CAA GAG GAT GGA TTC GAC TTA GAC TTG ACC TAT ATT TAT CCA 30
31 AAC ATT ATT GCT ATG GGA TTT CCT GCA GAA AGA CTT GAA GGC GTA 4 5
4 6 TAC AGG AAC AAT ATT GAT GAT GTA GTA AGG TTT TTG GAT TCA AAG 60
61 CAT AAA AAC CAT TAC AAG A TA  TAC AAT CTT TGT GCT GAA AGA CAT 75
76 TAT GAC ACC GCC AAA TTT AAT TGC AGA GTT GCA CAA TAT CCT TTT 90
91 GAA GAC CAT AAC CCA CCA CAG CTA GAA CTT ATC AAA CCC TTT TGT 105
106  GAA GAT CTT GAC CAA TGG CTA AGT GAA GAT GAC AAT CAT GTT GCA 120
121 [GCA ATT CAC TGT AAA GCT GGA AAG GGA CGA ACT GGT GTA ATG ATA| 135
136  TGT GCA TAT TTA TTA CAT CGG GGC AAA TTT TTA AAG GCA CAA GAG 150
151 GCC CTA GAT TTC TAT GGG GAA GTA AGG ACC AGA GAC AAA AAG GGA 165
1 66  GTA ACT ATT CCC AGT CAG AGG CGC TAT GTG TAT TAT TAT AGC TAC 18 0
181 CTG TTA  AAG AAT CAT CTG GAT TAT AGA CCA GTG GCA CTG TTG TTT 195
196  CAC AAG ATG ATG TTT GAA ACT ATT CCA ATG TTC AGT GGC GGA ACT 21 0
21 1  TGC AAT CCT CAG TTT GTG GTC TGC CAG CTA AAG GTG AAG A TA  TAT 22 5
2 2 6  TCC TCC AAT TCA GGA CCC ACA CGA CGG GAA GAC AAG TTC ATG TAC 24 0
241  TTT GAG TTC CCT CAG CCG TTA CCT GTG TGT GGT GAT ATC AAA GTA 255
2 5 6  GAG TTC TTC CAC AAA  CAG AAC AAG ATG CTA AAA AAG GAC AAA ATG 27 0
27 1  TTT CAC TTT TGG GTA AAT ACA TTC TTC ATA CCA GGA CCA GAG GAA 28 5
2 8 6  ACC TCA GAA AAA GTA GAA AAT GGA AGT CTA TGT GAT CAA GAA ATC 300
301 GAT AGC ATT TGC AGT A TA  GAG CGT GCA GAT AAT GAC AAG GAA TAT 315
3 1 6  CTA GTA CTT ACT TTA ACA AAA AAT GAT CTT GAC AAA GCA AAT AAA  330
331  GAC AAA GCC AAC CGA TAC TTT TCT CCA AAT TTT AAG GTG AAG CTG 345
34 6 TAC TTC ACA AAA ACA GTA GAG GAG CCG TCA AAT CCA GAG GCT AGC 360
361  AGT TCA ACT TCT GTA ACA CCA GAT GTT AGT GAC AAT GAA CCT GAT 375
37 6  CAT TAT AGA TAT TCT GAC ACC ACT GAC TCT GAT CCA GAG AAT GAA 390
391 CCT TTT GAT GAA GAT CAG CAT ACA CAA ATT ACA AAA GTC TGA
The putative phosphatase catalytic domain in Exon 5 (boxed) includes the 
catalytic motif (red) at residues 122-133. N-terminal homology to 
tensin/auxilin is highlighted in grey. GenBank accession AF067844.
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2. PTEN Genomic Sequences
Exons are highlighted in red and include a small portion of the adjacent intron, 
shown in black. Primer binding regions are shown highlighted in the text.
Exon 1 23338-23417bp
ccaccagcag cttctgccat ctctctcctc ctttttcttc agccacaggc
tcccagacat gacagccatc atcaaagaga tcgttagcag aaacaaaagg
agatatcaag aggatggatt cgacttagac ttgacctgta tccatttctg
cggctgctcc tctttacctt tctgtcactc
Primer PTEN 1
Exon 2 51995-52079 bp
ttcagatatt
tattgctatg
atattgatga
ttgatgttta
tctttcctta
ggatttcctg
tgtagtaagg
tattcatgtt
actaaagtac
cagaaagact
taagaatgct
gtgttttcat
tcagatattt
tgaaggcgta
ttgattttct
atccaaacat
tacaggaaca
atttcaaata
Exon 3 83481-83526 bp
ttcttgatag tattaatgta atttcaaatg ttagctcatt
gtggcttttt gtttgtttgt tttgttttaa
aaaaaccatt acaagatata caatctgtaa
gcttgcaaat atcttctaaa acaactatta
ggtttttgga
tttgttaatg
ttcaaagcat
gtatgttttc ttatttgtat
Exon 4 89015-89058 bp
ataactttat atcactttta aacttttctt ttagttgtgc tgaaagacat 
tatgacaccg ccaaatttaa ttgcagaggt aggtatgaat gtactgtact 
atgttgtata acttaaaccc
Exon 5 90987-91225 bp
ttctaaagtt acctacttgt 
attctgaggt tatcttttta
tatgcaacat
tttttttctt
tttgaagacc
agatcttgac
actgtaaagc
ttacatcggg
ggaagtaagg
tttcctcttc
ataacccacc
c a a t g H H
tggaaaggga
gcaaattttt
accagagaca
acagctagaa
cgaactggtg
aaaggcacaa
aaaaggtaag
taattaaaaa
ccacagttgc
cttatcaaac 
|gtt 
taatgatatg 
gaggccctag 
ttattttttg
ttcaagagtt
acaatatcct
ccttttgtga
gcagcaattc
tgcatattta
atttctatgg
atgtttttcc
Primers PTEN 4 PTEN 5A & 5B PTEN 5C & 5D
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Exon 6 110086-110227 bp
aacatttttt
aactattccc
agaatcatct
tttgaaacta
attctcatcc
ttcaatttgg
agtcagaggc
ggattataga
ttccaatgtt
ttccatgtat
cttctctttt
gctatgtgta
ccagtggcac
cagtggcgga
tggaacagtt
ttttctgtcc
ttattatagc
tgttgtttca
acttgcagta
ttcttaacca
accagggagt
tacctgttaa
caagatgatg
agtgcttgaa
Exon 7 115821-115987 bp
atcattaaaa
aataatactg
cagctaaagg
agacaagttc
atatcaaagt
tgtactttac
tcgtttttga
gtatgtattt
tgaagatata
atgtactttg
agagttcttc
tttcattggg
cagtttgaca
aaccatgcag
ttcctccaat 
agttccctca 
cacaaacaga 
agaaatatcc
gttaaaggca
atcctcagtt
tcaggaccca
gccgttacct
acaagatgct
aaaataagga
tttcctgtga
tgtggtctgc
cacgacggga
gtgtgtggtg
aaaaaaggtt
cagattaaaa
Exon 8 118862-119086
aaacatcatt
ttttttttta
ccaggaccag
tcaagaaatc
aatatctagt
acattttgtg
aattaaatat
ggacaaaatg
aggaaacctc
gatagcattt
acttacttta
accgatactt
ggggttggtg
gtcatttcat
tttcactttt
agaaaaagta
gcagtataga
acaaaaaatg
ttctccaaat
acttgtatgt
ttctttttct
gggtaaatac
gaaaatggaa
gcgtgcagat
atcttoB B i
tttaaggtca
atgtgatgtg
tttctttttt
attcttcata
gtctatgtga
aatgacaagg
gttaaattaa
tgtttaattc
Primers PTEN 8A & 8B PTEN 8C &
Exon 9 123258-123443 bp
tgttaaaaat
ttttcatttt
agtagaggag
cagatgttag
gactctgatc
tacaaaagtc
atatttcact
aaattttctt
ccgtcaaatc
tgacaatgaa
cagagaatga
tgaatttttt
aaatagttta
tctctaggtg
cagaggctag
cctgatcatt
accttttgat
tttatcaaga
agatgagtca
aagctgtact
cagttcaact
atagatattc
gaagatcagc
gggataaaac
tatttgtggg
tcacaaaaac
tctgtaacac
tgacaccact
atacacaaat
accatgaaaa
Primer PTEN 2a
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APPENDIX III
ipPTEN/PTH2 cDNA Sequence
1 AGG ACA GCC ATC ATC AAA GAG ATC GTT AGC AGA AAC AAA AGG AGA 15
16 TAT CAA GAG GAT GGA TTC GAC TTA GAC TTG ACC TAT ATT TAT CTA 30
31 AAC ATT ATT GCT ATG GGA TTT CCT GCA GAA AGA CTT GAA GGC GTA 4 5
4 6 TAC AGG AAC AAT ATT GAT GAT GTA GTA AGG TTT TTG GAT TCA AAG 60
61 CAT AAA AAC CAT TAC AAG ATA  CAC AAT CTT TGT GCT GAA AGA CAT 75
907 6 TAT GAC ACC GCC AAA TCT AAT TAC AGA GTT GCG CAA TAT CCT TTT
91 GAA GAC CAT AAC CCA CCA CAG CTA GAA CTT ATC AAA CCC TTT TGT 105
106  GAA GAT CTT GAC CAA TGG CTA AGT GAA GAT GAC AAT CAT GTT GCA 120
121 |GCA ATT CAC TGT AAA GCT GGA AAG GGA CGA ACT GGT ATA  ATG ATT| 1351 ..........................    -...............  - ........    ■ '■ y   -
136  TGT GCA TAT TTA  TTA  CAT CGG GGC AAA TTT TTA  AAG GCA CAA GAG 150
151  |GCC CTA GAT TTC TAT GGG GAA GTA AGR ACC AGA GAC AAA AAG GGA| 165
166 GTA ACT ATT CCC AGT CAG AGG c g ! TAT GTG TAT TAC TAT AGC TAC 180
181 CTG GTA AAG AAT CAT CTG GAT TAT AGA CCA GTG GCA CTG TTG TTT 195
196 CAC AAG ATG ATG TTT GAA ACT ATT CCA ATG TTC AGT GGC GGA ACT 210
211 TGC AAT CCT CAG TTT GTG GTC TGC CAG CTA AAG GTG AAG ATC TAT 225
22 6 TCC TCC AAT TCA GGA CCC ACA CGA TGG GAG GAC AAG TTC ATG TAT 24 0
241 TTT GAG TTC CCT CAG CCG TTA CCT GTG TGT GGT GAT ATC AAA GTA 25 5
25 6 GAG TTC TTC CAC AAA CAG AAC AAG ATG CTA AAA AAG GAC AAA ATG 27 0
271 TTT CAC TTT TGG GTA AAT ACA TTC TTC ATA CCA GGA CCA GAG GAA 285
2 8 6 ACC TCA GAA AAA GTA GAA AAT GGA AGT CTA TGT GAT CAA GAA A TT 300
301 GAT AGC ATT TGC AGT ATA GAG CGT GCA GAT AAT GAC AAG GAG TAT 315r
316 CTA GTA CTT ACT TTA ACA AAA AAT GAT CTT GAC AAA GCA AAT AAA 330
331 GAC AAA GCC AAC CGA TAC TTT TCT CCA AAT GTT tS lG GTG AAG CTG 345
346 TAC TTC ACA AAA ACA GTA GAG GAG CCG TCA AAT CCA GAG GCT AGC 360
361 AGT TCA ACT TCT GTA ACA CCA GAT GTT AGT GAC AAT GAA CCT GAT 375
376 CAT TAT AGA TAT TCT GAC ACC ACT GAC TCT GAT CCA GAG AAT GAA 390
391 CCT TTT GAT GAA GAT CAG CAT ACA CAA ATT ACA AAA GTC TGA
The nucleotide sequence of 4JPTEN/PTH2 cDNA,. Putative phosphatase 
catalytic domain in Exon 5 (boxed), catalytic motif (red), N-terminal 
homology to tensin/auxilin (grey), and Putative Tyrosine Phosphorylation 
site (yellow). M s e  I sites indicated by blue arrows, H h a  I sites indicated by 
green arrows. Bases that differ from PTEN are indicated in bold and 
underlined. Taken from Dahia, e t  al 1998.
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APPENDIX V
PCRPROGRAMMES
PTEN 1 Cycle Ris 2.2 cycle
□ DO N 110°C LID ON 110°C
95oC 5 minutes 95°C 5 minutes
95°C 1 minute / k 95°C 2 seconds
55°C 1 minute ) x 30 50°C 20 seconds
72°C 1 minute L X 72°C 20 seconds
72°C 10 minutes 72°C 10 minutes
LID OFF LID OFF
4°C oo 4°C O0
GAPDH Cycle PAI-1 Cycle
LID ON 110°C LID ON 110°C
95°C 5 minutes 95°C 5 minutes
95°C 1 minute 95°C 30 seconds
58°C 1 minute ) x 30 60°C 30 seconds
72°C 1 minute 72°C 30 seconds
72°C 10 minutes 72°C 10 minutes
LID OFF HEATED LID OFF
4°C OO 4°C oo
360
Bcl-2 PCR Cycle
HEATED LID ON 110°C 
95°C 5 minutes
95°C 30 seconds
61 °C 30 seconds
72°C 1 minute 30”
72°C 10 minutes
HEATED LID OFF 
4°C oo
Pfx3LX2 PCR Cycle
HEATED LID ON 110°C 
95°C 2 minutes
95°C 1 minute
55°C 1 minute
68°C 1 minute
68°C 20 minutes
HEATED LID OFF 
4°C oo
x 35
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APPENDIX VI 
Equipment Suppliers
Mini-Gel Submarine Electrophoresis Units
Biometra Ltd, P.O. Box 42, Sale, Manchester.
Protean III Vertical Mini-Gel Electrophoresis Unit & Mini-Gel Electrophoresis 
Power Pack 300.
BioRad Laboratories Ltd, Marylands Ave., Hemel Hempsted, Herts.
SSCP Gel Vertical Gel Apparatus Hoefer SE660 & 3000v Power Supply
Amersham Biosciences UK Ltd, Pollards Wood, Chalfont St. Giles, 
Bucks.
PCR Primus Thermocyclers
MWG Biotech (UK) Ltd, Mill Court, Milton Keynes.
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APPENDIX VII
1. Purity of RNA from Serum non-Starved HEC-1B Stimulated
with TGF-p1
Concentration TGF-&1 
/ Time (Hours) Flask Cone |jg/|jl Ratio 260/280
0ng/4hrs A 2.15 1.9
B 1.64 1.7
0ng/8hrs A 1.79 1.8
B 2.21 1.86
0ng/24hrs A 2.87 2.1
B 2.99 1.78
2ng/4hrs A 1.3 1.9
B 1.23 1.81
2ng/8hrs A 1.38 1.97
B 1.35 2.01
2ng/24hrs A 1.44 1.89
B 1.45 2.08
5ng/4hrs A 2.13 1.93
B 1.67 1.86
5ng/8hrs A 1.4 1.9
B 1.37 1.84
5ng/24hrs A 1.82 1.9
B 2.05 1.92
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2. Purity of RNA from Serum-Starved HEC-1B Stimulated with TGF-B1
Experiment 1
Concentration TGF-U1 / 
Time (Hours) Flask Cone pg/pl Ratio 260/280
10% Control A 1.64 1.65
B 2.96 1.67
0ng/4hrs A 3.65 1.76
B 5.68 1.9
0ng/8hrs A 3.26 1.9
B 4.96 1.86
0ng/24hrs A 1.53 1.88
B 2.1 1.98
2ng/4hrs A 5.42 1.8
B 4.91 1.81
2ng/8hrs A 1.29 1.86
B 5.45 1.79
2ng/24hrs A 6.82 1.84
B 6.43 1.99
5ng/4hrs A 4.15 1.83
B 5.26 1.84
5ng/8hrs A 1.72 1.75
B 1.82 1.75
5ng/24hrs A 7.67 1.89
B 6.76 1.92
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3. Purity of RNA from Serum-Starved HEC-1B Stimulated with TGF-b1
Experiment 2
Concentration TGF-&1 
/Time (Hours) Flask Cone ug/ul Ratio 260/280
10% Control A 1.168 1.79
B 3.37 1.71
0ng/4hrs A 4.92 1.7
B 3.24 1.56
0ng/8hrs A 4.49 1.7
B 4.09 1.75
0ng/24hrs A 4.62 1.45
B 6.1 1.73
2ng/4hrs A 3.56 1.5
B 3.97 1.46
2ng/8hrs A 6.1 1.75
B 7.83 1.78
2ng/24hrs A 7.68 1.74
B 8.1 1.75
5ng/4hrs A 2.59 1.76
B 6.94 1.68
5ng/8hrs A 2.98 1.6
B 5.99 1.68
5ng/24hrs A 2.21 1.45
B 6.11 1.65
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4. Purity of RNA from Ishikawa cells Stimulated with TGF-f31
Concentration TGF-&1 / 
Time (Hours) Flask Cone |jg/|jl Ratio 260/280
0ng/4hrs A 2.8 1.66
B 3.3 1.68
0ng/8hrs A 3.31 1.68
B 2.96 1.69
0ng/24hrs A 4.13 1.66
B 4.11 1.68
2ng/4hrs A 6.5 1.71
B 3.6 1.73
2ng/8hrs A 3.2 1.72
B 3.15 1.7
2ng/24hrs A 3.83 1.7
B 3.04 1.68
5ng/4hrs A 4.3 1.69
B 4.5 1.72
5ng/8hrs A 3.26 1.71
B 3.2 1.66
5ng/24hrs A 3.52 1.69
B 3.82 1.67
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APPENDIX VIII
Purity of RNA from HEC-1B Cell Density Experiment
Days in culture Flask
Initial Density
4x106 9x106
Day 1
A 1.85 1.88
B 1.83 1.9
C 1.88 1.89
Day 2
A 1.77 1.8
B 1.84 1.88
C 1.8 1.81
Day 3
A 1.8 1.82
B 1.91 1.9
C 1.8 1.8
Day 4
A 1.85 1.88
B 1.86 1.87
C 1.85 1.89
Day 4 MC
A 1.87 1.89
B 1.89 1.88
C 1.79 1.84
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